

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number  
**WO 02/26825 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 14/705**

(21) International Application Number: **PCT/US01/30661**

(22) International Filing Date:  
28 September 2001 (28.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

|            |                                |    |
|------------|--------------------------------|----|
| 60/236,546 | 29 September 2000 (29.09.2000) | US |
| 60/240,589 | 13 October 2000 (13.10.2000)   | US |
| 60/242,322 | 20 October 2000 (20.10.2000)   | US |
| 60/242,223 | 20 October 2000 (20.10.2000)   | US |
| 60/245,855 | 3 November 2000 (03.11.2000)   | US |
| 60/245,900 | 3 November 2000 (03.11.2000)   | US |
| 60/247,587 | 9 November 2000 (09.11.2000)   | US |
| 60/249,343 | 15 November 2000 (15.11.2000)  | US |

(71) Applicant (*for all designated States except US*): **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **GRAUL, Richard, C.** [US/US]; 682-29th Avenue, San Francisco, CA 94121 (US). **WALIA, Narinder, K.** [US/US]; 890 Davis Street #205, San Leandro, CA 94577 (US). **GANDHI, Ameena, R.** [US/US]; 837 Roble Avenue, #1, Menlo Park, CA 94025 (US). **HAFALIA, April, J., A.** [US/US]; 2227 Calle de Primavera, Santa Clara, CA 95054 (US). **RAMKUMAR, Jayalaxmi** [IN/US]; 34359 Maybird Circle, Fremont, CA 94555 (US). **TRIBOULEY, Catherine, M.** [FR/US]; 1121 Tennessee Street, #5, San Francisco, CA 94107 (US). **THORNTON, Michael** [US/US]; 9 Medway Road, Woodside, CA 94062 (US). **KALLICK, Deborah, A.** [US/US]; 900 Olive Street, Menlo Park, CA 94025 (US). **YAO, Monique, G.** [US/US]; 111 Frederick Court, Mountain View, CA 94043 (US). **ELLIOTT, Vicki, S.** [US/US]; 3770 Polton Place Way, San Jose, CA 95121 (US). **BURFORD, Neil** [GB/US]; 105 Wildwood Circle, Durham, CT 06422

(US). **KHAN, Farrah, A.** [IN/US]; 3617 Central Road #102, Glenview, IL 60025 (US). **YUE, Henry** [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). **LU, Yan** [CN/US]; 3885 Corrina Way, Palo Alto, CA 94303 (US). **ARVIZU, Chandra** [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). **ROOPA, Reddy** [IN/US]; 1233 W. McKinley Avenue, #3, Sunnyvale, CA 94086 (US). **NGUYEN, Danniell, B.** [US/US]; 1403 Ridgewood Drive, San Jose, CA 95118 (US). **LEE, Ernestine, A.** [US/US]; 624 Kains Street, Albany, CA 94706 (US). **LU, Dyung, Aina, M.** [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). **ISON, Craig, H.** [US/US]; 1242 Weathersfield Way, San Jose, CA 95118 (US). **WALSH, Roderick, T.** [IE/GB]; 8 Boundary Court, St. Lawrence Road, Canterbury, Kent CT1 3EZ (GB). **POLICKY, Jennifer, L.** [US/US]; 1511 Jarvis Court, San Jose, CA 95118 (US).

(74) Agents: **HAMLET-COX, Diana et al.**; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

(54) Title: G-PROTEIN COUPLED RECEPTORS

(57) Abstract: The invention provides human G-protein coupled receptors (GPCRs) and methods for their use. The GPCRs are encoded by nucleic acid sequences and are expressed in cells. The GPCRs are used to identify ligands that bind to the GPCRs. The GPCRs are used to identify ligands that bind to the GPCRs. The GPCRs are used to identify ligands that bind to the GPCRs.



WO 02/26825 A2

## G-PROTEIN COUPLED RECEPTORS

## TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of G-protein coupled receptors and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors. The present invention further relates to the use of specific G-protein coupled receptors to identify molecules that are involved in modulating taste or olfactory sensation.

## BACKGROUND OF THE INVENTION

Signal transduction is the general process by which cells respond to extracellular signals. Signal transduction across the plasma membrane begins with the binding of a signal molecule, e.g., a hormone, neurotransmitter, or growth factor, to a cell membrane receptor. The receptor, thus activated, triggers an intracellular biochemical cascade that ends with the activation of an intracellular target molecule, such as a transcription factor. This process of signal transduction regulates all types of cell functions including cell proliferation, differentiation, and gene transcription. The G-protein coupled receptors (GPCRs), encoded by one of the largest families of genes yet identified, play a central role in the transduction of extracellular signals across the plasma membrane. GPCRs have a proven history of being successful therapeutic targets.

GPCRs are integral membrane proteins characterized by the presence of seven hydrophobic transmembrane domains which together form a bundle of antiparallel alpha ( $\alpha$ ) helices. GPCRs range in size from under 400 to over 1000 amino acids (Strosberg, A.D. (1991) *Eur. J. Biochem.* 196:1-10; Coughlin, S.R. (1994) *Curr. Opin. Cell Biol.* 6:191-197). The amino-terminus of a GPCR is extracellular, is of variable length, and is often glycosylated. The carboxy-terminus is cytoplasmic and generally phosphorylated. Extracellular loops alternate with intracellular loops and link the transmembrane domains. Cysteine disulfide bridges linking the second and third extracellular loops may interact with agonists and antagonists. The most conserved domains of GPCRs are the transmembrane domains and the first two cytoplasmic loops. The transmembrane domains account, in part, for structural and functional features of the receptor. In most cases, the bundle of  $\alpha$  helices forms a ligand-binding pocket. The extracellular N-terminal segment, or one or more of the three extracellular loops, may also participate in ligand binding. Ligand binding activates the receptor by inducing a conformational change in intracellular portions of the receptor. In turn, the large, third intracellular loop of the activated receptor interacts with a heterotrimeric guanine nucleotide binding

(G) protein complex which mediates further intracellular signaling activities, including the activation of second messengers such as cyclic AMP (cAMP), phospholipase C, and inositol triphosphate, and the interaction of the activated GPCR with ion channel proteins. (See, e.g., Watson, S. and S. Arkininstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6;

- 5 Bolander, F.F. (1994) Molecular Endocrinology, Academic Press, San Diego CA, pp. 162-176;  
Baldwin, J.M. (1994) Curr. Opin. Cell Biol. 6:180-190.)

GPCRs include receptors for sensory signal mediators (e.g., light and olfactory stimulatory molecules); adenosine,  $\gamma$ -aminobutyric acid (GABA), hepatocyte growth factor, melanocortins, neuropeptide Y, opioid peptides, opsins, somatostatin, tachykinins, vasoactive intestinal polypeptide  
10 family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine and norepinephrine, histamine, glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin); chemokines; lipid mediators of inflammation (e.g., prostaglandins and prostanoids, platelet activating factor, and leukotrienes); and peptide hormones (e.g., bombesin, bradykinin, calcitonin, C5a anaphylatoxin, endothelin, follicle-stimulating hormone (FSH), gonadotropic-releasing hormone (GnRH), neurokinin,  
15 thyrotropin-releasing hormone (TRH), and oxytocin). GPCRs which act as receptors for stimuli that have yet to be identified are known as orphan receptors.

The diversity of the GPCR family is further increased by alternative splicing. Many GPCR genes contain introns, and there are currently over 30 such receptors for which splice variants have been identified. The largest number of variations are at the protein C-terminus. N-terminal and  
20 cytoplasmic loop variants are also frequent, while variants in the extracellular loops or transmembrane domains are less common. Some receptors have more than one site at which variance can occur. The splice variants appear to be functionally distinct, based upon observed differences in distribution, signaling, coupling, regulation, and ligand binding profiles (Kilpatrick, G.J. et al. (1999) Trends Pharmacol. Sci. 20:294-301).

25 GPCRs can be divided into three major subfamilies: the rhodopsin-like, secretin-like, and metabotropic glutamate receptor subfamilies. Members of these GPCR subfamilies share similar functions and the characteristic seven transmembrane structure, but have divergent amino acid sequences. The largest family consists of the rhodopsin-like GPCRs, which transmit diverse extracellular signals including hormones, neurotransmitters, and light. Rhodopsin is a photosensitive  
30 GPCR found in animal retinas. In vertebrates, rhodopsin molecules are embedded in membranous stacks found in photoreceptor (rod) cells. Each rhodopsin molecule responds to a photon of light by

35 GPCR molecules are directly converted to a neural impulse. Other rhodopsin-like GPCRs are directly involved in responding to neurotransmitters. These GPCRs include the receptors for adrenaline (adrenergic receptors), acetylcholine (muscarinic receptors), adenosine, galanin, and

glutamate (N-methyl-D-aspartate/NMDA receptors). (Reviewed in Watson, S. and S. Arkinstall (1994) The G-Protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 7-9, 19-22, 32-35, 130-131, 214-216, 221-222; Habert-Ortoli, E. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91:9780-9783.)

5           The galanin receptors mediate the activity of the neuroendocrine peptide galanin, which inhibits secretion of insulin, acetylcholine, serotonin and noradrenaline, and stimulates prolactin and growth hormone release. Galanin receptors are involved in feeding disorders, pain, depression, and Alzheimer's disease (Kask, K. et al. (1997) *Life Sci.* 60:1523-1533). Other nervous system rhodopsin-like GPCRs include a growing family of receptors for lysophosphatidic acid and other  
10   lysophospholipids, which appear to have roles in development and neuropathology (Chun, J. et al. (1999) *Cell Biochem. Biophys.* 30:213-242).

          The largest subfamily of GPCRs, the olfactory receptors, are also members of the rhodopsin-like GPCR family. These receptors function by transducing odorant signals. Numerous distinct olfactory receptors are required to distinguish different odors. Each olfactory sensory neuron  
15   expresses only one type of olfactory receptor, and distinct spatial zones of neurons expressing distinct receptors are found in nasal passages. For example, the RA1c receptor, which was isolated from a rat brain library, has been shown to be limited in expression to very distinct regions of the brain and a defined zone of the olfactory epithelium (Raming, K. et al. (1998) *Receptors Channels* 6:141-151). However, the expression of olfactory-like receptors is not confined to olfactory tissues. For example,  
20   three rat genes encoding olfactory-like receptors having typical GPCR characteristics showed expression patterns not only in taste and olfactory tissue, but also in male reproductive tissue (Thomas, M.B. et al. (1996) *Gene* 178:1-5).

          Members of the secretin-like GPCR subfamily have as their ligands peptide hormones such as secretin, calcitonin, glucagon, growth hormone-releasing hormone, parathyroid hormone, and  
25   vasoactive intestinal peptide. For example, the secretin receptor responds to secretin, a peptide hormone that stimulates the secretion of enzymes and ions in the pancreas and small intestine (Watson, *supra*, pp. 278-283). Secretin receptors are about 450 amino acids in length and are found in the plasma membrane of gastrointestinal cells. Binding of secretin to its receptor stimulates the production of cAMP.

30           Examples of secretin-like GPCRs implicated in inflammation and the immune response include the EGF module-containing, mucin-like hormone receptor (Emr1) and CD97 receptor proteins. These GPCRs are members of the recently characterized EGF-TM7 receptors subfamily. These seven transmembrane hormone receptors exist as heterodimers *in vivo* and contain between three and seven potential calcium-binding EGF-like motifs. CD97 is predominantly expressed in leukocytes and is  
35   markedly upregulated on activated B and T cells (McKnight, A.J. and S. Gordon (1998) *J. Leukoc.*



The third GPCR subfamily is the metabotropic glutamate receptor family. Glutamate is the major excitatory neurotransmitter in the central nervous system. The metabotropic glutamate receptors modulate the activity of intracellular effectors, and are involved in long-term potentiation (Watson, supra, p.130). The  $\text{Ca}^{2+}$ -sensing receptor, which senses changes in the extracellular concentration of calcium ions, has a large extracellular domain including clusters of acidic amino acids which may be involved in calcium binding. The metabotropic glutamate receptor family also includes pheromone receptors, the  $\text{GABA}_B$  receptors, and the taste receptors.

Other subfamilies of GPCRs include two groups of chemoreceptor genes found in the nematodes Caenorhabditis elegans and Caenorhabditis briggsae, which are distantly related to the mammalian olfactory receptor genes. The yeast pheromone receptors STE2 and STE3, involved in the response to mating factors on the cell membrane, have their own seven-transmembrane signature, as do the cAMP receptors from the slime mold Dictyostelium discoideum, which are thought to regulate the aggregation of individual cells and control the expression of numerous developmentally-regulated genes.

GPCR mutations, which may cause loss of function or constitutive activation, have been associated with numerous human diseases (Coughlin, supra). For instance, retinitis pigmentosa may arise from mutations in the rhodopsin gene. Furthermore, somatic activating mutations in the thyrotropin receptor have been reported to cause hyperfunctioning thyroid adenomas, suggesting that certain GPCRs susceptible to constitutive activation may behave as protooncogenes (Parma, J. et al. (1993) Nature 365:649-651). GPCR receptors for the following ligands also contain mutations associated with human disease: luteinizing hormone (precocious puberty); vasopressin  $\text{V}_2$  (X-linked nephrogenic diabetes); glucagon (diabetes and hypertension); calcium (hyperparathyroidism, hypocalcuria, hypercalcemia); parathyroid hormone (short limbed dwarfism);  $\beta_3$ -adrenoceptor (obesity, non-insulin-dependent diabetes mellitus); growth hormone releasing hormone (dwarfism); and adrenocorticotropin (glucocorticoid deficiency) (Wilson, S. et al. (1998) Br. J. Pharmacol. 125:1387-1392; Stadel, J.M. et al. (1997) Trends Pharmacol. Sci. 18:430-437). GPCRs are also involved in depression, schizophrenia, sleeplessness, hypertension, anxiety, stress, renal failure, and several cardiovascular disorders (Horn, F. and G. Vriend (1998) J. Mol. Med. 76:464-468).

In addition, within the past 20 years several hundred new drugs have been recognized that are directed towards activating or inhibiting GPCRs. The therapeutic targets of these drugs span a wide

range of diseases including epilepsy and chromic urticaria (Wilson, supra; Stadel, supra). For

example, the dopamine agonist L-dopa is used to treat Parkinson's disease, while a dopamine

antagonist is used to treat schizophrenia and the early stages of Huntington's disease. Agonists and

antagonists of adrenoceptors have been used for the treatment of asthma, high blood pressure, other cardiovascular disorders, and anxiety; muscarinic agonists are used in the treatment of glaucoma and tachycardia; serotonin 5HT<sub>1D</sub> antagonists are used against migraine; and histamine H<sub>1</sub> antagonists are used against allergic and anaphylactic reactions, hay fever, itching, and motion sickness (Horn, supra).

Recent research suggests potential future therapeutic uses for GPCRs in the treatment of metabolic disorders including diabetes, obesity, and osteoporosis. For example, mutant V<sub>2</sub> vasopressin receptors causing nephrogenic diabetes could be functionally rescued in vitro by co-expression of a C-terminal V<sub>2</sub> receptor peptide spanning the region containing the mutations. This result suggests a possible novel strategy for disease treatment (Schöneberg, T. et al. (1996) EMBO J. 15:1283-1291). Mutations in melanocortin-4 receptor (MC<sub>4</sub>R) are implicated in human weight regulation and obesity. As with the vasopressin V<sub>2</sub> receptor mutants, these MC<sub>4</sub>R mutants are defective in trafficking to the plasma membrane (Ho, G. and R.G. MacKenzie (1999) J. Biol. Chem. 274:35816-35822), and thus might be treated with a similar strategy. The type 1 receptor for parathyroid hormone (PTH) is a GPCR that mediates the PTH-dependent regulation of calcium homeostasis in the bloodstream. Study of PTH/receptor interactions may enable the development of novel PTH receptor ligands for the treatment of osteoporosis (Mannstadt, M. et al. (1999) Am. J. Physiol. 277:F665-F675).

The chemokine receptor group of GPCRs have potential therapeutic utility in inflammation and infectious disease. (For review, see Locati, M. and P.M. Murphy (1999) Annu. Rev. Med. 50:425-440.) Chemokines are small polypeptides that act as intracellular signals in the regulation of leukocyte trafficking, hematopoiesis, and angiogenesis. Targeted disruption of various chemokine receptors in mice indicates that these receptors play roles in pathologic inflammation and in autoimmune disorders such as multiple sclerosis. Chemokine receptors are also exploited by infectious agents, including herpesviruses and the human immunodeficiency virus (HIV-1) to facilitate infection. A truncated version of chemokine receptor CCR5, which acts as a coreceptor for infection of T-cells by HIV-1, results in resistance to AIDS, suggesting that CCR5 antagonists could be useful in preventing the development of AIDS.

The involvement of some GPCRs in taste and olfactory sensation has been reported. Complete or partial sequences of numerous human and other eukaryotic sensory receptors are currently known. (See, e.g., Pilpel, Y. and D. Lancet (1999) Protein Sci. 8:969-977; Mombaerts, P. (1999) Annu. Rev. Neurosci. 22:487-509. See also, e.g., patents EP 867508A2; US 5,874,243; WO 92/17585; WO 95/18140; WO 97/17444; and WO 99/67282.) It has been reported that the human genome contains approximately one thousand genes that encode a diverse repertoire of olfactory receptors (Rouquier, S. et al. (1998) Nat. Genet. 18:243-250; Trask, B.J. et al. (1998) Hum. Mol. Genet. 7:2007-2020).

The discovery of new G-protein coupled receptors, and the polynucleotides encoding them, satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.

### SUMMARY OF THE INVENTION

The invention features purified polypeptides, G-protein coupled receptors, referred to collectively as "GCREC" and individually as "GCREC-1," "GCREC-2," "GCREC-3," "GCREC-4," "GCREC-5," "GCREC-6," "GCREC-7," "GCREC-8," "GCREC-9," "GCREC-10," "GCREC-11," "GCREC-12," "GCREC-13," "GCREC-14," "GCREC-15," and "GCREC-16." In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-16.

The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-16. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:17-32.

The invention additionally provides G-protein coupled receptors that are involved in olfactory and/or taste sensation. The invention further provides polynucleotide sequences that encode said G-

The invention further provides a composition comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting

of SEQ ID NO:1-16, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16.

The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ

ID NO:17-32, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-16. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

The invention further provides a composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected

from the group consisting of SEQ ID NO:1-16, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16. The method comprises a) exposing a sample comprising the  
5 polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

10 Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid  
15 sequence selected from the group consisting of SEQ ID NO:1-16, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a  
20 pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid  
25 sequence selected from the group consisting of SEQ ID NO:1-16, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group  
30 consisting of SEQ ID NO:1-16. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino  
35 acid sequence selected from the group consisting of SEQ ID NO:1-16, b) a polypeptide comprising a

naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

The invention further provides methods of using G-protein coupled receptors of the invention involved in olfactory and/or taste sensation, biologically active fragments thereof (including those having receptor activity), and amino acid sequences having at least 90% sequence identity therewith, to identify compounds that agonize or antagonize the foregoing receptor polypeptides. These compounds are useful for modulating, blocking and/or mimicking specific tastes and/or odors.

The present invention also relates to the use of olfactory and/or taste receptors of the invention, biologically active fragments thereof (including those having receptor activity), and polypeptides having at least 90% sequence identity therewith, in combination with one or more other olfactory and/or taste receptor polypeptides, to identify a compound or plurality of compounds that modulate, mimic, and/or block a specific olfactory and/or taste sensation.

The invention also relates to cells that express an olfactory or taste receptor polypeptide of the invention, a biologically active fragment thereof (including those having receptor activity), or a polypeptide having at least 90% sequence identity therewith, and the use of such cells in cell-based screens to identify molecules that modulate, mimic, and/or block specific olfactory or taste sensations.

Still further, the invention relates to a cell that co-expresses at least one olfactory or taste G-protein coupled receptor polypeptide of the invention, and a G-protein, and optionally one or more other olfactory and/or taste G-protein coupled receptor polypeptides, and the use of such a cell in screens to identify molecules that modulate, mimic, and/or block specific olfactory and/or taste sensations.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, the method

comprising the steps of:

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b)

hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

20

### BRIEF DESCRIPTION OF THE TABLES

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

Table 5 shows the representative cDNA library for polynucleotides of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.



Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

### DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

### DEFINITIONS

"GCREC" refers to the amino acid sequences of substantially purified GCREC obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of GCREC. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.

An "allelic variant" is an alternative form of the gene encoding GCREC. Allelic variants may

include any number of mutations which may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides.

Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

“Altered” nucleic acid sequences encoding GCREC include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GCREC or a polypeptide with at least one functional characteristic of GCREC. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding GCREC, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GCREC. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GCREC. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GCREC is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where “amino acid sequence” is recited to refer to a sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

“Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of GCREC. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.

The term “antibody” refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind GCREC polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or

oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize  
5 the animal.

The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on  
10 the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "aptamer" refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Patent No.  
15 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2'-OH group of a ribonucleotide may be replaced by 2'-F or 2'-NH<sub>2</sub>), which may improve a desired property, e.g.,  
20 resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker. (See, e.g., Brody, E.N. and L. Gold (2000) J. Biotechnol. 74:5-13.)

The term "intramer" refers to an aptamer which is expressed in vivo. For example, a vaccinia  
25 virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl Acad. Sci. USA 96:3606-3610).

The term "spiegelmer" refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on  
30 substrates containing right-handed nucleotides.

The term "antisense" refers to any composition capable of base-pairing with the "sense"

oligopeptide nucleic acid (ENA), oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified  
35 sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having

modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic GCREC, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding GCREC or fragments of GCREC may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

|    | Original Residue | Conservative Substitution |
|----|------------------|---------------------------|
| 5  | Ala              | Gly, Ser                  |
|    | Arg              | His, Lys                  |
|    | Asn              | Asp, Gln, His             |
|    | Asp              | Asn, Glu                  |
|    | Cys              | Ala, Ser                  |
|    | Gln              | Asn, Glu, His             |
|    | Glu              | Asp, Gln, His             |
| 10 | Gly              | Ala                       |
|    | His              | Asn, Arg, Gln, Glu        |
|    | Ile              | Leu, Val                  |
|    | Leu              | Ile, Val                  |
|    | Lys              | Arg, Gln, Glu             |
|    | Met              | Leu, Ile                  |
|    | Phe              | His, Met, Leu, Trp, Tyr   |
| 15 | Ser              | Cys, Thr                  |
|    | Thr              | Ser, Val                  |
|    | Trp              | Phe, Tyr                  |
|    | Tyr              | His, Phe, Trp             |
| 20 | Val              | Ile, Leu, Thr             |

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A “deletion” refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term “derivative” refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A “detectable label” refers to a reporter molecule or enzyme that is capable of generating a  
35 measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

“Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample.

Exon shuffling refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be

assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

A "fragment" is a unique portion of GCREC or the polynucleotide encoding GCREC which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:17-32 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:17-32, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:17-32 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:17-32 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:17-32 and the region of SEQ ID NO:17-32 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-16 is encoded by a fragment of SEQ ID NO:17-32. A fragment of SEQ ID NO:1-16 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-16. For example, a fragment of SEQ ID NO:1-16 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-16. The precise length of a fragment of SEQ ID NO:1-16 and the region of SEQ ID NO:1-16 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A "full length" polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A "full length" polynucleotide sequence encodes a "full length" polypeptide sequence.

"Homology" refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a

standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default  
5 parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e  
sequence alignment program. This program is part of the LASERGENE software package, a suite of  
molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in  
Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS  
8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as  
10 follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue  
weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent  
similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms  
is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment  
15 Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from  
several sources, including the NCBI, Bethesda, MD, and on the Internet at  
<http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis  
programs including "blastn," that is used to align a known polynucleotide sequence with other  
polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2  
20 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2  
Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The  
"BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST  
programs are commonly used with gap and other parameters set to default settings. For example, to  
compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version  
25 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

*Matrix: BLOSUM62*

*Reward for match: 1*

*Penalty for mismatch: -2*

*Open Gap: 5 and Extension Gap: 2 penalties*

30 *Gap x drop-off: 50*

*Expect: 10*

Percent identity may be measured over the length of an entire defined sequence, for example,  
35 as defined by a particular SEQ ID number, or may be measured over a shorter length, for example,

over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a  
5 length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

10 The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of  
15 substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap  
20 penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version  
25 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

*Matrix: BLOSUM62*

*Open Gap: 11 and Extension Gap: 1 penalties*

*Gap x drop-off: 50*

30 *Expect: 10*

*Word Size: 3*

*Filter: on*

Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length,  
35 for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for



5 “Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

10 resembles a human antibody, and still retains its original binding ability.

15 after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be  
20 varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v) SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

5°C to 20°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating  $T_m$  and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

### High stringency conditions for hybridization between polynucleotides of the present invention

35 reagents are used to block non-specific hybridization. Such blocking reagents include, for instance,

sheared and denatured salmon sperm DNA at about 100-200  $\mu\text{g/ml}$ . Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency  
5 conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g.,  $C_0t$  or  $R_0t$  analysis) or formed between one  
10 nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

15 "Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of GCREC which is  
20 capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of GCREC which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides,  
25 polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of GCREC. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological,  
30 functional, or immunological properties of GCREC.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

35 "Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a

functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

5       “Peptide nucleic acid” (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

10       “Post-translational modification” of an GCREC may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of GCREC.

      “Probe” refers to nucleic acid sequences encoding GCREC, their complements, or fragments  
15 thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. “Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target  
20 DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

      Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100,  
25 or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

      Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold  
30 Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR

      ... known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge  
35 MA).

Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions

(UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

“Reporter molecules” are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An “RNA equivalent,” in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

The term “sample” is used in its broadest sense. A sample suspected of containing GCREC, nucleic acids encoding GCREC, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms “specific binding” and “specifically binding” refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope “A,” the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term “substantially purified” refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

A “substitution” refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

“Substrate” refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound

or are attached under given conditions at a given time.

“Transformation” describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods

well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or *in vitro* fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), *supra*.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The

presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

## THE INVENTION

The invention is based on the discovery of new human G-protein coupled receptors (GCREC), the polynucleotides encoding GCREC, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections.

Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS

program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

5           Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are G-protein coupled receptors. For example, SEQ ID NO:2 is 39% identical to rat seven transmembrane G-protein coupled receptor (GenBank ID g5525078) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is  $1.2e-89$ , which indicates the probability of obtaining the observed  
10 polypeptide sequence alignment by chance. SEQ ID NO:2 also contains a secretin family 7-transmembrane receptor domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and BLAST analyses provide further corroborative evidence that SEQ ID NO:2 is a G-protein coupled receptor. In an alternative example, SEQ ID NO:4 is 32% identical to  
15 human seven transmembrane-domain receptor (GenBank ID g2117161) as determined by BLAST. (See Table 2.) The BLAST probability score is  $3.2e-35$ . SEQ ID NO:4 also contains a latrophilin/CL-1-like GPS domain and a secretin family 7-transmembrane receptor domain as determined by searching the HMM-based PFAM database. (See Table 3.) Data from BLIMPS and MOTIFS analyses provide further corroborative evidence that SEQ ID NO:4 is a 7-transmembrane  
20 G-protein coupled receptor. In an alternative example, SEQ ID NO:5 is 34% identical to murine oxytocin receptor (GenBank ID g1902964) as determined by BLAST. (See Table 2.) The BLAST probability score is  $7.1e-21$ . SEQ ID NO:5 also contains a 7-transmembrane receptor domain as determined by searching the HMM-based PFAM database. (See Table 3.) Data from BLIMPS analyses provide further corroborative evidence that SEQ ID NO:5 is a G-protein coupled receptor.  
25 In an alternative example, SEQ ID NO:6 is 23% identical to a human cysteinyl leukotriene receptor (GenBank ID g5359718) as determined by BLAST. (See Table 2.) The BLAST probability score is  $2.5e-21$ . Data from BLIMPS analyses provide further corroborative evidence that SEQ ID NO:6 is a G-protein coupled receptor. In an alternative example, SEQ ID NO:8 is 32% identical to an opsin from the Mexican tetra, a blind cave fish, (GenBank ID g440626) as determined by BLAST. (See  
30 Table 2.) The BLAST probability score is  $2.2e-22$ . SEQ ID NO:8 also contains a rhodopsin family 7-transmembrane receptor domain as determined by searching the HMM-based PFAM database. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:8 is a rhodopsin family G-protein coupled receptor. In an alternative example, SEQ ID NO:9 is 44% identical to a putative human neurotransmitter receptor  
35 (GenBank ID g2465432) as determined by BLAST. The BLAST probability score is  $5.2e-69$ . SEQ



PC1/US01/30661

ID NO:9 also contains a rhodopsin family 7-transmembrane receptor domain as determined by searching the HMM-based PFAM database. (See Table 3.) Data from BLIMPS and BLAST analyses provide further corroborative evidence that SEQ ID NO:9 is a rhodopsin family G-protein coupled receptor. In an alternative example, SEQ ID NO:11 is 82% identical to Marnota marmota olfactory receptor (GenBank ID g5901488) as determined by BLAST. (See Table 2.) The BLAST probability score is 1.5e-101. SEQ ID NO:11 also contains a rhodopsin family 7-transmembrane receptor domain as determined by searching the HMM-based PFAM database. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:11 is a G-protein coupled receptor. In an alternative example, SEQ ID NO:12 is 64% identical to Homo sapiens olfactory receptor (GenBank ID g2792018) as determined by BLAST. (See Table 2.) The BLAST probability score is 8.4e-99. SEQ ID NO:12 also contains a rhodopsin family 7-transmembrane receptor domain as determined by searching the HMM-based PFAM database. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:12 is a G-protein coupled receptor. In an alternative example, SEQ ID NO:15 is 57% identical to chicken olfactory receptor 4 (GenBank ID g1246534) as determined by BLAST. (See Table 2.) The BLAST probability score is 1.1e-91. SEQ ID NO:15 also contains a 7-transmembrane receptor (rhodopsin family) domain as determined by searching the HMM-based PFAM database. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:15 is an olfactory receptor. SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:13-14, and SEQ ID NO:16 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-16 are described in Table 7.

As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:17-32 or that distinguish between SEQ ID NO:17-32 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA and/or genomic sequences used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and/or genomic sequences in column 5 relative to their respective

full length sequences.

The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 2536292F6 is the identification number of an Incyte cDNA sequence, and BRAINOT18 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 72051732V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., g3738039) which contributed to the assembly of the full length polynucleotide sequences. In addition, the identification numbers in column 5 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (*i.e.*, those sequences including the designation "ENST"). Alternatively, the identification numbers in column 5 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (*i.e.*, those sequences including the designation "NM" or "NT") or the NCBI RefSeq Protein Sequence Records (*i.e.*, those sequences including the designation "NP"). Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. For example, FL\_XXXXXX\_N<sub>1</sub>\_N<sub>2</sub>\_YYYYY\_N<sub>3</sub>\_N<sub>4</sub> represents a "stitched" sequence in which XXXXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and N<sub>1,2,3...</sub>, if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the identification numbers in column 5 may refer to assemblages of exons brought together by an "exon-stretching" algorithm. For example, FLXXXXXX\_gAAAAA\_gBBBBB\_1\_N is the identification number of a "stretched" sequence, with XXXXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the "exon-stretching" algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the "exon-stretching" algorithm, a RefSeq identifier (denoted by "NM," "NP," or "NT") may be used in place of the GenBank identifier (*i.e.*, gBBBBB).

Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V).

| Prefix | Type of analysis and/or examples of programs |
|--------|--|
|--------|--|

|                |   |
|----------------|---|
| GNN, GFG, ENST | Exon prediction from genomic sequences using, for example, GENSCAN (Stanford University, CA, USA) or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK).                      |
| GBI            | Hand-edited analysis of genomic sequences.  |
| FL             | Stitched or stretched genomic sequences (see Example V).  |
| 5 INCY         | Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript. |

In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

10 Table 5 shows the representative cDNA libraries for those full length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

15 The invention also encompasses GCREC variants. A preferred GCREC variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the GCREC amino acid sequence, and which contains at least one functional or structural characteristic of GCREC.

20 The invention also encompasses polynucleotides which encode GCREC. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:17-32, which encodes GCREC. The polynucleotide sequences of SEQ ID NO:17-32, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

25 The invention also encompasses a variant of a polynucleotide sequence encoding GCREC. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GCREC. A particular aspect of the invention is a variant of a polynucleotide sequence which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ

ID NO:17-32. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GCREC.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GCREC, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring GCREC, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GCREC and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring GCREC under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GCREC or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GCREC and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode GCREC and GCREC derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GCREC or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:17-32 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE

amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA  
5 sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

10 The nucleic acid sequences encoding GCREC may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.)

15 Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et  
20 al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060).

Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo  
25 Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about  
30 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been

screened. Cloning the 5' ends of genes are preferable for situations in which an ongoing library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence  
35 into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GCREC may be cloned in recombinant DNA molecules that direct expression of GCREC, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express GCREC.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GCREC-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of GCREC, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple

naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding GCREC may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) *Nucleic Acids Symp. Ser. 7*:215-223; and Horn, T. et al. (1980) *Nucleic Acids Symp. Ser. 7*:225-232.) Alternatively,

5 GCREC itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) *Proteins, Structures and Molecular Properties*, WH Freeman, New York NY, pp. 55-60; and Roberge, J.Y. et al. (1995) *Science* 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence  
10 of GCREC, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.)

15 The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, *supra*, pp. 28-53.)

In order to express a biologically active GCREC, the nucleotide sequences encoding GCREC or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding  
20 sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding GCREC. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GCREC. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak  
25 sequence. In cases where sequences encoding GCREC and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation  
30 codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See,

methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GCREC and appropriate transcriptional and translational  
35 control elements. These methods include *in vitro* recombinant DNA techniques, synthetic techniques,

and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

5 A variety of expression vector/host systems may be utilized to contain and express sequences encoding GCREC. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Sonnia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GCREC. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding GCREC can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding GCREC into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of GCREC are needed, e.g. for the production of antibodies, vectors which direct high level expression of GCREC may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of GCREC. A number of vectors



5 Bitter, G.A. et al. (1987) *Methods Enzymol.* 153:516-544; and Scorer, C.A. et al. (1994) *Bio/Technology* 12:181-184.)

6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

20 infective virus which expresses GCREC in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

25 DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.)

GCREC in cell lines is preferred. For example, sequences encoding GREC can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous

35 selective agent, and its presence allows growth and recovery of cells which successfully express the

introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine

5 phosphoribosyltransferase genes, for use in *tk* and *ap<sup>r</sup>* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g.,  
10 Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech),  $\beta$  glucuronidase and its substrate  $\beta$ -glucuronide, or luciferase and its substrate  
15 luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if  
20 the sequence encoding GCREC is inserted within a marker gene sequence, transformed cells containing sequences encoding GCREC can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GCREC under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

25 In general, host cells that contain the nucleic acid sequence encoding GCREC and that express GCREC may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

30 Immunological methods for detecting and measuring the expression of GCREC using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on GCREC is preferred, but a  
35 competitive binding assay may be employed. These and other assays are well known in the art. (See,

e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)

5 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GCREC include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding GCREC, or any fragments thereof, may be cloned into a vector  
10 for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for  
15 ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding GCREC may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence  
20 and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GCREC may be designed to contain signal sequences which direct secretion of GCREC through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of  
25 the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture  
30 Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

Sequences encoding GCREC may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric GCREC protein  
35 containing a heterologous moiety that can be recognized by a commercially available antibody may

facilitate the screening of peptide libraries for inhibitors of GCREC activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GCREC encoding sequence and the heterologous protein sequence, so that GCREC may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled GCREC may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, <sup>35</sup>S-methionine.

GCREC of the present invention or fragments thereof may be used to screen for compounds that specifically bind to GCREC. At least one and up to a plurality of test compounds may be screened for specific binding to GCREC. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of GCREC, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which GCREC binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express GCREC, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing GCREC or cell membrane fractions which contain GCREC are then contacted with a test compound and binding, stimulation, or inhibition of activity of either GCREC or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the

assay may comprise the steps of combining at least one test compound with GCREC, either in solution or affixed to a solid support, and detecting the binding of GCREC to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor.

Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

GCREC of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of GCREC. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for GCREC activity, wherein GCREC is combined with at least one test compound, and the activity of GCREC in the presence of a test compound is compared with the activity of GCREC in the absence of the test compound. A change in the activity of GCREC in the presence of the test compound is indicative of a compound that modulates the activity of GCREC. Alternatively, a test compound is combined with an in vitro or cell-free system comprising GCREC under conditions suitable for GCREC activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of GCREC may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding GCREC or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent No. 5,175,383 and U.S. Patent No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Embryonic stem (ES) cells may be differentiated into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al.

Polynucleotides encoding GCREC can also be used to create "knockin" humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding GCREC is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress GCREC, e.g., by secreting GCREC in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) *Biotechnol. Annu. Rev.* 4:55-74).

## 10 THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of GCREC and G-protein coupled receptors. In addition, the expression of GCREC is closely associated with brain tissue. Therefore, GCREC appears to play a role in cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections. In the treatment of disorders associated with increased GCREC expression or activity, it is desirable to decrease the expression or activity of GCREC. In the treatment of disorders associated with decreased GCREC expression or activity, it is desirable to increase the expression or activity of GCREC.

Therefore, in one embodiment, GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial

insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease,  $\alpha_1$ -antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver disease, and cholelithiasis, adenomas, and carcinomas; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia,

autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and tongavirus.

In another embodiment, a vector capable of expressing GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified GCREC in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of GCREC may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those listed above.

In a further embodiment, an antagonist of GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC. Examples of such disorders include, but are not limited to, those cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections described above. In one aspect, an antibody which specifically binds GCREC may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GCREC.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary



sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of GCREC may be produced using methods which are generally known in the art. In particular, purified GCREC may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GCREC. Antibodies to GCREC may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with GCREC or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GCREC have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of GCREC amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to GCREC may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and

additionally techniques developed for the production of chimeric antibodies, such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc.

Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce GCREC-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for GCREC may also be generated. For example, such fragments include, but are not limited to,  $F(ab')_2$  fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the  $F(ab')_2$  fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GCREC and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GCREC epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GCREC. Affinity is expressed as an association constant,  $K_a$ , which is defined as the molar concentration of GCREC-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The  $K_a$  determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GCREC epitopes, represents the average affinity, or avidity, of the antibodies for GCREC. The  $K_a$  determined for a preparation of monoclonal antibodies, which are monospecific for a particular GCREC epitope, represents a true measure of affinity. High-affinity antibody preparations with  $K_a$  ranging from about  $10^9$  to  $10^{12}$  L/mole are preferred for use in immunoassays in which the GCREC-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with  $K_a$  ranging from about  $10^6$  to  $10^7$  L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GCREC, preferably in active form, from the

antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of GCREC-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding GCREC, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding GCREC. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GCREC. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding GCREC may be used for

the treatment of a severe combined immunodeficiency (SCID) disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency

(Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in GCREC expression or regulation causes disease, the expression of GCREC from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

15 In a further embodiment of the invention, diseases or disorders caused by deficiencies in GCREC are treated by constructing mammalian expression vectors encoding GCREC and introducing these vectors by mechanical means into GCREC-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and 20 (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of GCREC include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors 25 (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). GCREC may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or  $\beta$ -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. 30 USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V. and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous

gene encoding GCREC from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental  
5 parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with  
10 respect to GCREC expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding GCREC under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are  
15 commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) *Proc. Natl. Acad. Sci. USA* 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) *J. Virol.* 61:1647-1650; Bender, M.A. et al. (1987) *J. Virol.* 61:1639-1646; Adam, M.A. and  
20 A.D. Miller (1988) *J. Virol.* 62:3802-3806; Dull, T. et al. (1998) *J. Virol.* 72:8463-8471; Zufferey, R. et al. (1998) *J. Virol.* 72:9873-9880). U.S. Patent No. 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4<sup>+</sup> T-cells), and the  
25 return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) *J. Virol.* 71:7020-7029; Bauer, G. et al. (1997) *Blood* 89:2259-2267; Bonyhadi, M.L. (1997) *J. Virol.* 71:4707-4716; Ranga, U. et al. (1998) *Proc. Natl. Acad. Sci. USA* 95:1201-1206; Su, L. (1997) *Blood* 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver  
30 polynucleotides encoding GCREC to cells which have one or more genetic abnormalities with respect to the expression of GCREC. The construction and packaging of adenovirus-based vectors are well known in the art and are incorporated by reference herein. Adenovirus-based vectors are versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csote, M.E. et al. (1995) *Transplantation* 27:263-268). Potentially useful adenoviral vectors are

described in U.S. Patent No. 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) *Annu. Rev. Nutr.* 19:511-544 and Verma, I.M. and N. Somia (1997) *Nature* 18:389:239-242, both incorporated by reference herein.

5 In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding GCREC to target cells which have one or more genetic abnormalities with respect to the expression of GCREC. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing GCREC to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with  
10 ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) *Exp. Eye Res.* 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent No. 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is hereby incorporated by reference. U.S. Patent No. 5,804,413 teaches the use of recombinant HSV d92  
15 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) *J. Virol.* 73:519-532 and Xu, H. et al. (1994) *Dev. Biol.* 163:152-161, hereby incorporated by reference. The manipulation of cloned  
20 herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to  
25 deliver polynucleotides encoding GCREC to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) *Curr. Opin. Biotechnol.* 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA,  
30 resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for GCREC into the alphavirus genome in place of the capsid-coding region results in the production of a large number of GCREC-coding RNAs and the synthesis of high levels of GCREC in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a  
35 persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN)

indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of GCREC into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of

5 manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can

10 be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A

15 complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example,

20 engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GCREC.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides,

25 corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared

30 by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, complementary cDNA clones may be synthesized using recombinant DNA technology. cDNA clones may be constructed using plasmid vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA

35 constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell

lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding GCREC. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased GCREC expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding GCREC may be therapeutically useful, and in the treatment of disorders associated with decreased GCREC expression or activity, a compound which specifically promotes expression of the polynucleotide encoding GCREC may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding GCREC is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding GCREC are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding GCREC. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to



a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruice, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of GCREC, antibodies to GCREC, and mimetics, agonists, antagonists, or inhibitors of GCREC.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting drugs has been used to deliver drugs directly to the lungs. However, pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without

needle injection, and obviates the need for potentially toxic penetration enhancers.

Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

5 Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising GCREC or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, GCREC or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to  
10 transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and  
15 route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example GCREC or fragments thereof, antibodies of GCREC, and agonists, antagonists or inhibitors of GCREC, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be  
20 determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the  $ED_{50}$  (the dose therapeutically effective in 50% of the population) or  $LD_{50}$  (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the  $LD_{50}/ED_{50}$  ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are  
25 used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the  $ED_{50}$  with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the  
30 subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or  
35 biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about 0.1  $\mu\text{g}$  to 100,000  $\mu\text{g}$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

## DIAGNOSTICS

In another embodiment, antibodies which specifically bind GCREC may be used for the diagnosis of disorders characterized by expression of GCREC, or in assays to monitor patients being treated with GCREC or agonists, antagonists, or inhibitors of GCREC. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for GCREC include methods which utilize the antibody and a label to detect GCREC in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

A variety of protocols for measuring GCREC, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of GCREC expression. Normal or standard values for GCREC expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to GCREC under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of GCREC expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding GCREC may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of GCREC may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of GCREC, and to monitor regulation of GCREC levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide identity markers and sequences which encode GCREC. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the

probe identifies only naturally occurring sequences encoding GCREC, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the GCREC encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:17-32 or from genomic sequences including promoters, enhancers, and introns of the GCREC gene.

Means for producing specific hybridization probes for DNAs encoding GCREC include the cloning of polynucleotide sequences encoding GCREC or GCREC derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding GCREC may be used for the diagnosis of disorders associated with expression of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic

paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular disorder such as

5 arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid

10 aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal

15 carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease,

20 Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease,  $\alpha_1$ -antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis,

25 peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia,

30 autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis,

allergic rhinitis, eczema, vitiligo, atrophic gastritis, proctocolonephritis, Crohn's disease, multiple sclerosis, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome,

35 multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis,

osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic  
5 infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and tongavirus. The polynucleotide sequences encoding GCREC may be used in Southern or northern analysis, dot blot, or  
10 other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GCREC expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding GCREC may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide  
15 sequences encoding GCREC may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding GCREC in the  
20 sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of GCREC, a normal or standard profile for expression is established. This may be accomplished by  
25 combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GCREC, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values  
30 obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from  
35 successive assays may be used to show the efficacy of treatment over a period ranging from several

With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding GCREC may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding GCREC, or a fragment of a polynucleotide complementary to the polynucleotide encoding GCREC, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the

Other methods that may be used to quantify the expression of GCREC include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) *J. Immunol. Methods* 159:235-244; Duplaa, C.

et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

5 In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene  
10 function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and  
15 display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, GCREC, fragments of GCREC, or antibodies specific for GCREC may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

20 A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent No.  
25 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The  
30 resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention  
35 may also be used in conjunction with in vitro model systems and preclinical evaluation of



pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) *Mol. Carcinog.* 24:153-159; Steiner, S. and N.L. Anderson (2000) *Toxicol. Lett.* 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating

proteins by two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins

are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for GCREC to quantify the levels of GCREC expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoz, L.G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological

sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding GCREC may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding GCREC on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the

Linkage analysis using chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse,

may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) *Nature* 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, GCREC, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between GCREC and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with GCREC, or fragments thereof, and washed. Bound GCREC is then detected by methods well known in the art. Purified GCREC can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GCREC specifically compete with a test compound for binding GCREC. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GCREC.

In additional embodiments, the nucleotide sequences which encode GCREC may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, including U.S. Ser. No. 60/236,546, U.S. Ser. No. 60/240,589, U.S. Ser. No. 60/242,223, U.S. Ser.

## EXAMPLES

### 5 I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic  
10 solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was  
15 isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA  
20 libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the  
25 appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid  
30 (Invitrogen, Carlsbad CA), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto CA), or pINCY (Incyte

Genomics, Palo Alto CA). The libraries were packaged using the supra described method using ElectroMAX DH10B from Life Technologies.

### 35 II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

### III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary

structures of gene families. See, for example, Eddy, S.R. (1996) *Curr. Opin. Struct. Biol.* 6:361-365.)

The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER.

The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences.

Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or

5 Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may  
10 begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering,  
15 South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of  
20 Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a  
25 match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:17-32. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and  
30 amplification technologies are described in Table 4, column 4.

#### **IV. Identification and Editing of Coding Sequences from Genomic DNA**

Identification program against public genomic sequence databases (e.g., genbank and genbank) is a general-purpose gene identification program which analyzes genomic DNA sequences from a  
35 variety of organisms (See Burge, C. and S. Karlin (1997) *J. Mol. Biol.* 268:78-94, and Burge, C. and

S. Karlin (1998) *Curr. Opin. Struct. Biol.* 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode G-protein coupled receptors, the encoded polypeptides were analyzed by querying against PFAM models for G-protein coupled receptors. Potential G-protein coupled receptors were also identified by homology to Incyte cDNA sequences that had been annotated as G-protein coupled receptors. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbprl public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

#### V. Assembly of Genomic Sequence Data with cDNA Sequence Data

##### 20 "Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent



type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

5 **"Stretched" Sequences**

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST  
10 analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous  
15 genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

**VI. Chromosomal Mapping of GCREC Encoding Polynucleotides**

The sequences which were used to assemble SEQ ID NO:17-32 were compared with  
20 sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:17-32 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for  
25 Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between  
30 chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in human genome.)

Human genome maps include markers mapped by radiation hybrid techniques and markers whose sequences were included in each of the clusters. Human genome maps and other  
35 resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site

(<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

## VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel (1995) *supra*, ch. 4 and 16.)

Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum \{length(Seq. 1), length(Seq. 2)\}}}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

Alternatively, polynucleotide sequences encoding GCRC are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia,

male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding GCRC. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA).

#### VIII. Extension of GCRC Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing  $Mg^{2+}$ ,  $(NH_4)_2SO_4$ , and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100  $\mu$ l PICOGREEN reagent into each well of a 96-well opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the

concentration of DNA. A 5  $\mu$ l to 10  $\mu$ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

#### **IX. Labeling and Use of Individual Hybridization Probes**

Hybridization probes derived from SEQ ID NO:17-32 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane-based

hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

#### X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Skena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Skena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

#### 1. Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)<sup>+</sup> RNA is purified using the oligo-(dT) cellulose method. Each poly(A)<sup>+</sup> RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/ $\mu$ l oligo-(dT) primer (21mer), 1X first

strand buffer, 0.03 units/ $\mu$ l RNase inhibitor, 500  $\mu$ M dATP, 500  $\mu$ M dGTP, 500  $\mu$ M dTTP, 40  $\mu$ M dCTP, 40  $\mu$ M dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)<sup>+</sup> RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)<sup>+</sup> RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37°C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85°C to stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and resuspended in 14  $\mu$ l 5X SSC/0.2% SDS.

### Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5  $\mu$ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in U.S. Patent No. 5,807,522, incorporated herein by reference. 1  $\mu$ l of the array element DNA, at an average concentration of 100 ng/ $\mu$ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

### Hybridization

Hybridization reactions contain 9  $\mu$ l of sample mixture consisting of 0.2  $\mu$ g each of Cy3 and

Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm<sup>2</sup> coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140  
5  $\mu$ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC, 0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

### Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an  
10 Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a  
15 resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The  
20 emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on  
25 the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and  
30 adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital converter. The digitized signal intensity is mapped using a  
linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high  
35 signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and

measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

## XI. Complementary Polynucleotides

Sequences complementary to the GCREC-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GCREC. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of GCREC. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GCREC-encoding transcript.

## XII. Expression of GCREC

Expression and purification of GCREC is achieved using bacterial or virus-based expression systems. For expression of GCREC in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac (tac)* hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express GCREC upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GCREC in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding GCREC by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, GCREC is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step,



affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GCREC at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified GCREC obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.

### XIII. Functional Assays

GCREC function is assessed by expressing the sequences encoding GCREC at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10  $\mu$ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2  $\mu$ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are

GCREC function can be assessed using highly purified populations of cells transfected with sequences encoding GCREC and either CD64 or CD64-GFP.

CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions

of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding GCREC and other genes of interest can be analyzed by northern analysis or microarray techniques.

#### **XIV. Production of GCREC Specific Antibodies**

GCREC substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the GCREC amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-GCREC activity by, for example, binding the peptide or GCREC to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

#### **XV. Purification of Naturally Occurring GCREC Using Specific Antibodies**

Naturally occurring or recombinant GCREC is substantially purified by immunoaffinity chromatography using antibodies specific for GCREC. An immunoaffinity column is constructed by covalently coupling anti-GCREC antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing GCREC are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of GCREC (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GCREC binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GCREC is collected.

#### **XVI. Identification of Molecules Which Interact with GCREC**

Molecules which interact with GCREC may include agonists and antagonists, as well as

molecules involved in signal transduction, such as G proteins. GCREC, or a fragment thereof, is labeled with  $^{125}\text{I}$  Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) A fragment of GCREC includes, for example, a fragment comprising one or more of the three extracellular loops, the extracellular N-terminal region, or the third intracellular loop.

- 5 Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GCREC, washed, and any wells with labeled GCREC complex are assayed. Data obtained using different concentrations of GCREC are used to calculate values for the number, affinity, and association of GCREC with the candidate ligand molecules.

- Alternatively, molecules interacting with GCREC are analyzed using the yeast two-hybrid  
10 system as described in Fields, S. and O. Song (1989) *Nature* 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech). GCREC may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S.  
15 Patent No. 6,057,101).

Potential GCREC agonists or antagonists may be tested for activation or inhibition of GCREC receptor activity using the assays described in sections XVII and XVIII. Candidate molecules may be selected from known GPCR agonists or antagonists, peptide libraries, or combinatorial chemical libraries.

- 20 Methods for detecting interactions of GCREC with intracellular signal transduction molecules such as G proteins are based on the premise that internal segments or cytoplasmic domains from an orphan G protein-coupled seven transmembrane receptor may be exchanged with the analogous domains of a known G protein-coupled seven transmembrane receptor and used to identify the G-proteins and downstream signaling pathways activated by the orphan receptor domains (Kobilka, B.K.  
25 et al. (1988) *Science* 240:1310-1316). In an analogous fashion, domains of the orphan receptor may be cloned as a portion of a fusion protein and used in binding assays to demonstrate interactions with specific G proteins. Studies have shown that the third intracellular loop of G protein-coupled seven transmembrane receptors is important for G protein interaction and signal transduction (Conklin, B.R. et al. (1993) *Cell* 73:631-641). For example, the DNA fragment corresponding to the third intracellular  
30 loop of GCREC may be amplified by the polymerase chain reaction (PCR) and subcloned into a fusion vector such as pGEX (Pharmacia Biotech). The construct is transformed into an appropriate bacterial

#### affinity protein affinity chromatography

- For in vitro binding assays, cell extracts containing G proteins are prepared by extraction with  
35 50 mM Tris, pH 7.8, 1 mM EGTA, 5 mM  $\text{MgCl}_2$ , 20 mM CHAPS, 20% glycerol, 10  $\mu\text{g}$  of both

aprotinin and leupeptin, and 20  $\mu$ l of 50 mM phenylmethylsulfonyl fluoride. The lysate is incubated on ice for 45 min with constant stirring, centrifuged at 23,000 g for 15 min at 4°C, and the supernatant is collected. 750  $\mu$ g of cell extract is incubated with glutathione S-transferase (GST) fusion protein beads for 2 h at 4°C. The GST beads are washed five times with phosphate-buffered saline. Bound G protein subunits are detected by [<sup>32</sup>P]ADP-ribosylation with pertussis or cholera toxins. The reactions are terminated by the addition of SDS sample buffer (4.6% (w/v) SDS, 10% (v/v)  $\beta$ -mercaptoethanol, 20% (w/v) glycerol, 95.2 mM Tris-HCl, pH 6.8, 0.01% (w/v) bromophenol blue). The [<sup>32</sup>P]ADP-labeled proteins are separated on 10% SDS-PAGE gels, and autoradiographed. The separated proteins in these gels are transferred to nitrocellulose paper, blocked with blotto (5% nonfat dried milk, 50 mM Tris-HCl (pH 8.0), 2 mM CaCl<sub>2</sub>, 80 mM NaCl, 0.02% NaN<sub>3</sub>, and 0.2% Nonidet P-40) for 1 hour at room temperature, followed by incubation for 1.5 hours with G $\alpha$  subtype selective antibodies (1:500; Calbiochem-Novabiochem). After three washes, blots are incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin (1:2000, Cappel, Westchester PA) and visualized by the chemiluminescence-based ECL method (Amersham Corp.).

## **XVII. Demonstration of GCREC Activity**

An assay for GCREC activity measures the expression of GCREC on the cell surface. cDNA encoding GCREC is transfected into an appropriate mammalian cell line. Cell surface proteins are labeled with biotin as described (de la Fuente, M.A. et al. (1997) Blood 90:2398-2405). Immunoprecipitations are performed using GCREC-specific antibodies, and immunoprecipitated samples are analyzed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of GCREC expressed on the cell surface.

In the alternative, an assay for GCREC activity is based on a prototypical assay for ligand/receptor-mediated modulation of cell proliferation. This assay measures the rate of DNA synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides encoding GCREC is added to quiescent 3T3 cultured cells using transfection methods well known in the art. The transiently transfected cells are then incubated in the presence of [<sup>3</sup>H]thymidine, a radioactive DNA precursor molecule. Varying amounts of GCREC ligand are then added to the cultured cells. Incorporation of [<sup>3</sup>H]thymidine into acid-precipitable DNA is measured over an appropriate time interval using a radioisotope counter, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold GCREC ligand concentration range is indicative of receptor activity. One unit of activity per milliliter is defined as the concentration of GCREC producing a 50% response level, where 100% represents maximal incorporation of [<sup>3</sup>H]thymidine into acid-precipitable DNA (McKay, I. and I. Leigh, eds. (1993)

Growth Factors: A Practical Approach, Oxford University Press, New York NY, p. 73.)

In a further alternative, the assay for GCREC activity is based upon the ability of GPCR family proteins to modulate G protein-activated second messenger signal transduction pathways (e.g., cAMP; Gaudin, P. et al. (1998) J. Biol. Chem. 273:4990-4996). A plasmid encoding full length GCREC is transfected into a mammalian cell line (e.g., Chinese hamster ovary (CHO) or human embryonic kidney (HEK-293) cell lines) using methods well-known in the art. Transfected cells are grown in 12-well trays in culture medium for 48 hours, then the culture medium is discarded, and the attached cells are gently washed with PBS. The cells are then incubated in culture medium with or without ligand for 30 minutes, then the medium is removed and cells lysed by treatment with 1 M perchloric acid. The cAMP levels in the lysate are measured by radioimmunoassay using methods well-known in the art. Changes in the levels of cAMP in the lysate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.

To measure changes in inositol phosphate levels, the cells are grown in 24-well plates containing  $1 \times 10^5$  cells/well and incubated with inositol-free media and [ $^3\text{H}$ ]myoinositol, 2  $\mu\text{Ci}$ /well, for 48 hr. The culture medium is removed, and the cells washed with buffer containing 10 mM LiCl followed by addition of ligand. The reaction is stopped by addition of perchloric acid. Inositol phosphates are extracted and separated on Dowex AG1-X8 (Bio-Rad) anion exchange resin, and the total labeled inositol phosphates counted by liquid scintillation. Changes in the levels of labeled inositol phosphate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.

#### **XVIII. Identification of GCREC Ligands**

GCREC is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or HEK (Human Embryonic Kidney) 293 which have a good history of GPCR expression and which contain a wide range of G-proteins allowing for functional coupling of the expressed GCREC to downstream effectors. The transformed cells are assayed for activation of the expressed receptors in the presence of candidate ligands. Activity is measured by changes in intracellular second messengers, such as cyclic AMP or  $\text{Ca}^{2+}$ . These may be measured directly using standard methods well known in the art, or by the use of reporter gene assays in which a luminescent protein (e.g. firefly luciferase or green fluorescent protein) is under the transcriptional control of a promoter responsive to the stimulation of protein kinase C by the activated receptor (Milligan, G. et al. (1996) Trends Pharmacol. Sci. 17:235-237). Assay technologies are available for both of these second messenger

assays. For example, changes in intracellular  $\text{Ca}^{2+}$  levels can be measured using fluorescent indicators such as Fluo-4 AM (Molecular Probes) in combination with the FLIPR fluorimetric plate reading system (Molecular Devices). In cases where the physiologically relevant second messenger pathway is not

known, GCREC may be coexpressed with the G-proteins  $G_{\alpha 15/16}$  which have been demonstrated to couple to a wide range of G-proteins (Offermanns, S. and M.I. Simon (1995) J. Biol. Chem. 270:15175-15180), in order to funnel the signal transduction of the GCREC through a pathway involving phospholipase C and  $Ca^{2+}$  mobilization. Alternatively, GCREC may be expressed in  
5 engineered yeast systems which lack endogenous GPCRs, thus providing the advantage of a null background for GCREC activation screening. These yeast systems substitute a human GPCR and  $G_{\alpha}$  protein for the corresponding components of the endogenous yeast pheromone receptor pathway. Downstream signaling pathways are also modified so that the normal yeast response to the signal is converted to positive growth on selective media or to reporter gene expression (Broach, J.R. and J.  
10 Thorner (1996) Nature 384 (supp.):14-16). The receptors are screened against putative ligands including known GPCR ligands and other naturally occurring bioactive molecules. Biological extracts from tissues, biological fluids and cell supernatants are also screened.

Various modifications and variations of the described methods and systems of the invention  
15 will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the  
20 following claims.

Table 1

| Incyte<br>Object ID | Polypeptide<br>SEQ ID NO: | Incyte<br>Polypeptide ID | Polynucleotide<br>SEQ ID NO: | Incyte<br>Polynucleotide ID |
|---------------------|---------------------------|--------------------------|------------------------------|-----------------------------|
| 2536292             | 1                         | 2536292CD1               | 17                           | 2536292CB1                  |
| 7477708             | 2                         | 7477708CD1               | 18                           | 7477708CB1                  |
| 7474823             | 3                         | 7474823CD1               | 19                           | 7474823CB1                  |
| 644692              | 4                         | 644692CD1                | 20                           | 644692CB1                   |
| 3837054             | 5                         | 3837054CD1               | 21                           | 3837054CB1                  |
| 6157025             | 6                         | 6157025CD1               | 22                           | 6157025CB1                  |
| 5012817             | 7                         | 5012817CD1               | 23                           | 5012817CB1                  |
| 7475061             | 8                         | 7475061CD1               | 24                           | 7475061CB1                  |
| 7477374             | 9                         | 7477374CD1               | 25                           | 7477374CB1                  |
| 7479890             | 10                        | 7479890CD1               | 26                           | 7479890CB1                  |
| 482825              | 11                        | 7482825CD1               | 27                           | 7482825CB1                  |
| 483087              | 12                        | 7483087CD1               | 28                           | 7483087CB1                  |
| 483134              | 13                        | 7483134CD1               | 29                           | 7483134CB1                  |
| 478550              | 14                        | 7478550CD1               | 30                           | 7478550CB1                  |
| 483142              | 15                        | 7483142CD1               | 31                           | 7483142CB1                  |
| 483151              | 16                        | 7483151CD1               | 32                           | 7483151CB1                  |

Table 2

| Polypeptide<br>SEQ ID NO: | Incyte<br>Polypeptide<br>ID | GenBank<br>ID NO:    | Probability<br>Score | GenBank<br>Homolog   |
|---------------------------|-----------------------------|----------------------|----------------------|--|
| 1                         | 2536292CD1                  | g1039470             | 8.1E-07              | [Rattus norvegicus] pheromone receptor VN1<br>(Dulac, C. and R. Axel (1996) Cell 83:195-206)   |
| 2                         | 7477708CD1                  | g5525078             | 1.2E-89              | [Rattus norvegicus] seven transmembrane receptor<br>(Abe, J. et al. (1999) J. Biol. Chem. 274:19957-19964)   |
| 3                         | 7474823CD1                  | g10241847            | 6.0E-79              | [Homo sapiens] histamine H4 receptor<br>(Oda, T. et al. (2000) J. Biol. Chem. 275:36781-36786)   |
| 4                         | 644692CD1                   | g2117161             | 3.2E-35              | [Homo sapiens] seven transmembrane-domain receptor<br>(Osterhoff, C. et al. (1997) DNA Cell Biol. 16:379-389)  |
| 5                         | 3837054CD1                  | g1902964             | 7.1E-21              | [Mus sp.] oxytocin receptor<br>(Kubota, Y. (1996) Mol. Cell. Endocrinol. 124:25-32)  |
| 6                         | 6157025CD1                  | g5359718             | 2.5E-21              | [Homo sapiens] cysteinyl leukotriene receptor<br>(Sarau, H.M. et al. (1999) Mol. Pharmacol. 56:657-663)  |
| 7                         | 55012817CD1                 | g6006811             | 8.6E-60              | [Mus musculus] serpentine receptor   |
| 8                         | 7475061CD1                  | g440626              | 2.2E-22              | [Astyanax mexicanus] opsin   |
| 9                         | 7477374CD1                  | g14600082            | 0.0                  | [Homo sapiens] trace amine receptor 3<br>(Borowsky, B. et al. (2001) Proc. Natl. Acad. Sci. USA<br>98:8966-8971)   |
| 10                        | 7479890CD1                  | g10441732            | 0.0                  | [Homo sapiens] leucine-rich repeat-containing G<br>protein-coupled receptor 6<br>(Hsu, S.Y. et al. (2000) Mol. Endocrinol. 14:1257-1271)                     |
| 11                        | 7482825CD1                  | g4680254             | 1.3E-68              | [Mus musculus] odorant receptor S1<br>(Hirono, M.B. et al. (1999) Cell 96:713-723)   |
| 12                        | 7483087CD1                  | g5901488<br>g2792018 | 1.5E-101<br>8.4E-99  | [Marmota marmota] olfactory receptor<br>[Homo sapiens] olfactory receptor<br>(Vanderhaeghen, P. et al. (1997) Biochem. Biophys. Res.<br>Commun. 237:283-287) |
| 13                        | 7483134CD1                  | g6178008             | 8.3E-92              | [Mus musculus] odorant receptor MOR18<br>(Tsuboi, A. et al. (1999) J. Neurosci. 19:8409-8418)  |
| 14                        | 7478550CD1                  | g3983394             | 1.2E-53              | [Mus musculus] olfactory receptor F7<br>(Krautwurst, D. et al. (1998) Cell 95:917-926)   |
| 15                        | 7483142CD1                  | g1246534             | 1.1E-91              | [Gallus gallus] olfactory receptor 4<br>(Leibovici, M. et al. (1996) Dev. Biol. 175:118-131)   |
| 16                        | 7483151CD1                  | g1246532             | 1.9E-78              | [Gallus gallus] olfactory receptor 3<br>(Leibovici, M. et al. (1996) Dev. Biol. 175:118-131)   |



Table 3

| Seq ID NO | Protein ID | Amino Acid Residues | Potential Phosphorylation Sites   | Potential Glycosylation Sites      | Signature Sequences, Domains and Motifs   | Analytical Methods and Databases   |
|-----------|------------|---------------------|---|------------------------------------|---|--|
| 1         | 292CD1     | 217                 | S183 S53 T172<br>T206 T45 Y128  | N117 N181                          | Transmembrane domain: L63-L88   | HMMER  |
| 2         | 708CD1     | 578                 | S179 S196<br>S224 S248<br>S255 S570<br>T185 T190<br>T346 T46 T499<br>T539 T97 S4<br>T16 T51 | N122 N130<br>N175 N183<br>N228 N90 | Transmembrane domains:<br>Y318-V341, L400-I419, I479-V497<br>7 transmembrane receptor (secretin family): S313-V560<br>Latrophilin/CL-1-like GPS domain:<br>R260-L311<br>Secretin-like GPCR super family:<br>I518-A538, S376-F397, Y318-W342, T9-V33, A390-I413<br>G-protein coupled receptor PD000752:<br>S307-Q559<br>EMRI hormone receptor:<br>DM05221 I37225 347-738: C264-Q559<br>DM05221 P48960 347-738: C265-Q559<br>DM05221 A57172 465-886: V231-F558<br>Signal peptide: M1-A51<br>Transmembrane domain: Y226-N247<br>7 transmembrane receptor (rhodopsin family): F131-W255<br>G-protein coupled receptor motif:<br>A153-V169<br>G-protein coupled receptors signature: D147-V194<br>G-protein coupled receptor BL00237:<br>W133-A172, F236-N247, T177-M203<br>Rhodopsin-like GPCR superfamily PR00237:<br>K184-L205, L228-Y251, V182-V206, W225-Y251, K184-E208, D147-V169 | HMMER<br>HMMER-PFAM<br>HMMER-PFAM<br>HMMER-PFAM<br>BLIMPS-PRINTS<br>BLAST-PRODOM<br>BLAST-DOMO<br>SPScan<br>HMMER<br>HMMER-PFAM<br>MOTIFS<br>ProfileScan<br>BLIMPS-BLOCKS<br>BLIMPS-PRINTS |
| 3         | 823CD1     | 441                 | S174 S209<br>S215 S232<br>S314 S322<br>S359 S415<br>T129 T320<br>T363 T428<br>T433          | N324 N393<br>N6                    |   |  |

Table 3 (cont.)

| SEQ ID NO: | Incyte Polypeptide ID | Amino Acid Residues | Potential Phosphorylation Sites   | Potential Glycosylation Sites   | Signature Sequences, Domains and Motifs  | Analytical Methods and Databases  |
|------------|-----------------------|---------------------|---|---|--|---|
| 3          |                       |                     |   |   | G-protein coupled receptor:<br>DM00013 P30546 22-383: V119-H259<br>DM00013 P22270 103-599: S118-R257<br>DM00013 S58868 45-481: S118-R257<br>DM00013 P31390 21-315: I120-G281   | BLAST-DOMO  |
| 4          | 644692CD1             | 797                 | S249 S3 S344<br>S349 S350<br>S368 S389<br>S466 S492<br>S499 S647<br>S660 S665<br>S666 S696<br>S746 S781<br>S788 T192<br>T225 T233<br>T294 T338<br>T423 T459 T47<br>T558 T661<br>T721 T768<br>T786 | N159 N178<br>N191 N247<br>N261 N312<br>N316 N387<br>N413 N657<br>N709 N82 | Egf: C63-C74<br>Signal_peptide: M1-G26<br>Transmembrane domain: N8-W30, V470-I489, I567-Q592, V632-W652, S672-L689<br>7 transmembrane receptor (Secretin family) 7tm_2: P431-V726<br>Latrophilin/CL-1-like GPS domain GPS: Y379-D427<br>G-protein coupled receptor BL00649: S389-T416, G441-V486, C526-L551, G574-Q598, W626-N655, S666-A687, T710-L735<br>C.elegans integral membrane protein Srb signature PR00699E: V467-F487<br>HORMONE; EMR1; LEUCOCYTE; ANTIGEN: DM05221 A57172 465-886: C526-Y720<br>DM05221 I37225 347-738: Y603-T751<br>GPROTEIN COUPLED TRANSMEMBRANE RECEPTOR PD000752: N511-E730<br>G-PROTEIN COUPLED RECEPTORS: DM00013 P47901 28-353: R43-V182, W260-A357, W227-L256<br>G-protein coupled receptor BL00237: A115-P154, R288-A314, N344-C360<br>Transmembrane domain: R45-C65<br>7-transmembrane receptor (rhodopsin family, 7tm_1): G59-F181, H228-Y352<br>Signal cleavage: M1-A58 | MOTIFS<br>HMER<br>HMER<br>HMER-PFAM<br>HMER-PFAM<br>BLIMPS-BLOCKS<br>BLIMPS-PRINTS<br>BLAST-DOMO<br>BLAST-PRODROM<br>BLAST-DOMO<br>BLIMPS-BLOCKS<br>HMER<br>HMER-PFAM<br>SPSCAN |
| 5          | 3837054CD1            | 434                 | S41 S131 S293   | N15 N27<br>N60  |  |   |

Table 3 (cont.)

| Seq. ID No. | Anticpeptide ID | Amino Acid Residues | Potential Phosphorylation Sites                       | Potential Glycosylation Sites | Signature Sequences, Domains and Motifs  | Analytical Methods and Databases                               |
|-------------|-----------------|---------------------|---|-------------------------------|--|--|
| 7           | 7025CD1         | 339                 | T6 S10 Y175<br>S217 S276<br>S332                      | N5 N9 N308                    | G-PROTEIN COUPLED RECEPTORS:<br>DM00013 P34993 36-327: L20-F285<br>DM00013 P30872 52-338: L20-F285<br>G-protein coupled receptor BL00237:<br>H218-F244, N9-F25, W81-C120<br>Transmembrane domain: I21-M45,<br>V43-S63, M99-I116, M139-Y155,<br>I185-V208, N227-L249  | BLAST-DOMO   |
| 7           | 2817CD1         | 549                 | S19 S57 T103<br>T153 T224 T3<br>T407 T415<br>T537 T84 | N144 N210<br>N413 N98         | Signal peptide: M1-G20<br>Signal peptide: M1-E22<br>Transmembrane domains:<br>G499-I523, L477-F495, H436-F458,<br>Y378-L405, A274-L293<br>7 transmembrane receptor (Secretin family): V265-S528<br>G-protein coupled receptor BL00649:<br>M280-V325, C338-L363, G386-D410,<br>Y429-F458, N472-A493<br>Secretin-like GPCR superfamily<br>PR00249:<br>R270-R294, A340-L363, F379-G404,<br>L492-I517, K475-F495, V503-L524<br>EMR1 leucocyte antigen:<br>DM05221 I37225 347-738: P207-I517<br>DM05221 P48960 347-738: P207-I517<br>DM05221 A57172 465-886: L177-I517<br>G-protein coupled receptor PD000752:<br>I271-L524 | SPScan<br>HMMER<br>HMMER<br>HMMER-PFAM                         |
| 8           | 061CD1          | 188                 | S163 S179 S64<br>T159 T174                            |                               | Signal peptide: M1-I50<br>Transmembrane domains:<br>F34-F52, M90-F112  | BLIMPS-PRINTS<br>BLAST-DOMO<br>BLAST-PRODOR<br>SPScan<br>HMMER |

Table 3 (cont.)

| SEQ ID NO: | Incyte Polypeptide ID | Amino Acid Residues | Potential Phosphorylation Sites      | Potential Glycosylation Sites | Signature Sequences, Domains and Motifs   | Analytical Methods and Databases  |
|------------|-----------------------|---------------------|--------------------------------------|-------------------------------|---|---|
| 8          |                       |                     |                                      |                               | 7 transmembrane receptor (rhodopsin family): I38-Y141<br>Visual pigments (opsins) retinal binding site: A130-F148<br>Visual pigments (opsins) retinal binding site: A111-G166<br>G-protein coupled receptor BL00237: P13-F52, L43-Y54, V80-V106, A133-A149<br>Rhodopsin-like GPCR superfamily PR00237: L36-K60, G31-F52, A27-V49, L91-F112, I35-I58, L85-W109, S123-A149<br>G-protein coupled receptors: DM00013 P51472 36-326: P2-C151<br>DM00013 S39028 36-326: P2-C151<br>DM00013 P32312 31-322: P2-C151<br>DM00013 P32310 35-326: P2-C151 | HMMER-PFAM<br>MOTIFS<br>ProfileScan<br>BLIMPS-BLOCKS<br>BLIMPS-PRINTS<br>BLAST-DOMO |
| 9          | 7477374CD1            | 332                 | S224 S228<br>S311 S6 T109<br>T90 Y99 | N19 N4                        | Transmembrane domains: S33-I55, F187-V207<br>7 transmembrane receptor (rhodopsin family): G49-Y131, V183-Y295<br>G-protein coupled receptor BL00237: W98-W137, F190-Y201, K235-D261, N287-G303<br>Rhodopsin-like GPCR superfamily PR00237: T67-F88, D112-G134, W182-F205, A240-I264, Y277-G303, I34-L58<br>G-protein coupled receptors: DM00013 S55549 13-327: M132-V310<br>DM00013 P32251 21-399: P26-A240<br>DM00013 I49480 45-449: Y27-A222<br>DM00013 P18825 45-452: Y27-I215   | HMMER<br>HMMER-PFAM<br>BLIMPS-BLOCKS<br>BLIMPS-PRINTS<br>BLAST-DOMO                 |

Table 3 (cont.)

| Sequence ID | Amino Acid Residues | Potential Phosphorylation Sites   | Potential Glycosylation Sites | Signature Sequences, Domains and Motifs  | Analytical Methods and Databases   |
|-------------|---------------------|---|-------------------------------|--|--|
| 9890CD1     | 948                 | S107 S144 S19<br>S488 S489<br>S666 S688<br>S843 S855<br>T309 Y456<br>Y504 | N189                          | G-protein coupled receptor PD000009:<br>K61-M132<br>Signal peptide: M1-G24<br>Signal peptide: M1-A25<br>Transmembrane domains:<br>A548-G571, V756-P783<br>Leucine rich repeats:<br>R239-P262, L263-P286, K287-T309,<br>S310-P333, R334-Q355, K356-S379,<br>S380-H403, S404-M427, S144-P167,<br>A168-T191, S192-H215, N216-G238<br>Leucine rich repeat N-terminal<br>domain: A34-D65<br>Leucine zipper pattern: L57-L78<br>G-protein coupled receptor BL00237:<br>R616-V655, P800-R816<br>Glycoprotein hormone receptor<br>PR00373: F533-W550, F610-C623,<br>C623-S637, W748-L766<br>G-protein coupled receptors:<br>DM00013 P14763 407-693: P535-L819<br>DM00013 P35376 355-641: P535-D818<br>DM00013 P22888 352-638: P535-D818<br>DM00013 P35409 519-807: I545-L819<br>Orphan G-protein coupled receptor<br>HG38:<br>PD175529: H428-F568<br>PD169963: M259-P333<br>PD166277: A168-H215<br>G-PROTEIN COUPLED RECEPTORS:<br>DM00013 P23270 18-311: L25-L306 | BLAST-<br>PRODOR<br>SPScan<br>HMMER<br>HMMER<br>HMMER-PFAM<br>HMMER-PFAM<br>MOTIFS<br>BLIMPS-<br>BLOCKS<br>BLIMPS-<br>PRINTS<br>BLAST-DOMO<br>BLAST-<br>PRODOR<br>BLAST-DOMO |
| 825CD1      | 315                 | S234 S54 S69<br>T10 T292 T6   | N67 N8                        |  |  |

Table 3 (cont.)

| SEQ ID NO: | Incyte Polypeptide ID | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequences, Domains and Motifs   | Analytical Methods and Databases  |
|------------|-----------------------|---------------------|---------------------------------|-------------------------------|---|---|
| 11         |                       |                     |                                 |                               | RECEPTOR OLFACTORY PROTEIN<br>RECEPTORLIKE GPROTEIN COUPLED<br>TRANSMEMBRANE GLYCOPROTEIN MULTIGENE<br>FAMILY PD000921: L167-L246<br>G-protein coupled receptors proteins<br>BL00237: T283-H299, A91-P130,<br>L208-Y219, R236-A262<br>Olfactory receptor signature PR00245:<br>M61-K82, F178-D192, F239-G254,<br>F275-F286, T292-L306<br>Rhodopsin-like GPCR superfamily<br>signature PR00237: L28-V52, M61-K82,<br>F105-I127, T200-V223, K273-H299<br>G-protein coupled receptors signature<br>g_protein_receptor.prf: F103-T149<br>Transmembrane domain: F27-V51,<br>F102-D122, M143-A165, L201-T217<br>7 transmembrane receptor (rhodopsin<br>family) 7tm_1: G43-Y291<br>G Protein Receptor: All1-I127 | BLAST-<br>PRODOM<br><br>BLIMPS-<br>BLOCKS<br><br>BLIMPS-<br>PRINTS<br><br>BLIMPS-<br>PRINTS<br><br>PROFILESCAN<br><br>HMMER<br><br>HMMER-PFAM<br><br>MOTIFS |
| 12         | 7483087CD1            | 312                 | S152 S267<br>S268 S291 S67      | N5 N93                        | G-PROTEIN COUPLED RECEPTORS:<br>DM00013 P23265 17-306: E22-I305<br>DM00013 P23268 18-307: D20-I305<br>DM00013 P30955 18-305: D20-I305<br>DM00013 S29707 18-306: P21-L301<br>RECEPTOR OLFACTORY PROTEIN<br>RECEPTORLIKE GPROTEIN COUPLED<br>TRANSMEMBRANE GLYCOPROTEIN MULTIGENE<br>FAMILY PD000921: L166-I246<br>OLFACTORY RECEPTOR PROTEIN<br>RECEPTORLIKE GPROTEIN COUPLED<br>TRANSMEMBRANE GLYCOPROTEIN MULTIGENE<br>FAMILY PD149621: V247-R307  | BLAST-<br>PRODOM<br><br>BLAST-<br>PRODOM  |

Table 3 (cont.)

| SE<br>ID<br>NO<br>1: | peptide<br>ID | Amino<br>Acid<br>Residues | Potential<br>Phosphoryla-<br>tion Sites | Potential<br>Glycosyla-<br>tion Sites | Signature Sequences,<br>Domains and Motifs   | Analytical<br>Methods and<br>Databases |
|----------------------|---------------|---------------------------|---|---------------------------------------|--|--|
| 1:                   | 134CD1        | 309                       | S227 S305 S65<br>T286 T52 T83           | N6                                    | G-protein coupled receptors proteins<br>BL00237: T282-L298, Q90-P129   | BLIMPS-<br>BLOCKS                      |
|                      |               |                           |   |                                       | Olfactory receptor signature PR00245:<br>M59-K80, F177-D191, F238-G253,<br>A274-L285, S291-I305  | BLIMPS-<br>PRINTS                      |
|                      |               |                           |   |                                       | Transmembrane domain: L30-I46,<br>Q100-M118, L143-M162, I197-F216  | HMMER                                  |
|                      |               |                           |   |                                       | 7 transmembrane receptor (rhodopsin<br>family) 7tm_1: G41-Y290   | HMMER-PFAM                             |
|                      |               |                           |   |                                       | G Protein Receptor: L110-I126  | MOTIFS                                 |
|                      |               |                           |   |                                       | G-protein coupled receptors signature<br>g_protein_receptor.prf: C102-V151   | PROFILES CAN                           |
|                      |               |                           |   |                                       | G-PROTEIN COUPLED RECEPTORS:<br>DM00013 S29710 15-301: F26-F300<br>DM00013 P23266 17-306: E20-L299<br>DM00013 S29708 18-306: E20-M296<br>DM00013 P23274 18-306: E20-M296 | BLAST-DOMO                             |
|                      |               |                           |   |                                       | RECEPTOR OLFACTORY PROTEIN<br>RECEPTORLIKE GPROTEIN COUPLED<br>TRANSMEMBRANE GLYCOPROTEIN MULTIGENE<br>FAMILY PD000921: L164-I243  | BLAST-<br>PRODOM                       |
|                      |               |                           |   |                                       | G-protein coupled receptors proteins<br>BL00237: K88-P127, P277-K293   | BLIMPS-<br>BLOCKS                      |
|                      |               |                           |   |                                       | Rhodopsin-like GPCR superfamily<br>signature PR00237: T24-N48, M57-K78,<br>A102-I124, K138-L159, V197-L220,<br>K267-K293   | BLIMPS-<br>PRINTS                      |
|                      |               |                           |   |                                       | Olfactory receptor signature<br>PR00245: M57-K78, F175-D189,<br>V235-M250, T286-F300   | BLIMPS-<br>PRINTS                      |
|                      |               |                           |   |                                       | Transmembrane domains:<br>V28-I45, I204-N222   | HMMER                                  |

Table 3 (cont.)

| SEQ ID NO: | Incyte Polypeptide ID | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequences, Domains and Motifs   | Analytical Methods and Databases   |
|------------|-----------------------|---------------------|---------------------------------|-------------------------------|---|--|
| 13         |                       |                     |                                 |                               | 7 transmembrane receptor (rhodopsin family) 7tm_1: G39-Y285<br>G Protein Receptor: T108-I124<br>G-protein coupled receptors signature g_protein_receptor.prf: F100-A145<br>Signal cleavage: M1-G39<br>Transmembrane domains: L68-I86, M238-S256<br>7 transmembrane receptor (rhodopsin family): G81-Y292<br>G-protein coupled receptors signature: F142-G186<br>G-protein coupled receptor BL00237: K130-S169 (E-value<0.018)<br>Olfactory receptor signature PR00245: M99-K120, F217-D231, F278-A293<br>Rhodopsin-like GPCR superfamily signature PR00237: F144-I166, M180-V201, V239-L262, A277-R301, F66-H90, M99-K120<br>RECEPTOR OLFACTORY G PROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY PD000921: I206-L285<br>G-PROTEIN COUPLED RECEPTORS DM00013 P23266 17-306: L67-L307<br>DM00013 S51356 18-307: L67-S305<br>DM00013 S29707 18-306: L58-T308<br>DM00013 P23274 18-306: L58-T308<br>G-protein coupled receptors signature: S150-I166 | HMMER_PFAM<br>MOTIFS<br>PROFILESCAN<br>SPSCAN<br>HMMER<br>HMMER_PFAM<br>PROFILESCAN<br>BLIMPS-BLOCKS<br>BLIMPS-PRINTS<br>BLIMPS-PRINTS<br>BLAST-PRODOR<br>BLAST-DOMO<br>MOTIFS |
| 14         | 7478550CD1            | 309                 | S107 T21 T26 T3 T48             | N46 N61                       |   |  |



Table 3 (cont.)

| ncyte<br>peptide<br>ID   | Amino<br>Acid<br>Residues | Potential<br>Phosphoryla-<br>tion Sites | Potential<br>Glycosyla-<br>tion Sites | Signature Sequences,<br>Domairs and Motifs  | Analytical<br>Methods and<br>Databases |
|--|---------------------------|---|---------------------------------------|---|--|
| 3142CD1  | 315                       | S191 S294 S70                           | N68 N8                                | Signal cleavage: M1-G54   | SPSCAN                                 |
|  |                           |   |                                       | Transmembrane domain: F31-L51   | HMMER                                  |
|  |                           |   |                                       | 7 transmembrane receptor (rhodopsin family): W44-Y293                                     | HMMER-PFAM                             |
|  |                           |   |                                       | G-protein coupled receptor BL00237: K93-P132, W238-R264, I285-K301                        | BLIMPS-BLOCKS                          |
|  |                           |   |                                       | Olfactory receptor signature PR00245: F180-D194, C241-G256, V277-L288, S294-L308, M62-N83 | BLIMPS-PRINTS                          |
|  |                           |   |                                       | GPR orphan receptor signature PR00644: I52-Y63, S294-W305                                 | BLIMPS-PRINTS                          |
|  |                           |   |                                       | G-protein coupled receptors signature: F105-V153  | PROFILES SCAN                          |
|  |                           |   |                                       | RECEPTOR OLFACTORY G PROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY:         | BLAST-PRODROM                          |
|  |                           |   |                                       | PD000921: L169-M249   | BLAST-DOMO                             |
|  |                           |   |                                       | PD149621: V250-K311   |  |
| G-PROTEIN COUPLED RECEPTORS:<br>DM00013 P37067 17-306: T21-L304<br>DM00013 S29709 11-299: T21-L308<br>DM00013 P23266 17-306: P24-L308<br>DM00013 S51356 18-307: T21-L304 |                           |   |                                       |   |  |
|  |                           |   |                                       | G-protein coupled receptors signature: S113-I129  | MOTIFS                                 |

Table 3 (cont.)

| SEQ ID NO: | Incyte Polypeptide ID | Amino Acid Residues | Potential Phosphorylation Sites | Potential Glycosylation Sites | Signature Sequences, Domains and Motifs  | Analytical Methods and Databases  |
|------------|-----------------------|---------------------|---------------------------------|-------------------------------|--|---|
| 16         | 7483151CD1            | 307                 | S230 S261<br>S266 S291 T78      | N107                          | Transmembrane domains:<br>F28-A47, I196-I215<br>7 transmembrane receptor (rhodopsin family): G41-Y290<br>G-protein coupled receptor BL00237:<br>H90-P129, I282-I298<br>G-protein coupled receptors signature: Y102-F150<br>Olfactory receptor signature PR00245:<br>S291-M305, I59-K80, F177-N191, F238-G253, Y274-L285<br>Rhodopsin-like GPCR superfamily signature PR00237:<br>I59-K80, F104-I126, I201-A224, K272-I298, P26-W50<br>RECEPTOR OLFACTORY G PROTEIN COUPLED TRANSMEMBRANE GLYCOPROTEIN MULTIGENE FAMILY:<br>PD000921: L166-L246<br>PD149621: V248-M305<br>G-PROTEIN COUPLED RECEPTORS<br>DM00013 P37067 17-306: L17-I304<br>DM00013 S51356 18-307: L17-R303<br>DM00013 S29709 11-299: T18-M305<br>DM00013 P23274 18-306: Q24-M305<br>G-protein coupled receptors signature: T110-I126 | HMMER<br>HMMER-PFAM<br>BLIMPS-BLOCKS<br>PROFILESCAN<br>BLIMPS-PRINTS<br>BLIMPS-PRINTS<br>BLAST-PRODOR<br>BLAST-DOMO<br>MOTIFS |

Table 4

| Polynucleotide NO: | Incyte Polynucleotide ID | Sequence Length | Selected Fragments                                      | Sequence Fragments                     | 5' Position | 3' Position |
|--------------------|--------------------------|-----------------|---|--|-------------|-------------|
|                    | 2536292CB1               | 2422            | 288-1079,<br>2271-2422,<br>105-150,<br>1835-1898        | 72051732V1                             | 787         | 2422        |
|                    |                          |                 |   | 2536292F6 (BRAINT18)                   | 836         | 1680        |
|                    |                          |                 |   | FL2536292_g6007890_000006_g499<br>5709 | 301         | 1175        |
|                    |                          |                 |   | 55062753H1                             | 1           | 636         |
|                    |                          |                 |   | 55062751J1                             | 480         | 2422        |
|                    |                          |                 |   | 55062763H1                             | 648         | 2422        |
|                    | 7477708CB1               | 1912            | 1798-1912,<br>1-1741,<br>1304-1481                      | 72049620V1                             | 1488        | 2422        |
|                    |                          |                 |   | 55062754J1                             | 658         | 2422        |
|                    |                          |                 |   | 55094142J1                             | 1           | 639         |
|                    |                          |                 |   | FL7477708_g8217793_000019_g552<br>5078 | 338         | 1912        |
|                    |                          |                 |   | 1971428H1 (UCMCL5T01)                  | 1028        | 1255        |
|                    |                          |                 |   | GBI.g7547159_000017_000014.edi<br>t    | 144         | 782         |
|                    | 644692CB1                | 3058            | 1-1633,<br>2354-3058,<br>2369-2504,<br>1-2201           | GNN.g7547159_000014_004                | 517         | 1326        |
|                    |                          |                 |   | GNN.g7106155_000002_002.edit           | 1           | 516         |
|                    |                          |                 |   | 71737648V1                             | 1922        | 2535        |
|                    |                          |                 |   | 55052474J1                             | 370         | 1195        |
|                    |                          |                 |   | 71735994V1                             | 1490        | 2079        |
|                    |                          |                 |   | 55067945J1                             | 1           | 671         |
|                    | 3837054CB1               | 1993            | 1-1063,<br>1540-1714,<br>1-87,<br>1543-1993,<br>447-829 | 71907834V1                             | 2612        | 3058        |
|                    |                          |                 |   | 71736314V1                             | 2293        | 2985        |
|                    |                          |                 |   | 6933242R8 (SINTMR02)                   | 910         | 1678        |
|                    |                          |                 |   | g3738039                               | 1088        | 1541        |
|                    |                          |                 |   | FL3837054_g8575884_g1150834_1_<br>2    | 849         | 1349        |
|                    |                          |                 |   | GNN.g8575884_004                       | 359         | 1420        |
|                    |                          |                 |   | 56005250J1                             | 1649        | 1993        |
|                    |                          |                 |   | 3837054F6 (DENDTNT01)                  | 1371        | 1935        |
|                    |                          |                 |   | 2814920H1 (OVARNOT10)                  | 1           | 187         |

Table 4 (cont).

| Polynucleotide<br>SEQ ID NO: | Incyte<br>Polynucleotide<br>ID | Sequence<br>Length | Selected<br>Fragments  | Sequence<br>Fragments                       | 5'<br>Position | 3'<br>Position |
|------------------------------|--------------------------------|--------------------|--|---|----------------|----------------|
| 21                           |                                |                    |  | 3406743H1 (PROSTUS08)                       | 103            | 354            |
|                              |                                |                    |  | GNN.g5686520_000054_002.edit                | 116            | 565            |
| 22                           | 6157025CB1                     | 1499               | 1-81,<br>248-1499,<br>850-920,<br>1265-1499                  | 6834181F6 (BRSTNON02)                       | 826            | 1499           |
|                              |                                |                    |  | FL6157025_g10567930_000001_g53<br>53887_1_1 | 381            | 1296           |
| 23                           | 55012817CB1                    | 2455               | 1397-1482,<br>318-704,<br>1893-2171,<br>1-1014,<br>1619-2182 | 7169316F8 (MCLRNOC01)                       | 1              | 676            |
|                              |                                |                    |  | 4425914H1 (BRAPDIT01)                       | 32             | 288            |
|                              |                                |                    |  | 71691523V1                                  | 1746           | 2401           |
|                              |                                |                    |  | 71691480V1                                  | 1405           | 2082           |
|                              |                                |                    |  | 71691220V1                                  | 1              | 646            |
|                              |                                |                    |  | 71690572V1                                  | 654            | 1377           |
|                              |                                |                    |  | 71691571V1                                  | 608            | 1338           |
|                              |                                |                    |  | 71691384V1                                  | 1351           | 2058           |
|                              |                                |                    |  | 71688567V1                                  | 2162           | 2455           |
| 24                           | 7475061CB1                     | 2056               | 1-688,<br>1207-2056,<br>1736-1917,<br>1207-1680              | 72488727D1                                  | 841            | 1769           |
|                              |                                |                    |  | 72489896D1                                  | 1              | 953            |
|                              |                                |                    |  | 72487236D1                                  | 1046           | 2056           |
|                              |                                |                    |  | 72492196D1                                  | 1200           | 2056           |
| 25                           | 7477374CB1                     | 999                | 1-138,<br>264-999  | FL7477374_g9930948_000007_6739<br>496       | 1              | 999            |
| 26                           | 7479890CB1                     | 3429               | 1-2724,<br>2850-2900,<br>1-2300,<br>2367-2732                | 4021537F6 (BRAXNOT02)                       | 1427           | 2110           |
|                              |                                |                    |  | GBI.g9967464_000017_000007_000<br>001.edit  | 1              | 588            |
|                              |                                |                    |  | 55017814H1                                  | 737            | 1280           |
|                              |                                |                    |  | 58013229J1                                  | 2532           | 3429           |
|                              |                                |                    |  | 8042178J1 (OVRTUE01)                        | 2032           | 2692           |
|                              |                                |                    |  | GNN.g9967464_000015_002                     | 729            | 2847           |
|                              |                                |                    |  | 71702678V1                                  | 2160           | 2786           |
|                              |                                |                    |  | 6609077H2 (PLACFEC01)                       | 366            | 877            |
|                              |                                |                    |  | 7720776H1 (THYRDIE01)                       | 880            | 1291           |
|                              |                                |                    |  | 7726057J1 (THYRDIE01)                       | 1242           | 1974           |

Table 4 (cont.)

| Polynucleotide NO: | Incyte Polynucleotide ID | Sequence Length | Selected Fragments                      | Sequence Fragments                             | 5' Position | 3' Position |
|--------------------|--------------------------|-----------------|---|--|-------------|-------------|
|                    | 7482825CB1               | 948             | 1-87,<br>210-299,<br>923-948            | GNN:g10045182_000002_006                       | 1           | 948         |
|                    | 7483087CB1               | 939             | 259-939,<br>1-86,<br>912-939            | GNN:g6015288_000044_010                        | 1           | 939         |
|                    | 7483134CB1               | 930             | 1-327,<br>1-100,<br>889-930,<br>400-930 | GNN:g7143464_000018_002                        | 1           | 930         |
|                    | 7478550CB1               | 1161            | 112-335,<br>116-358,<br>925-1161        | 7077972R8 (BRAUTDR04)<br>7077972F8 (BRAUTDR04) | 1<br>416    | 926<br>1161 |
|                    | 7483142CB1               | 948             | 1-26,<br>605-782,<br>913-948            | FL7483142_g808648_000017_g374<br>6443_1_1      | 1           | 948         |
|                    | 7483151CB1               | 924             | 876-924                                 | FL7483151_g9438337_000003_g151<br>4480_1_1-2   | 1           | 924         |

Table 5

| Polynucleotide<br>SEQ ID NO: | Incyte<br>Project ID | Representative<br>Library |
|------------------------------|----------------------|---------------------------|
| 17                           | 2536292CB1           | BRAINOT18                 |
| 19                           | 7474823CB1           | UCMCL5T01                 |
| 20                           | 644692CB1            | SINTTMR02                 |
| 21                           | 3837054CB1           | DENDTNT01                 |
| 22                           | 6157025CB1           | MONOTXN05                 |
| 23                           | 55012817CB1          | BRAPDIT01                 |
| 26                           | 7479890CB1           | LJUNGNON07                |
| 30                           | 7478550CB1           | BRAUTDR04                 |

Table 6

| BP | Vector   | Library Description  |
|----|----------|--|
| B1 | pINCY    | Library was constructed using RNA isolated from left temporal lobe brain tissue removed from a 34-year-old Caucasian male during cerebral meninges lesion excision. Pathology for the associated tumor tissue indicated metastatic malignant melanoma. Neoplastic cells strongly expressed HMB-45. Patient history included malignant melanoma of skin of the trunk. Family history included liver cancer, acute myocardial infarction, atherosclerotic coronary artery disease, and cerebrovascular disease.  |
| B1 | pINCY    | Library was constructed using RNA isolated from diseased pons tissue removed from the brain of a 57-year-old Caucasian male, who died from a cerebrovascular accident. Serology was negative. Patient history included Huntington's disease, emphysema, and tobacco abuse.   |
| B1 | PCDNA2.1 | Library was constructed using RNA isolated from striatum, dorsal caudate nucleus, dorsal putamen, and ventral nucleus accumbens tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated no diagnostic abnormalities in the brain or intracranial vessels. There was mild meningeal fibrosis predominately over the convexities. Special stains showed no evidence of amyloid plaques or metastatic lesions. There were scattered axonal spheroids in the white matter of the cingulate cortex and thalamus. There were a few scattered neurofibrillary tangles in the entorhinal cortex and periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor, surrounded by foci of bile lakes beneath the hepatic surface scar. The liver had extensive surface scarring, congestion, cholestasis, hemorrhage, necrosis, and chronic inflammation. The patient presented with nausea, vomiting, dehydration, malnutrition, oliguria, and acute renal failure. Patient history included post-operative Budd-Chiari syndrome, biliary ascites, acute bilateral bronchopneumonia with microabscesses, hydrothorax, and bilateral leg pitting edema. Previous surgeries included cholecystectomy, liver resection, hysterectomy, bilateral salpingo-oophorectomy, and portocaval shunt. The patient was treated with a nasogastric feeding tube, biliary drainage stent, paracentesis, pleurodesis, and abdominal ultrasound. Patient medications included Ampicillin, niacin, furosemide, Aldactone, Benadryl, and morphine. |

Table 6 (cont.)

| Library   | Vector      | Library Description   |
|-----------|-------------|---|
| DENDTNT01 | pINCY       | Library was constructed using RNA isolated from treated dendritic cells from peripheral blood.  |
| LUNGNON07 | pINCY       | This normalized lung tissue library was constructed from 5.1 million independent clones from a lung tissue library. Starting RNA was made from RNA isolated from lung tissue. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research (1996) 6:791, except that a significantly longer (48 hours/round) reannealing hybridization was used.  |
| MONOTXN05 | pINCY       | This normalized treated monocyte cell tissue library was constructed from 1.03 million independent clones from a monocyte tissue library. Starting RNA was made from RNA isolated from treated monocytes from peripheral blood removed from a 42-year-old female. The cells were treated with interleukin-10 (IL-10) and lipopolysaccharide (LPS). The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91:9228-9232 and Bonaldo et al., Genome Research 6 (1996):791, except that a significantly longer (48 hours/round) reannealing hybridization was used. |
| SINTTMR02 | PCDNA2.1    | This random primed library was constructed using RNA isolated from small intestine tissue removed from a 59-year-old male. Pathology for the matched tumor tissue indicated multiple (9) carcinoma tumors, grade 1, in the small bowel. The largest tumor was associated with a large mesenteric mass. Multiple convoluted segments of bowel were adhered to the tumor. A single (1 of 13) regional lymph node was positive for malignancy. The peritoneal biopsy indicated focal fat necrosis.   |
| UCMCL5T01 | PBLUESCRIPT | Library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of 12 individuals. The cells were cultured for 12 days with IL-5 before RNA was obtained from the pooled lysates.  |



Table 7

| Program   | Description   | Reference  | Parameter Threshold   |
|-----------|---|--|---|
| RA        | A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.  | Applied Biosystems, Foster City, CA.   |   |
| TELFDF    | A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.   | Applied Biosystems, Foster City, CA;<br>Paracel Inc., Pasadena, CA.  | Mismatch <50%   |
| Assembler | A program that assembles nucleic acid sequences.  | Applied Biosystems, Foster City, CA.   |   |
| BL        | A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.                    | Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.  | ESTs: Probability value= 1.0E-8 or less<br>Full Length sequences: Probability value= 1.0E-10 or less  |
| FA        | A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch. | Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.              | ESTs: fasta E value=1.06E-6<br>Assembled ESTs: fasta Identity= 95% or greater and<br>Match length=200 bases or greater;<br>fastx E value=1.0E-8 or less<br>Full Length sequences:<br>fastx score=100 or greater |
| BL        | A BLocks IMProved Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.            | Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424. | Probability value= 1.0E-3 or less   |
| HN        | An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.  | Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.   | PFAM hits: Probability value= 1.0E-3 or less<br>Signal peptide hits: Score= 0 or greater  |

Table 7 (cont.)

| Program     | Description   | Reference  | Parameter Threshold  |
|-------------|---|--|--|
| ProfileScan | An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.   | Gribskov, M. et al. (1988) CABIOS 4:61-66;<br>Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.                                    | Normalized quality score $\geq$ GCG-specified "HIGH" value for that particular Prosite motif.<br>Generally, score=1.4-2.1. |
| Phred       | A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.  | Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.  |  |
| Phrap       | A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences. | Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.             | Score= 120 or greater;<br>Match length= 56 or greater  |
| Consed      | A graphical tool for viewing and editing Phrap assemblies.  | Gordon, D. et al. (1998) Genome Res. 8:195-202.  |  |
| SPScan      | A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.  | Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.  | Score=3.5 or greater   |
| TMAP        | A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.   | Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.   |  |
| TMHMMER     | A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.   | Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182. |  |
| Motifs      | A program that searches amino acid sequences for patterns that matched those defined in Prosite.  | Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.   |  |

1. An isolated polypeptide selected from the group consisting of:
  - a) a polypeptide comprising an amino acid sequence selected from the group consisting  
5 of SEQ ID NO:1-16,
  - b) a polypeptide comprising a naturally occurring amino acid sequence at least 90%  
identical to an amino acid sequence selected from the group consisting of SEQ ID  
NO:1-16,
  - c) a biologically active fragment of a polypeptide having an amino acid sequence  
10 selected from the group consisting of SEQ ID NO:1-16, and
  - d) an immunogenic fragment of a polypeptide having an amino acid sequence selected  
from the group consisting of SEQ ID NO:1-16.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-16.  
15
3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
- 20 5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID  
NO:17-32.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a  
polynucleotide of claim 3.  
25
7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
- 30 9. A method of producing a polypeptide of claim 1, the method comprising:
  - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein  
the cell is transformed with a recombinant polynucleotide of claim 6, the recombinant  
polynucleotide encoding the polypeptide of claim 1, and
  - 35 b) recovering the polypeptide so expressed.

10. A method of claim 9, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-16.

11. An isolated antibody which specifically binds to a polypeptide of claim 1.

12. An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32,
- b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:17-32,
- c) a polynucleotide complementary to a polynucleotide of a),
- d) a polynucleotide complementary to a polynucleotide of b), and
- e) an RNA equivalent of a)-d).

13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.

14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.

16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- b) detecting the presence or absence of said amplified target polynucleotide or fragment

thereof, and, optionally, if present, the amount thereof.

17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

5

18. A composition of claim 17, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-16.

19. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition of claim 17.

20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- 15       a)       exposing a sample comprising a polypeptide of claim 1 to a compound, and  
         b)       detecting agonist activity in the sample.

21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.

20

22. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 21.

23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- 25       a)       exposing a sample comprising a polypeptide of claim 1 to a compound, and  
         b)       detecting antagonist activity in the sample.

24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.

25       25. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 24.

35

26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- 5 b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising:

- 10 a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- 15 c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

28. A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- 25 b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

29. A method of assessing toxicity of a test compound, the method comprising:

- 30 a) treating a biological sample containing nucleic acids with the test compound,
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a
- 35 polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof,

- c) quantifying the amount of hybridization complex, and
- d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

30. A diagnostic test for a condition or disease associated with the expression of GCREC in a biological sample, the method comprising:

- a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and
- b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

31. The antibody of claim 11, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')<sub>2</sub> fragment, or
- e) a humanized antibody.

32. A composition comprising an antibody of claim 11 and an acceptable excipient.

33. A method of diagnosing a condition or disease associated with the expression of GCREC in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

34. A composition of claim 32, wherein the antibody is labeled.

35. A method of diagnosing a condition or disease associated with the expression of GCREC in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim

11, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibodies from said animal, and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16.

37. A polyclonal antibody produced by a method of claim 36.

38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

39. A method of making a monoclonal antibody with the specificity of the antibody of claim

11, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibody producing cells from the animal,
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
- d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16.

40. A monoclonal antibody produced by a method of claim 39.

41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.

43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant



immunoglobulin library.

44. A method of detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16 in a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16 in the sample.

45. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16 from a sample, the method comprising:

- a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
- b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16.

46. A microarray wherein at least one element of the microarray is a polynucleotide of claim

13.

47. A method of generating a transcript image of a sample which contains polynucleotides, the method comprising:

- a) labeling the polynucleotides of the sample,
- b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
- c) quantifying the expression of the polynucleotides in the sample.

48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 nucleotides of a target nucleic acid.

49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is

completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

5

51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.

52. An array of claim 48, which is a microarray.

10

53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.

54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

15

55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.

20

56. A method of identifying a compound that modulates, mimics and/or blocks an olfactory and/or taste sensation, the method comprising:

25

- a) contacting the compound with an olfactory and/or taste receptor polypeptide selected from the group consisting of:
  - i) a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16,
  - ii) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-16, and
  - iii) an olfactory and/or taste receptor having an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-16.
- b) identifying whether the compound specifically binds to and/or affects the activity of

30

said receptor polypeptide.

57. The method of claim 56, wherein said receptor polypeptide is expressed on the surface of a mammalian cell.

5

58. The method of claim 57, wherein said mammalian cell expresses a G-protein.

59. The method of claim 58, wherein said mammalian cell expresses a plurality of G-protein coupled receptors.

10

60. The method of claim 59, wherein said mammalian cell expresses another olfactory and/or taste receptor polypeptide.

61. The method of claim 56, wherein said receptor polypeptide is fused to another polypeptide.

15

62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

20

64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

25

66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

30

69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.

71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.

72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.

5 73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.

74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.

75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.

10

76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.

77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.

15

78. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:17.

79. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:18.

80. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:19.

20

81. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:20.

82. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:21.

25

83. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:22.

84. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:23.

85. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:24.

30

86. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:25.

87. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:26.

88. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:27.

89. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:28.

5 90. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:29.

91. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:30.

92. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:31.

10

93. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:32.

PI-0236 PCT

<110> INCYTE GENOMICS, INC.  
BAUGHN, Mariah R.  
GRAUL Richard C.  
WALIA, Narinder K.  
GANDHI, Ameena R.  
HAFALIA, April J.A.  
RAMKUMAR, Jayalaxmi  
TRIBOULEY, Catherine M.  
THORNTON, Michael  
KALLICK, Deborah A.  
YAO, Monique G.  
ELLIOTT, Vicki S.  
BURFORD, Neil  
KHAN, Farrah A.  
YUE, Henry  
LU, Yan  
ARVIZU, Chandra  
ROOPA, Reddy  
NGUYEN, Danniel B.  
LEE, Ernestine A.  
LU, Dyung Aina M.  
ISON, Craig H.  
WALSH, Roderick T.  
POLICKY, Jennifer L.

&lt;120&gt; G-PROTEIN COUPLED RECEPTORS

&lt;130&gt; PI-0236 PCT

&lt;140&gt; To Be Assigned

&lt;141&gt; Herewith

<150> 60/236,546; 60/242,223; 60/245,900; 60/247,587; 60/249,343; 60/240,589;  
60/242,322; 60/245,855

<151> 2000-09-29; 2000-10-20; 2000-11-03; 2000-11-09; 2000-11-15; 2000-10-13;  
2000-10-20; 2000-11-03

&lt;160&gt; 32

&lt;170&gt; PERL Program

&lt;210&gt; 1

&lt;211&gt; 217

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2536292CD1

&lt;400&gt; 1

Met Lys Ser Phe Leu Pro Gly Thr Cys Ile Leu Leu Cys Ser Ala  
1 5 10 15

PI-0236 PCT

Phe Asn Leu Met Phe Phe Ser Leu Phe Arg Leu Lys Tyr Asn Ile  
 20 25 30  
 Cys Ile Ile Leu Arg Ala Cys Asn Thr Met Leu Ser Ser Asn Thr  
 35 40 45  
 Ile Met Glu Ile Phe Phe Leu Ser His Ile Asp Ile Gly Ile Trp  
 50 55 60  
 Arg Asn Leu Leu Leu Leu Leu Met Pro Ile Tyr Thr Phe Leu Ile  
 65 70 75  
 Cys Pro Gln Gln Lys Lys Pro Met Gly Leu Leu Phe Leu His Leu  
 80 85 90  
 Ser Val Ala Asn Thr Met Thr Leu Leu Arg Lys Val Ile Pro Leu  
 95 100 105  
 Ala Val Lys Ser Phe Asn Thr Lys Asn Leu Leu Asn Tyr Thr Gly  
 110 115 120  
 Cys Arg Glu Phe Glu Phe Leu Tyr Arg Val Ser Trp Gly Leu Pro  
 125 130 135  
 Leu Cys Thr Thr Tyr Leu Leu Ser Met Val Gln Ala Leu Arg Gly  
 140 145 150  
 Ser Pro Ser Lys Ser Arg Val Ile Asn Ser Leu Ile Tyr Ile Lys  
 155 160 165  
 Leu Val Pro Phe Val Asp Thr Ile Lys Tyr Gly Ser Val Thr Lys  
 170 175 180  
 Asn Leu Ser Ile Lys Met Cys Leu Ala Thr Pro His Met Gly Asn  
 185 190 195  
 Thr Ile Ala Val Ser His Thr Ser Val Ile Thr Phe Gln Asp Leu  
 200 205 210  
 Ile Phe Leu Val Leu Met Ser  
 215

&lt;210&gt; 2

&lt;211&gt; 578

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7477708CD1

&lt;400&gt; 2

Met Gly Phe Ser Cys Arg Gln Lys Thr Trp His Lys Ile Thr Asp  
 1 5 10 15  
 Thr Cys Arg Thr Leu Asn Ala Leu Asn Ile Phe Glu Glu Asp Ser  
 20 25 30  
 Arg Leu Val Gln Pro Phe Glu Asp Asn Ile Lys Ile Ser Val Tyr  
 35 40 45  
 Thr Gly Lys Ser Glu Thr Ile Thr Asp Met Leu Leu Gln Lys Cys  
 50 55

80 85 90  
 Ile Ser Thr Ala Ile Trp Thr Gly Val Asp Glu Ala Lys Met Gln

PI-0236 PCT

|                 |                     |                     |     |  |     |
|-----------------|---------------------|---------------------|-----|--|-----|
|                 | 95                  |                     | 100 |  | 105 |
| Ser Tyr Ser Thr | Ile Ala Asn His Ile | Leu Asn Ser Lys Ser | Ile |  |     |
|                 | 110                 |                     | 115 |  | 120 |
| Ser Asn Trp Thr | Phe Ile Pro Asp Arg | Asn Ser Ser Tyr Ile | Leu |  |     |
|                 | 125                 |                     | 130 |  | 135 |
| Leu His Ser Val | Asn Ser Phe Ala Arg | Arg Leu Phe Ile Asp | Asn |  |     |
|                 | 140                 |                     | 145 |  | 150 |
| Ile Pro Val Asp | Ile Ser Asp Val Phe | Ile His Thr Met Gly | Thr |  |     |
|                 | 155                 |                     | 160 |  | 165 |
| Thr Ile Ser Gly | Asp Asn Ile Gly Lys | Asn Phe Thr Phe Ser | Met |  |     |
|                 | 170                 |                     | 175 |  | 180 |
| Arg Ile Asn Asp | Thr Ser Asn Glu Val | Thr Gly Arg Val Leu | Ile |  |     |
|                 | 185                 |                     | 190 |  | 195 |
| Ser Arg Asp Glu | Leu Arg Lys Val Pro | Ser Pro Ser Gln Val | Ile |  |     |
|                 | 200                 |                     | 205 |  | 210 |
| Ser Ile Ala Phe | Pro Thr Ile Gly Ala | Ile Leu Glu Ala Ser | Leu |  |     |
|                 | 215                 |                     | 220 |  | 225 |
| Leu Glu Asn Val | Thr Val Asn Gly Leu | Val Leu Ser Ala Ile | Leu |  |     |
|                 | 230                 |                     | 235 |  | 240 |
| Pro Lys Glu Leu | Lys Arg Ile Ser Leu | Ile Phe Glu Lys Ile | Ser |  |     |
|                 | 245                 |                     | 250 |  | 255 |
| Lys Ser Glu Glu | Arg Arg Thr Gln Cys | Val Gly Trp His Ser | Val |  |     |
|                 | 260                 |                     | 265 |  | 270 |
| Glu Asn Arg Trp | Asp Gln Gln Ala Cys | Lys Met Ile Gln Glu | Asn |  |     |
|                 | 275                 |                     | 280 |  | 285 |
| Ser Gln Gln Ala | Val Cys Lys Cys Arg | Pro Ser Lys Leu Phe | Thr |  |     |
|                 | 290                 |                     | 295 |  | 300 |
| Ser Phe Ser Ile | Leu Met Ser Pro His | Ile Leu Glu Ser Leu | Ile |  |     |
|                 | 305                 |                     | 310 |  | 315 |
| Leu Thr Tyr Ile | Thr Tyr Val Gly Leu | Gly Ile Ser Ile Cys | Ser |  |     |
|                 | 320                 |                     | 325 |  | 330 |
| Leu Ile Leu Cys | Leu Ser Ile Glu Val | Leu Val Trp Ser Gln | Val |  |     |
|                 | 335                 |                     | 340 |  | 345 |
| Thr Lys Thr Glu | Ile Thr Tyr Leu Arg | His Val Cys Ile Val | Asn |  |     |
|                 | 350                 |                     | 355 |  | 360 |
| Ile Ala Ala Thr | Leu Leu Met Ala Asp | Val Trp Phe Ile Val | Ala |  |     |
|                 | 365                 |                     | 370 |  | 375 |
| Ser Phe Leu Ser | Gly Pro Ile Thr His | His Lys Gly Cys Val | Ala |  |     |
|                 | 380                 |                     | 385 |  | 390 |
| Ala Thr Phe Phe | Val His Phe Phe Tyr | Leu Ser Val Phe Phe | Trp |  |     |
|                 | 395                 |                     | 400 |  | 405 |
| Met Leu Ala Lys | Ala Leu Leu Ile Leu | Tyr Gly Ile Met Ile | Val |  |     |
|                 | 410                 |                     | 415 |  | 420 |
| Phe His Thr Leu | Pro Lys Ser Val Leu | Val Ala Ser Leu Phe | Ser |  |     |
|                 | 425                 |                     | 430 |  | 435 |
| Val Gly Tyr Gly | Cys Pro Leu Ala Ile | Ala Ala Ile Thr Val | Ala |  |     |
|                 | 440                 |                     | 445 |  | 450 |
| Ala Thr Glu Pro | Gly Lys Gly Tyr Leu | Arg Pro Glu Ile Cys | Trp |  |     |
|                 | 455                 |                     | 460 |  | 465 |
| Leu Asn Trp Asp | Met Thr Lys Ala Leu | Leu Ala Phe Val Ile | Pro |  |     |
|                 | 470                 |                     | 475 |  | 480 |
| Ala Leu Ala Ile | Val Val Val Asn Leu | Ile Thr Val Thr Leu | Val |  |     |



PI-0236 PCT

|                 |                     |                     |     |  |     |
|-----------------|---------------------|---------------------|-----|--|-----|
|                 | 485                 |                     | 490 |  | 495 |
| Ile Val Lys Thr | Gln Arg Ala Ala Ile | Gly Asn Ser Met Phe | Gln |  |     |
|                 | 500                 |                     | 505 |  | 510 |
| Glu Val Arg Ala | Ile Val Arg Ile Ser | Lys Asn Ile Ala Ile | Leu |  |     |
|                 | 515                 |                     | 520 |  | 525 |
| Thr Pro Leu Leu | Gly Leu Thr Trp Gly | Phe Gly Val Ala Thr | Val |  |     |
|                 | 530                 |                     | 535 |  | 540 |
| Ile Asp Asp Arg | Ser Leu Ala Phe His | Ile Ile Phe Ser Leu | Leu |  |     |
|                 | 545                 |                     | 550 |  | 555 |
| Asn Ala Phe Gln | Val Ser Pro Asp Ala | Ser Asp Gln Val Gln | Ser |  |     |
|                 | 560                 |                     | 565 |  | 570 |
| Glu Arg Ile His | Glu Asp Val Leu     |                     |     |  |     |
|                 | 575                 |                     |     |  |     |

&lt;210&gt; 3

&lt;211&gt; 441

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7474823CD1

&lt;400&gt; 3

|   |     |         |
|---|-----|---------|
| Met Val Leu Gly Lys Asn Val Ser Met Ser Gly Pro Arg Pro Ala |     |         |
| 1   | 5   | 10 15   |
| Ser Trp Gln Ser His Pro Gln Gly Leu Glu Leu Val Phe Gly Lys |     |         |
|   | 20  | 25 30   |
| Trp Pro Cys Arg Cys Ser Tyr Ser Ala Val Leu Val Ile Ser Ser |     |         |
|   | 35  | 40 45   |
| Ile Ser Ser Ser Gly Ala Gly Asp Ile Pro Asp Gln Asp Ser Gly |     |         |
|   | 50  | 55 60   |
| Gln Tyr Trp Phe Leu Met Arg Ala Val Phe Leu Ala Cys Arg Arg |     |         |
|   | 65  | 70 75   |
| Leu Pro Ser Thr Cys Val Leu Lys Arg Pro Phe Ser Glu Cys Ala |     |         |
|   | 80  | 85 90   |
| Gln Arg Glu Arg Thr Asn Leu Val Leu Met Lys Lys Trp Glu Phe |     |         |
|   | 95  | 100 105 |
| Leu Glu Val Pro Asp Thr Phe Glu Val Thr Gln Gln Ser Val Ile |     |         |
|   | 110 | 115 120 |
| Ser Ile Pro Leu Tyr Ile Pro His Thr Leu Phe Glu Trp Asp Phe |     |         |
|   | 125 | 130 135 |
| Gly Lys Glu Ile Cys Val Phe Trp Leu Thr Thr Asp Tyr Leu Leu |     |         |
|   | 140 | 145 150 |
| Cys Thr Ala Ser Val Tyr Asn Ile Val Leu Ile Ser Tyr Asp Arg |     |         |
|   | 155 | 160 165 |

|                 |                     |                         |
|-----------------|---------------------|-------------------------|
| Ala Phe Leu Val | Asn Gly Pro Met Ile | Leu Val Ser Glu Ser Trp |
| 200             | 205                 | 210                     |

PI-0236 PCT

Lys Asp Glu Gly Ser Glu Cys Glu Pro Gly Phe Phe Ser Glu Trp  
 215 220 225  
 Tyr Ile Leu Ala Ile Thr Ser Phe Leu Glu Phe Val Ile Pro Val  
 230 235 240  
 Ile Leu Val Ala Tyr Phe Asn Met Asn Ile Tyr Trp Ser Leu Trp  
 245 250 255  
 Lys Arg Asp His Leu Arg Leu Gly His Pro Lys Gly Trp Gly Gln  
 260 265 270  
 Leu Val Leu Arg Leu Pro His Gly Val Glu Gly Gln Pro Trp Arg  
 275 280 285  
 Leu Gln Leu Val Pro Arg Met Gly Tyr Ile Glu Val Gly Gly Leu  
 290 295 300  
 Leu Cys Thr Ala Ala Gly Glu Met Ser Thr His Ala Arg Ser Ala  
 305 310 315  
 Lys Leu Leu Ser Thr Gly Ser Glu Asn Asp Thr Leu Pro Val Pro  
 320 325 330  
 Ser Leu Ala Ser Arg Ser Leu Cys Pro Ser Val Leu Ser Leu Gly  
 335 340 345  
 Ser Phe Pro Ser Cys Gln Ser Cys Leu Ser Asp Gln Met Ser Gln  
 350 355 360  
 Cys Asp Thr Glu Pro Glu Arg Lys Ser Phe Leu Ser Met Met Gln  
 365 370 375  
 Gly Thr Gln His Phe Asp Asn Pro Asp Gly Met Trp Ser Ser His  
 380 385 390  
 Gly Arg Asn Val Ser Ser Gly Gly Leu His Asn His Cys Ile Leu  
 395 400 405  
 Gln Met Gly Thr Gly Ser Ala Gly Ala Ser His Pro Glu Gly Pro  
 410 415 420  
 Arg Gly Gly Gln Gly Gln Val Thr Thr Arg Ala Thr Thr Gln Lys  
 425 430 435  
 Arg Val Ala Ala Ser Gly  
 440

&lt;210&gt; 4

&lt;211&gt; 797

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 644692CD1

&lt;400&gt; 4

Met Ala Ser Cys Arg Ala Trp Asn Leu Arg Val Leu Val Ala Val  
 1 5 10 15  
 Val Cys Gly Leu Leu Thr Gly Ile Ile Leu Gly Leu Gly Ile Trp  
 20 25 30  
 Arg Ile Val Ile Arg Ile Gln Arg Gly Lys Ser Thr Ser Ser Ser  
 35 40 45  
 Ser Thr Pro Thr Glu Phe Cys Arg Asn Gly Gly Thr Trp Glu Asn  
 50 55 60  
 Gly Arg Cys Ile Cys Thr Glu Glu Trp Lys Gly Leu Arg Cys Thr

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|     |     |     |     |     | 65  |     |     |     |     | 70  |     |     |     | 75  |
| Ile | Ala | Asn | Phe | Cys | Glu | Asn | Ser | Thr | Tyr | Met | Gly | Phe | Thr | Phe |
|     |     |     |     | 80  |     |     |     |     |     | 85  |     |     |     | 90  |
| Ala | Arg | Ile | Pro | Val | Gly | Arg | Tyr | Gly | Pro | Ser | Leu | Gln | Thr | Cys |
|     |     |     |     | 95  |     |     |     |     |     | 100 |     |     |     | 105 |
| Gly | Lys | Asp | Thr | Pro | Asn | Ala | Gly | Asn | Pro | Met | Ala | Val | Arg | Leu |
|     |     |     |     | 110 |     |     |     |     |     | 115 |     |     |     | 120 |
| Cys | Ser | Leu | Ser | Leu | Tyr | Gly | Glu | Ile | Glu | Leu | Gln | Lys | Val | Thr |
|     |     |     |     | 125 |     |     |     |     |     | 130 |     |     |     | 135 |
| Ile | Gly | Asn | Cys | Asn | Glu | Asn | Leu | Glu | Thr | Leu | Glu | Lys | Gln | Val |
|     |     |     |     | 140 |     |     |     |     |     | 145 |     |     |     | 150 |
| Lys | Asp | Val | Thr | Ala | Pro | Leu | Asn | Asn | Ile | Ser | Ser | Glu | Val | Gln |
|     |     |     |     | 155 |     |     |     |     |     | 160 |     |     |     | 165 |
| Ile | Leu | Thr | Ser | Asp | Ala | Asn | Lys | Leu | Thr | Ala | Glu | Asn | Ile | Thr |
|     |     |     |     | 170 |     |     |     |     |     | 175 |     |     |     | 180 |
| Ser | Ala | Thr | Arg | Val | Val | Gly | Gln | Ile | Phe | Asn | Thr | Ser | Arg | Asn |
|     |     |     |     | 185 |     |     |     |     |     | 190 |     |     |     | 195 |
| Ala | Ser | Pro | Glu | Ala | Lys | Lys | Val | Ala | Ile | Val | Thr | Val | Ser | Gln |
|     |     |     |     | 200 |     |     |     |     |     | 205 |     |     |     | 210 |
| Leu | Leu | Asp | Ala | Ser | Glu | Asp | Ala | Phe | Gln | Arg | Val | Ala | Ala | Thr |
|     |     |     |     | 215 |     |     |     |     |     | 220 |     |     |     | 225 |
| Ala | Asn | Asp | Asp | Ala | Leu | Thr | Thr | Leu | Ile | Glu | Gln | Met | Glu | Thr |
|     |     |     |     | 230 |     |     |     |     |     | 235 |     |     |     | 240 |
| Tyr | Ser | Leu | Ser | Leu | Gly | Asn | Gln | Ser | Val | Val | Glu | Pro | Asn | Ile |
|     |     |     |     | 245 |     |     |     |     |     | 250 |     |     |     | 255 |
| Ala | Ile | Gln | Ser | Ala | Asn | Phe | Ser | Ser | Glu | Asn | Ala | Val | Gly | Pro |
|     |     |     |     | 260 |     |     |     |     |     | 265 |     |     |     | 270 |
| Ser | Asn | Val | Arg | Phe | Ser | Val | Gln | Lys | Gly | Ala | Ser | Ser | Ser | Leu |
|     |     |     |     | 275 |     |     |     |     |     | 280 |     |     |     | 285 |
| Val | Ser | Ser | Ser | Thr | Phe | Ile | His | Thr | Asn | Val | Asp | Gly | Leu | Asn |
|     |     |     |     | 290 |     |     |     |     |     | 295 |     |     |     | 300 |
| Pro | Asp | Ala | Gln | Thr | Glu | Leu | Gln | Val | Leu | Leu | Asn | Met | Thr | Lys |
|     |     |     |     | 305 |     |     |     |     |     | 310 |     |     |     | 315 |
| Asn | Tyr | Thr | Lys | Thr | Cys | Gly | Phe | Val | Val | Tyr | Gln | Asn | Asp | Lys |
|     |     |     |     | 320 |     |     |     |     |     | 325 |     |     |     | 330 |
| Leu | Phe | Gln | Ser | Lys | Thr | Phe | Thr | Ala | Lys | Ser | Asp | Phe | Ser | Gln |
|     |     |     |     | 335 |     |     |     |     |     | 340 |     |     |     | 345 |
| Lys | Ile | Ile | Ser | Ser | Lys | Thr | Asp | Glu | Asn | Glu | Gln | Asp | Gln | Ser |
|     |     |     |     | 350 |     |     |     |     |     | 355 |     |     |     | 360 |
| Ala | Ser | Val | Asp | Met | Val | Phe | Ser | Pro | Lys | Tyr | Asn | Gln | Lys | Glu |
|     |     |     |     | 365 |     |     |     |     |     | 370 |     |     |     | 375 |
| Phe | Gln | Leu | Tyr | Ser | Tyr | Ala | Cys | Val | Tyr | Trp | Asn | Leu | Ser | Ala |
|     |     |     |     | 380 |     |     |     |     |     | 385 |     |     |     | 390 |
| Lys | Asp | Trp | Asp | Thr | Tyr | Gly | Cys | Gln | Lys | Asp | Lys | Gly | Thr | Asp |
|     |     |     |     | 395 |     |     |     |     |     | 400 |     |     |     | 405 |
| Gly | Phe | Leu | Arg | Cys | Arg | Cys | Asn | His | Thr | Thr | Asn | Phe | Ala | Val |

PI-0236 PCT

|                 |                     |                     |     |
|-----------------|---------------------|---------------------|-----|
|                 | 455                 | 460                 | 465 |
| Ser Val Thr Trp | Val Leu Val Asn Leu | Cys Ile Ser Met Leu | Ile |
|                 | 470                 | 475                 | 480 |
| Phe Asn Leu Leu | Phe Val Phe Gly Ile | Glu Asn Ser Asn Lys | Asn |
|                 | 485                 | 490                 | 495 |
| Leu Gln Thr Ser | Asp Gly Asp Ile Asn | Asn Ile Asp Phe Asp | Asn |
|                 | 500                 | 505                 | 510 |
| Asn Asp Ile Pro | Arg Thr Asp Thr Ile | Asn Ile Pro Asn Pro | Met |
|                 | 515                 | 520                 | 525 |
| Cys Thr Ala Ile | Ala Ala Leu Leu His | Tyr Phe Leu Leu Val | Thr |
|                 | 530                 | 535                 | 540 |
| Phe Thr Trp Asn | Ala Leu Ser Ala Ala | Gln Leu Tyr Tyr Leu | Leu |
|                 | 545                 | 550                 | 555 |
| Ile Arg Thr Met | Lys Pro Leu Pro Arg | His Phe Ile Leu Phe | Ile |
|                 | 560                 | 565                 | 570 |
| Ser Leu Ile Gly | Trp Gly Val Pro Ala | Ile Val Val Ala Ile | Thr |
|                 | 575                 | 580                 | 585 |
| Val Gly Val Ile | Tyr Ser Gln Asn Gly | Asn Asn Pro Gln Trp | Glu |
|                 | 590                 | 595                 | 600 |
| Leu Asp Tyr Arg | Gln Glu Lys Ile Cys | Trp Leu Ala Ile Pro | Glu |
|                 | 605                 | 610                 | 615 |
| Pro Asn Gly Val | Ile Lys Ser Pro Leu | Leu Trp Ser Phe Ile | Val |
|                 | 620                 | 625                 | 630 |
| Pro Val Thr Ile | Ile Leu Ile Ser Asn | Val Val Met Phe Ile | Thr |
|                 | 635                 | 640                 | 645 |
| Ile Ser Ile Lys | Val Leu Trp Lys Asn | Asn Gln Asn Leu Thr | Ser |
|                 | 650                 | 655                 | 660 |
| Thr Lys Lys Val | Ser Ser Met Lys Lys | Ile Val Ser Thr Leu | Ser |
|                 | 665                 | 670                 | 675 |
| Val Ala Val Val | Phe Gly Ile Thr Trp | Ile Leu Ala Tyr Leu | Met |
|                 | 680                 | 685                 | 690 |
| Leu Val Asn Asp | Asp Ser Ile Arg Ile | Val Phe Ser Tyr Ile | Phe |
|                 | 695                 | 700                 | 705 |
| Cys Leu Phe Asn | Thr Thr Gln Gly Leu | Gln Ile Phe Ile Leu | Tyr |
|                 | 710                 | 715                 | 720 |
| Thr Val Arg Thr | Lys Val Phe Gln Ser | Glu Ala Ser Lys Val | Leu |
|                 | 725                 | 730                 | 735 |
| Met Leu Leu Ser | Ser Ile Gly Arg Arg | Lys Ser Leu Pro Ser | Val |
|                 | 740                 | 745                 | 750 |
| Thr Arg Pro Arg | Leu Arg Val Lys Met | Tyr Asn Phe Leu Arg | Ser |
|                 | 755                 | 760                 | 765 |
| Leu Pro Thr Leu | His Glu Arg Phe Arg | Leu Leu Glu Thr Ser | Pro |
|                 | 770                 | 775                 | 780 |
| Ser Thr Glu Glu | Ile Thr Leu Ser Glu | Ser Asp Asn Ala Lys | Glu |
|                 | 785                 | 790                 | 795 |
| Ser Ile         |                     |                     |     |

&lt;210&gt; 5

&lt;211&gt; 434

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

PI-0236 PCT

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3837054CD1

&lt;400&gt; 5

```

Met Glu Asp Leu Phe Ser Pro Ser Ile Leu Pro Pro Ala Pro Asn
 1          5          10          15
Ile Ser Val Pro Ile Leu Leu Gly Trp Gly Leu Asn Leu Thr Leu
          20          25          30
Gly Gln Gly Ala Pro Ala Ser Gly Pro Pro Ser Arg Arg Val Arg
          35          40          45
Leu Val Phe Leu Gly Val Ile Leu Val Val Ala Val Ala Gly Asn
          50          55          60
Thr Thr Val Leu Cys Arg Leu Cys Gly Gly Gly Gly Pro Trp Ala
          65          70          75
Gly Pro Lys Arg Arg Lys Met Asp Phe Leu Leu Val Gln Leu Ala
          80          85          90
Leu Ala Asp Leu Tyr Ala Cys Gly Gly Thr Ala Leu Ser Gln Leu
          95          100          105
Ala Trp Glu Leu Leu Gly Glu Pro Arg Ala Ala Thr Gly Asp Leu
          110          115          120
Ala Cys Arg Phe Leu Gln Leu Leu Gln Ala Ser Gly Arg Gly Ala
          125          130          135
Ser Ala His Leu Val Val Leu Ile Ala Leu Glu Arg Arg Arg Ala
          140          145          150
Val Arg Leu Pro His Gly Arg Pro Leu Pro Ala Arg Ala Leu Ala
          155          160          165
Ala Leu Gly Trp Leu Leu Ala Leu Leu Ala Leu Pro Pro Ala
          170          175          180
Phe Val Val Arg Gly Asp Ser Pro Ser Pro Leu Pro Pro Pro Pro
          185          190          195
Pro Pro Thr Ser Leu Gln Pro Gly Ala Pro Pro Ala Ala Arg Ala
          200          205          210
Trp Pro Gly Glu Arg Arg Cys His Gly Ile Phe Ala Pro Leu Pro
          215          220          225
Arg Trp His Leu Gln Val Tyr Ala Phe Tyr Glu Ala Val Ala Gly
          230          235          240
Phe Val Ala Pro Val Thr Val Leu Gly Val Ala Cys Gly His Leu
          245          250          255
Leu Ser Val Trp Trp Arg His Arg Pro Gln Ala Pro Ala Ala Ala
          260          265          270
Ala Pro Trp Ser Ala Ser Pro Gly Arg Ala Pro Ala Pro Ser Ala
          275          280          285
Leu Pro Arg Ala Lys Val Gln Ser Leu Lys Met Ser Leu Leu Leu
          290          295          300

```

```

Glu Gly Leu Ser Ala Ala Leu Arg Val Val Ala Met Ala Asn Ser
          335          340          345

```

PI-0236 PCT

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Ala | Leu | Asn | Pro | Phe | Val | Tyr | Leu | Phe | Phe | Gln | Ala | Gly | Asp | Cys |  |
|     |     |     |     | 350 |     |     |     |     | 355 |     |     |     |     | 360 |  |
| Arg | Leu | Arg | Arg | Gln | Leu | Arg | Lys | Arg | Leu | Gly | Ser | Leu | Cys | Cys |  |
|     |     |     |     | 365 |     |     |     |     | 370 |     |     |     |     | 375 |  |
| Ala | Pro | Gln | Gly | Gly | Ala | Glu | Asp | Glu | Glu | Gly | Pro | Arg | Gly | His |  |
|     |     |     |     | 380 |     |     |     |     | 385 |     |     |     |     | 390 |  |
| Gln | Ala | Leu | Tyr | Arg | Gln | Arg | Trp | Pro | His | Pro | His | Tyr | His | His |  |
|     |     |     |     | 395 |     |     |     |     | 400 |     |     |     |     | 405 |  |
| Ala | Arg | Arg | Glu | Pro | Leu | Asp | Glu | Gly | Gly | Leu | Arg | Pro | Pro | Pro |  |
|     |     |     |     | 410 |     |     |     |     | 415 |     |     |     |     | 420 |  |
| Pro | Arg | Pro | Arg | Pro | Leu | Pro | Cys | Ser | Cys | Glu | Ser | Ala | Phe |     |  |
|     |     |     |     | 425 |     |     |     |     | 430 |     |     |     |     |     |  |

&lt;210&gt; 6

&lt;211&gt; 339

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 6157025CD1

&lt;400&gt; 6

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Met | Pro | Gly | His | Asn | Thr | Ser | Arg | Asn | Ser | Ser | Cys | Asp | Pro | Ile |  |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |  |
| Val | Thr | Pro | His | Leu | Ile | Ser | Leu | Tyr | Phe | Ile | Val | Leu | Ile | Gly |  |
|     |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |  |
| Gly | Leu | Val | Gly | Val | Ile | Ser | Ile | Leu | Phe | Leu | Leu | Val | Lys | Met |  |
|     |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |  |
| Asn | Thr | Arg | Ser | Val | Thr | Thr | Met | Ala | Val | Ile | Asn | Leu | Val | Val |  |
|     |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |  |
| Val | His | Ser | Val | Phe | Leu | Leu | Thr | Val | Pro | Phe | Arg | Leu | Thr | Tyr |  |
|     |     |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |  |
| Leu | Ile | Lys | Lys | Thr | Trp | Met | Phe | Gly | Leu | Pro | Phe | Cys | Lys | Phe |  |
|     |     |     |     | 80  |     |     |     |     | 85  |     |     |     |     | 90  |  |
| Val | Ser | Ala | Met | Leu | His | Ile | His | Met | Tyr | Leu | Thr | Phe | Leu | Phe |  |
|     |     |     |     | 95  |     |     |     |     | 100 |     |     |     |     | 105 |  |
| Tyr | Val | Val | Ile | Leu | Val | Thr | Arg | Tyr | Leu | Ile | Phe | Phe | Lys | Cys |  |
|     |     |     |     | 110 |     |     |     |     | 115 |     |     |     |     | 120 |  |
| Lys | Asp | Lys | Val | Glu | Phe | Tyr | Arg | Lys | Leu | His | Ala | Val | Ala | Ala |  |
|     |     |     |     | 125 |     |     |     |     | 130 |     |     |     |     | 135 |  |
| Ser | Ala | Gly | Met | Trp | Thr | Leu | Val | Ile | Val | Ile | Val | Val | Pro | Leu |  |
|     |     |     |     | 140 |     |     |     |     | 145 |     |     |     |     | 150 |  |
| Val | Val | Ser | Arg | Tyr | Gly | Ile | His | Glu | Glu | Tyr | Asn | Glu | Glu | His |  |
|     |     |     |     | 155 |     |     |     |     | 160 |     |     |     |     | 165 |  |
| Cys | Phe | Lys | Phe | His | Lys | Glu | Leu | Ala | Tyr | Thr | Tyr | Val | Lys | Ile |  |
|     |     |     |     | 170 |     |     |     |     | 175 |     |     |     |     | 180 |  |
| Ile | Asn | Tyr | Met | Ile | Val | Ile | Phe | Val | Ile | Ala | Val | Ala | Val | Ile |  |
|     |     |     |     | 185 |     |     |     |     | 190 |     |     |     |     | 195 |  |
| Leu | Leu | Val | Phe | Gln | Val | Phe | Ile | Ile | Met | Leu | Met | Val | Gln | Lys |  |
|     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |     | 210 |  |
| Leu | Arg | His | Ser | Leu | Leu | Ser | His | Gln | Glu | Phe | Trp | Ala | Gln | Leu |  |

PI-0236 PCT

|                 |                     |                 |         |  |     |
|-----------------|---------------------|-----------------|---------|--|-----|
|                 | 215                 |                 | 220     |  | 225 |
| Lys Asn Leu Phe | Phe Ile Gly Val Ile | Leu Val Cys Phe | Leu Pro |  |     |
|                 | 230                 |                 | 235     |  | 240 |
| Tyr Gln Phe Phe | Arg Ile Tyr Tyr Leu | Asn Val Val Thr | His Ser |  |     |
|                 | 245                 |                 | 250     |  | 255 |
| Asn Ala Cys Asn | Ser Lys Val Ala Phe | Tyr Asn Glu Ile | Phe Leu |  |     |
|                 | 260                 |                 | 265     |  | 270 |
| Ser Val Thr Ala | Ile Ser Cys Tyr Asp | Leu Leu Leu Phe | Val Phe |  |     |
|                 | 275                 |                 | 280     |  | 285 |
| Gly Gly Ser His | Trp Phe Lys Gln Lys | Ile Met Ala Tyr | Gly Ile |  |     |
|                 | 290                 |                 | 295     |  | 300 |
| Val Phe Val Pro | Leu Ala Thr Asn Tyr | Ser Ile His Ile | Cys Phe |  |     |
|                 | 305                 |                 | 310     |  | 315 |
| Leu Tyr Ile Gly | Asn Lys Asn Gly Tyr | Arg Gly Gly Lys | Asn Gly |  |     |
|                 | 320                 |                 | 325     |  | 330 |
| Ile Ser Leu Leu | Asp Gln Ser Met     | Pro             |         |  |     |
|                 | 335                 |                 |         |  |     |

&lt;210&gt; 7

&lt;211&gt; 549

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 55012817CD1

&lt;400&gt; 7

|                 |                 |                 |             |
|-----------------|-----------------|-----------------|-------------|
| Met Ala Thr Pro | Arg Gly Leu Gly | Ala Leu Leu Leu | Leu Leu     |
| 1               | 5               | 10              | 15          |
| Leu Pro Thr Ser | Gly Gln Glu Lys | Pro Thr Glu Gly | Pro Arg Asn |
|                 | 20              | 25              | 30          |
| Thr Cys Leu Gly | Ser Asn Asn Met | Tyr Asp Ile Phe | Asn Leu Asn |
|                 | 35              | 40              | 45          |
| Asp Lys Ala Leu | Cys Phe Thr Lys | Cys Arg Gln Ser | Gly Ser Asp |
|                 | 50              | 55              | 60          |
| Ser Cys Asn Val | Glu Asn Leu Gln | Arg Tyr Trp Leu | Asn Tyr Glu |
|                 | 65              | 70              | 75          |
| Ala His Leu Met | Lys Glu Gly Leu | Thr Gln Lys Val | Asn Thr Pro |
|                 | 80              | 85              | 90          |
| Phe Leu Lys Ala | Leu Val Gln Asn | Leu Ser Thr Asn | Thr Ala Glu |
|                 | 95              | 100             | 105         |
| Asp Phe Tyr Phe | Ser Leu Glu Pro | Ser Gln Val Pro | Arg Gln Val |
|                 | 110             | 115             | 120         |
| Met Lys Asp Glu | Asp Lys Pro Pro | Asp Arg Val Arg | Leu Pro Lys |
|                 | 125             | 130             | 135         |

|                 |                 |                 |             |
|-----------------|-----------------|-----------------|-------------|
| Pro Arg Leu Gly | Leu Gly Asp Gly | Ser Gly Val Leu | Asn Asn Arg |
| 170             | 175             | 180             |             |

PI-0236 PCT

|   |     |     |     |
|---|-----|-----|-----|
| Leu Val Gly Leu Ser Val Gly Gln Met His Val Thr Lys Leu Ala | 185 | 190 | 195 |
| Glu Pro Leu Glu Ile Val Phe Ser His Gln Arg Pro Pro Pro Asn | 200 | 205 | 210 |
| Met Thr Leu Thr Cys Val Phe Trp Asp Val Thr Lys Gly Thr Thr | 215 | 220 | 225 |
| Gly Asp Trp Ser Ser Glu Gly Cys Ser Thr Glu Val Arg Pro Glu | 230 | 235 | 240 |
| Gly Thr Val Cys Cys Cys Asp His Leu Thr Phe Phe Ala Leu Leu | 245 | 250 | 255 |
| Leu Arg Pro Thr Leu Asp Gln Ser Thr Val His Ile Leu Thr Arg | 260 | 265 | 270 |
| Ile Ser Gln Ala Gly Cys Gly Val Ser Met Ile Phe Leu Ala Phe | 275 | 280 | 285 |
| Thr Ile Ile Leu Tyr Ala Phe Leu Arg Leu Ser Arg Glu Arg Phe | 290 | 295 | 300 |
| Lys Ser Glu Asp Ala Pro Lys Ile His Val Ala Leu Gly Gly Ser | 305 | 310 | 315 |
| Leu Phe Leu Leu Asn Leu Ala Phe Leu Val Asn Val Gly Ser Gly | 320 | 325 | 330 |
| Ser Lys Gly Ser Asp Ala Ala Cys Trp Ala Arg Gly Ala Val Phe | 335 | 340 | 345 |
| His Tyr Phe Leu Leu Cys Ala Phe Thr Trp Met Gly Leu Glu Ala | 350 | 355 | 360 |
| Phe His Leu Tyr Leu Leu Ala Val Arg Val Phe Asn Thr Tyr Phe | 365 | 370 | 375 |
| Gly His Tyr Phe Leu Lys Leu Ser Leu Val Gly Trp Gly Leu Pro | 380 | 385 | 390 |
| Ala Leu Met Val Ile Gly Thr Gly Ser Ala Asn Ser Tyr Gly Leu | 395 | 400 | 405 |
| Tyr Thr Ile Arg Asp Arg Glu Asn Arg Thr Ser Leu Glu Leu Cys | 410 | 415 | 420 |
| Trp Phe Arg Glu Gly Thr Thr Met Tyr Ala Leu Tyr Ile Thr Val | 425 | 430 | 435 |
| His Gly Tyr Phe Leu Ile Thr Phe Leu Phe Gly Met Val Val Leu | 440 | 445 | 450 |
| Ala Leu Val Val Trp Lys Ile Phe Thr Leu Ser Arg Ala Thr Ala | 455 | 460 | 465 |
| Val Lys Glu Arg Gly Lys Asn Arg Lys Lys Val Leu Thr Leu Leu | 470 | 475 | 480 |
| Gly Leu Ser Ser Leu Val Gly Val Thr Trp Gly Leu Ala Ile Phe | 485 | 490 | 495 |
| Thr Pro Leu Gly Leu Ser Thr Val Tyr Ile Phe Ala Leu Phe Asn | 500 | 505 | 510 |
| Ser Leu Gln Gly Val Phe Ile Cys Cys Trp Phe Thr Ile Leu Tyr | 515 | 520 | 525 |
| Leu Pro Ser Gln Ser Thr Thr Val Ser Ser Ser Thr Ala Arg Leu | 530 | 535 | 540 |
| Asp Gln Ala His Ser Ala Ser Gln Glu                         | 545 |     |     |

&lt;210&gt; 8



PI-0236 PCT

&lt;211&gt; 188

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7475061CD1

&lt;400&gt; 8

```

Met Pro Leu Val Gly Leu Gly Asp Tyr Val Pro Glu Pro Phe Gly
 1              5              10              15
Thr Ser Cys Thr Leu Asp Trp Trp Leu Ala Gln Ala Ser Val Gly
              20              25              30
Gly Gln Val Phe Ile Leu Asn Ile Leu Phe Phe Cys Leu Leu Leu
              35              40              45
Pro Thr Ala Val Ile Val Phe Ser Tyr Val Lys Ile Ile Ala Lys
              50              55              60
Val Lys Ser Ser Ser Lys Glu Val Ala His Phe Asp Ser Arg Ile
              65              70              75
His Ser Ser His Val Leu Glu Met Lys Leu Thr Lys Val Ala Met
              80              85              90
Leu Ile Cys Ala Gly Phe Leu Ile Ala Trp Ile Pro Tyr Ala Val
              95              100             105
Val Ser Val Trp Ser Ala Phe Gly Arg Pro Asp Ser Ile Pro Ile
              110             115             120
Gln Leu Ser Val Val Pro Thr Leu Leu Ala Lys Ser Ala Ala Met
              125             130             135
Tyr Asn Pro Ile Ile Tyr Gln Val Ile Asp Tyr Lys Phe Ala Cys
              140             145             150
Cys Gln Thr Gly Gly Leu Lys Ala Thr Lys Lys Lys Ser Leu Glu
              155             160             165
Gly Phe Arg Leu His Thr Val Thr Thr Val Arg Lys Ser Ser Ala
              170             175             180
Val Leu Glu Ile His Glu Glu Val
              185

```

&lt;210&gt; 9

&lt;211&gt; 332

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7477374CD1

&lt;400&gt; 9

```

Pro Arg Ser Ile Leu Tyr Ala Val Leu Gly Phe Gly Ala Val Leu
              35              40              45

```

PI-0236 PCT

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ala | Phe | Gly | Asn | Leu | Leu | Val | Met | Ile | Ala | Ile | Leu | His | Phe | 50  | 55  | 60  |
| Lys | Gln | Leu | His | Thr | Pro | Thr | Asn | Phe | Leu | Ile | Ala | Ser | Leu | Ala | 65  | 70  | 75  |
| Cys | Ala | Asp | Phe | Leu | Val | Gly | Val | Thr | Val | Met | Pro | Phe | Ser | Thr | 80  | 85  | 90  |
| Val | Arg | Ser | Val | Glu | Ser | Cys | Trp | Tyr | Phe | Gly | Asp | Ser | Tyr | Cys | 95  | 100 | 105 |
| Lys | Phe | His | Thr | Cys | Phe | Asp | Thr | Ser | Phe | Cys | Phe | Ala | Ser | Leu | 110 | 115 | 120 |
| Phe | His | Leu | Cys | Cys | Ile | Ser | Val | Asp | Arg | Tyr | Met | Leu | Gly | Tyr | 125 | 130 | 135 |
| Ala | Trp | Phe | Phe | Pro | Gly | Phe | Phe | Ser | Val | Thr | Tyr | Ser | Phe | Ser | 140 | 145 | 150 |
| Ile | Phe | Asn | Thr | Gly | Ala | Asn | Glu | Glu | Gly | Ile | Glu | Glu | Leu | Val | 155 | 160 | 165 |
| Val | Ala | Leu | Thr | Cys | Val | Gly | Gly | Cys | Gln | Ala | Pro | Leu | Asn | Gln | 170 | 175 | 180 |
| Asn | Trp | Val | Leu | Leu | Cys | Phe | Leu | Leu | Phe | Phe | Ile | Pro | Asn | Val | 185 | 190 | 195 |
| Ala | Met | Val | Phe | Ile | Tyr | Ser | Lys | Ile | Phe | Leu | Val | Ala | Lys | His | 200 | 205 | 210 |
| Gln | Ala | Arg | Lys | Ile | Glu | Ser | Thr | Ala | Ser | Gln | Ala | Gln | Ser | Ser | 215 | 220 | 225 |
| Ser | Glu | Ser | Tyr | Lys | Glu | Arg | Val | Ala | Lys | Arg | Glu | Arg | Lys | Ala | 230 | 235 | 240 |
| Ala | Lys | Thr | Leu | Gly | Ile | Ala | Met | Ala | Ala | Phe | Leu | Val | Ser | Trp | 245 | 250 | 255 |
| Leu | Pro | Tyr | Leu | Val | Asp | Ala | Val | Ile | Asp | Ala | Tyr | Met | Asn | Phe | 260 | 265 | 270 |
| Ile | Thr | Pro | Pro | Tyr | Val | Tyr | Glu | Ile | Leu | Val | Trp | Cys | Val | Tyr | 275 | 280 | 285 |
| Tyr | Asn | Ser | Ala | Met | Asn | Pro | Leu | Ile | Tyr | Ala | Phe | Phe | Tyr | Gln | 290 | 295 | 300 |
| Trp | Phe | Gly | Lys | Ala | Ile | Lys | Leu | Ile | Val | Ser | Gly | Lys | Val | Leu | 305 | 310 | 315 |
| Arg | Thr | Asp | Ser | Ser | Thr | Thr | Asn | Leu | Phe | Ser | Glu | Glu | Val | Glu | 320 | 325 | 330 |
| Thr | Asp |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

&lt;210&gt; 10

&lt;211&gt; 948

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7479890CD1

&lt;400&gt; 10

Met Pro Ser Pro Pro Gly Leu Arg Ala Leu Trp Leu Cys Ala Ala

| 1   | 5   | 10  | 15 |
|---|-----|-----|----|
| Leu Cys Ala Ser Arg Arg Ala Gly Gly Ala Pro Gln Pro Gly Pro |     |     |    |
| 20  | 25  | 30  |    |
| Gly Pro Thr Ala Cys Pro Ala Pro Cys His Cys Gln Glu Asp Gly |     |     |    |
| 35  | 40  | 45  |    |
| Ile Met Leu Ser Ala Asp Cys Ser Glu Leu Gly Leu Ser Ala Val |     |     |    |
| 50  | 55  | 60  |    |
| Pro Gly Asp Leu Asp Pro Leu Thr Ala Tyr Leu Leu Gly Cys Pro |     |     |    |
| 65  | 70  | 75  |    |
| Pro Pro Leu Gln Lys Ala Gln Ala Val Gly Gln Leu Gly Glu Tyr |     |     |    |
| 80  | 85  | 90  |    |
| Glu Lys Gln Phe Gly Pro Arg Gln Val Lys Leu Phe Pro Gln Ser |     |     |    |
| 95  | 100 | 105 |    |
| Leu Ser Lys Pro Glu Leu Ala Cys Glu Val Pro Ala Asn Leu Pro |     |     |    |
| 110   | 115 | 120 |    |
| His Tyr Cys Arg Arg Leu Asp Ala Asn Leu Ile Ser Leu Val Pro |     |     |    |
| 125   | 130 | 135 |    |
| Glu Arg Ser Phe Glu Gly Leu Ser Ser Leu Arg His Leu Trp Leu |     |     |    |
| 140   | 145 | 150 |    |
| Asp Asp Asn Ala Leu Thr Glu Ile Pro Val Arg Ala Leu Asn Asn |     |     |    |
| 155   | 160 | 165 |    |
| Leu Pro Ala Leu Gln Ala Met Ala Leu Ala Leu Asn Arg Ile Ser |     |     |    |
| 170   | 175 | 180 |    |
| His Ile Pro Asp Tyr Ala Phe Gln Asn Leu Thr Ser Leu Val Val |     |     |    |
| 185   | 190 | 195 |    |
| Leu His Leu His Asn Asn Arg Ile Gln His Leu Gly Thr His Ser |     |     |    |
| 200   | 205 | 210 |    |
| Phe Glu Gly Leu His Asn Leu Glu Thr Leu Asp Leu Asn Tyr Asn |     |     |    |
| 215   | 220 | 225 |    |
| Lys Leu Gln Glu Phe Pro Val Ala Ile Arg Thr Leu Gly Arg Leu |     |     |    |
| 230   | 235 | 240 |    |
| Gln Glu Leu Gly Phe His Asn Asn Asn Ile Lys Ala Ile Pro Glu |     |     |    |
| 245   | 250 | 255 |    |
| Lys Ala Phe Met Gly Asn Pro Leu Leu Gln Thr Ile His Phe Tyr |     |     |    |
| 260   | 265 | 270 |    |
| Asp Asn Thr Ile Gln Phe Val Gly Arg Ser Ala Phe Gln Tyr Leu |     |     |    |
| 275   | 280 | 285 |    |
| Pro Lys Leu His Thr Leu Ser Leu Asn Gly Ala Met Asp Ile Gln |     |     |    |
| 290   | 295 | 300 |    |
| Glu Phe Pro Gly Leu Lys Gly Thr Thr Ser Leu Glu Ile Leu Thr |     |     |    |
| 305   | 310 | 315 |    |
| Leu Thr Arg Ala Gly Ile Arg Leu Leu Pro Ser Gly Met Cys Gln |     |     |    |
| 320   | 325 | 330 |    |
| Gln Leu Pro Arg Leu Arg Val Leu Glu Leu Ser His Asn Gln Ile |     |     |    |
| 335   | 340 | 345 |    |
| Glu Glu Leu Pro Ser Leu His Arg Cys Gln Lys Leu Glu Glu Ile |     |     |    |
| 350   | 355 | 360 |    |
| Leu Thr Arg Ala Gly Ile Arg Leu Leu Pro Ser Gly Met Cys Gln |     |     |    |
| 365   | 370 | 375 |    |
| Gln Leu Pro Arg Leu Arg Val Leu Glu Leu Ser His Asn Gln Ile |     |     |    |
| 380   | 385 | 390 |    |
| Ile Arg Ser Ile His Pro Glu Ala Phe Ser Thr Leu His Ser Leu |     |     |    |

PI-0236 PCT

|                 |                     |                     |     |  |     |
|-----------------|---------------------|---------------------|-----|--|-----|
|                 | 395                 |                     | 400 |  | 405 |
| Val Lys Leu Asp | Leu Thr Asp Asn Gln | Leu Thr Thr Leu Pro | Leu |  |     |
|                 | 410                 |                     | 415 |  | 420 |
| Ala Gly Leu Gly | Gly Leu Met His Leu | Lys Leu Lys Gly Asn | Leu |  |     |
|                 | 425                 |                     | 430 |  | 435 |
| Ala Leu Ser Gln | Ala Phe Ser Lys Asp | Ser Phe Pro Lys Leu | Arg |  |     |
|                 | 440                 |                     | 445 |  | 450 |
| Ile Leu Glu Val | Pro Tyr Ala Tyr Gln | Cys Cys Pro Tyr Gly | Met |  |     |
|                 | 455                 |                     | 460 |  | 465 |
| Cys Ala Ser Phe | Phe Lys Ala Ser Gly | Gln Trp Glu Ala Glu | Asp |  |     |
|                 | 470                 |                     | 475 |  | 480 |
| Leu His Leu Asp | Asp Glu Glu Ser Ser | Lys Arg Pro Leu Gly | Leu |  |     |
|                 | 485                 |                     | 490 |  | 495 |
| Leu Ala Arg Gln | Ala Glu Asn His Tyr | Asp Gln Asp Leu Asp | Glu |  |     |
|                 | 500                 |                     | 505 |  | 510 |
| Leu Gln Leu Glu | Met Glu Asp Ser Lys | Pro His Pro Ser Val | Gln |  |     |
|                 | 515                 |                     | 520 |  | 525 |
| Cys Ser Pro Thr | Pro Gly Pro Phe Lys | Pro Cys Glu Tyr Leu | Phe |  |     |
|                 | 530                 |                     | 535 |  | 540 |
| Glu Ser Trp Gly | Ile Arg Leu Ala Val | Trp Ala Ile Val Leu | Leu |  |     |
|                 | 545                 |                     | 550 |  | 555 |
| Ser Val Leu Cys | Asn Gly Leu Val Leu | Leu Thr Val Phe Ala | Gly |  |     |
|                 | 560                 |                     | 565 |  | 570 |
| Gly Pro Ala Pro | Leu Pro Pro Val Lys | Phe Val Val Gly Ala | Ile |  |     |
|                 | 575                 |                     | 580 |  | 585 |
| Ala Gly Ala Asn | Thr Leu Thr Gly Ile | Ser Cys Gly Leu Leu | Ala |  |     |
|                 | 590                 |                     | 595 |  | 600 |
| Ser Val Asp Ala | Leu Thr Phe Gly Gln | Phe Ser Glu Tyr Gly | Ala |  |     |
|                 | 605                 |                     | 610 |  | 615 |
| Arg Trp Glu Thr | Gly Leu Gly Cys Arg | Ala Thr Gly Phe Leu | Ala |  |     |
|                 | 620                 |                     | 625 |  | 630 |
| Val Leu Gly Ser | Glu Ala Ser Val Leu | Leu Leu Thr Leu Ala | Ala |  |     |
|                 | 635                 |                     | 640 |  | 645 |
| Val Gln Cys Ser | Val Ser Val Ser Cys | Val Arg Ala Tyr Gly | Lys |  |     |
|                 | 650                 |                     | 655 |  | 660 |
| Ser Pro Ser Leu | Gly Ser Val Arg Ala | Gly Val Leu Gly Cys | Leu |  |     |
|                 | 665                 |                     | 670 |  | 675 |
| Ala Leu Ala Gly | Leu Ala Ala Ala Leu | Pro Leu Ala Ser Val | Gly |  |     |
|                 | 680                 |                     | 685 |  | 690 |
| Glu Tyr Gly Ala | Ser Pro Leu Cys Leu | Pro Tyr Ala Pro Pro | Glu |  |     |
|                 | 695                 |                     | 700 |  | 705 |
| Gly Gln Pro Ala | Ala Leu Gly Phe Thr | Val Ala Leu Val Met | Met |  |     |
|                 | 710                 |                     | 715 |  | 720 |
| Asn Ser Phe Cys | Phe Leu Val Val Ala | Gly Ala Tyr Ile Lys | Leu |  |     |
|                 | 725                 |                     | 730 |  | 735 |
| Tyr Cys Asp Leu | Pro Arg Gly Asp Phe | Glu Ala Val Trp Asp | Cys |  |     |
|                 | 740                 |                     | 745 |  | 750 |
| Ala Met Val Arg | His Val Ala Trp Leu | Ile Phe Ala Asp Gly | Leu |  |     |
|                 | 755                 |                     | 760 |  | 765 |
| Leu Tyr Cys Pro | Val Ala Phe Leu Ser | Phe Ala Ser Met Leu | Gly |  |     |
|                 | 770                 |                     | 775 |  | 780 |
| Leu Phe Pro Val | Thr Pro Glu Ala Val | Lys Ser Val Leu Leu | Val |  |     |

PI-0236 PCT

|                 |                     |                 |         |
|-----------------|---------------------|-----------------|---------|
|                 | 785                 | 790             | 795     |
| Val Leu Pro Leu | Pro Ala Cys Leu Asn | Pro Leu Leu Tyr | Leu Leu |
|                 | 800                 | 805             | 810     |
| Phe Asn Pro His | Phe Arg Asp Asp Leu | Arg Arg Leu Arg | Pro Arg |
|                 | 815                 | 820             | 825     |
| Ala Gly Asp Ser | Gly Pro Leu Ala Tyr | Ala Ala Ala Gly | Glu Leu |
|                 | 830                 | 835             | 840     |
| Glu Lys Ser Ser | Cys Asp Ser Thr Gln | Ala Leu Val Ala | Phe Ser |
|                 | 845                 | 850             | 855     |
| Asp Val Asp Leu | Ile Leu Glu Ala Ser | Glu Ala Gly Arg | Pro Pro |
|                 | 860                 | 865             | 870     |
| Gly Leu Glu Thr | Tyr Gly Phe Pro Ser | Val Thr Leu Ile | Ser Cys |
|                 | 875                 | 880             | 885     |
| Gln Gln Pro Gly | Ala Pro Arg Leu Glu | Gly Ser His Cys | Val Glu |
|                 | 890                 | 895             | 900     |
| Pro Glu Gly Asn | His Phe Gly Asn Pro | Gln Pro Ser Met | Asp Gly |
|                 | 905                 | 910             | 915     |
| Glu Leu Leu Leu | Arg Ala Glu Gly Ser | Thr Pro Ala Gly | Gly Gly |
|                 | 920                 | 925             | 930     |
| Leu Ser Gly Gly | Gly Gly Phe Gln Pro | Ser Gly Leu Ala | Phe Ala |
|                 | 935                 | 940             | 945     |
| Ser His Val     |                     |                 |         |

&lt;210&gt; 11

&lt;211&gt; 315

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7482825CD1

&lt;400&gt; 11

|                 |                             |                     |
|-----------------|-----------------------------|---------------------|
| Met Glu Ile Val | Ser Thr Gly Asn Glu Thr     | Ile Thr Glu Phe Val |
| 1               | 5                           | 10                  |
| Leu Leu Gly Phe | Tyr Asp Ile Pro Glu Leu His | Phe Leu Phe Phe     |
|                 | 20                          | 25                  |
| Ile Val Phe Thr | Ala Val Tyr Val Phe Ile     | Ile Ile Gly Asn Met |
|                 | 35                          | 40                  |
| Leu Ile Ile Val | Ala Val Val Ser Ser Gln     | Arg Leu His Lys Pro |
|                 | 50                          | 55                  |
| Met Tyr Ile Phe | Leu Ala Asn Leu Ser Phe     | Leu Asp Ile Leu Tyr |
|                 | 65                          | 70                  |
| Thr Ser Ala Val | Met Pro Lys Met Leu Glu     | Gly Phe Leu Gln Glu |
|                 | 80                          | 85                  |
|                 |                             | 90                  |

|                 |                         |                     |
|-----------------|-------------------------|---------------------|
| Tyr Asp Arg Tyr | Leu Ala Ile Cys Tyr Pro | Leu His Tyr Pro Leu |
| 125             | 130                     | 135                 |

PI-0236 PCT

|   |     |     |     |
|---|-----|-----|-----|
| Leu Met Gly Pro Arg Arg Tyr Met Gly Leu Val Val Thr Thr Trp | 140 | 145 | 150 |
| Leu Ser Gly Phe Val Val Asp Gly Leu Val Val Ala Leu Val Ala | 155 | 160 | 165 |
| Gln Leu Arg Phe Cys Gly Pro Asn His Ile Asp Gln Phe Tyr Cys | 170 | 175 | 180 |
| Asp Phe Met Leu Phe Val Gly Leu Ala Cys Ser Asp Pro Arg Val | 185 | 190 | 195 |
| Ala Gln Val Thr Thr Leu Ile Leu Ser Val Phe Cys Leu Thr Ile | 200 | 205 | 210 |
| Pro Phe Gly Leu Ile Leu Thr Ser Tyr Ala Arg Ile Val Val Ala | 215 | 220 | 225 |
| Val Leu Arg Val Pro Ala Gly Ala Ser Arg Arg Arg Ala Phe Ser | 230 | 235 | 240 |
| Thr Cys Ser Ser His Leu Ala Val Val Thr Thr Phe Tyr Gly Thr | 245 | 250 | 255 |
| Leu Met Ile Phe Tyr Val Ala Pro Ser Ala Val His Ser Gln Leu | 260 | 265 | 270 |
| Leu Ser Lys Val Phe Ser Leu Leu Tyr Thr Val Val Thr Pro Leu | 275 | 280 | 285 |
| Phe Asn Pro Val Ile Tyr Thr Met Arg Asn Lys Glu Val His Gln | 290 | 295 | 300 |
| Ala Leu Arg Lys Ile Leu Cys Ile Lys Gln Thr Glu Thr Leu Asp | 305 | 310 | 315 |

&lt;210&gt; 12

&lt;211&gt; 312

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7483087CD1

&lt;400&gt; 12

|   |     |     |     |    |
|---|-----|-----|-----|----|
| Met Lys Ala Gly Asn Phe Ser Asp Thr Pro Glu Phe Phe Leu Leu | 1   | 5   | 10  | 15 |
| Gly Leu Ser Gly Asp Pro Glu Leu Gln Pro Ile Leu Phe Met Leu | 20  | 25  | 30  |    |
| Phe Leu Ser Met Tyr Leu Ala Thr Met Leu Gly Asn Leu Leu Ile | 35  | 40  | 45  |    |
| Ile Leu Ala Val Asn Ser Asp Ser His Leu His Thr Pro Met Tyr | 50  | 55  | 60  |    |
| Phe Leu Leu Ser Ile Leu Ser Leu Val Asp Ile Cys Phe Thr Ser | 65  | 70  | 75  |    |
| Thr Thr Met Pro Lys Met Leu Val Asn Ile Gln Ala Gln Ala Gln | 80  | 85  | 90  |    |
| Ser Ile Asn Tyr Thr Gly Cys Leu Thr Gln Ile Cys Phe Val Leu | 95  | 100 | 105 |    |
| Val Phe Val Gly Leu Glu Asn Gly Ile Leu Val Met Met Ala Tyr | 110 | 115 | 120 |    |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Arg | Phe | Val | Ala | Ile | Cys | His | Pro | Leu | Arg | Tyr | Asn | Val | Ile |
|     |     |     |     | 125 |     |     |     |     |     | 130 |     |     |     | 135 |
| Met | Asn | Pro | Lys | Leu | Cys | Gly | Leu | Leu | Leu | Leu | Leu | Ser | Phe | Ile |
|     |     |     |     | 140 |     |     |     |     |     | 145 |     |     |     | 150 |
| Val | Ser | Val | Leu | Asp | Ala | Leu | Leu | His | Thr | Leu | Met | Val | Leu | Gln |
|     |     |     |     | 155 |     |     |     |     |     | 160 |     |     |     | 165 |
| Leu | Thr | Phe | Cys | Ile | Asp | Leu | Glu | Ile | Pro | His | Phe | Phe | Cys | Glu |
|     |     |     |     | 170 |     |     |     |     |     | 175 |     |     |     | 180 |
| Leu | Ala | His | Ile | Leu | Lys | Leu | Ala | Cys | Ser | Asp | Val | Leu | Ile | Asn |
|     |     |     |     | 185 |     |     |     |     |     | 190 |     |     |     | 195 |
| Asn | Ile | Leu | Val | Tyr | Leu | Val | Thr | Ser | Leu | Leu | Gly | Val | Val | Pro |
|     |     |     |     | 200 |     |     |     |     |     | 205 |     |     |     | 210 |
| Leu | Ser | Gly | Ile | Ile | Phe | Ser | Tyr | Thr | Arg | Ile | Val | Ser | Ser | Val |
|     |     |     |     | 215 |     |     |     |     |     | 220 |     |     |     | 225 |
| Met | Lys | Ile | Pro | Ser | Ala | Gly | Gly | Lys | Tyr | Lys | Ala | Phe | Ser | Ile |
|     |     |     |     | 230 |     |     |     |     |     | 235 |     |     |     | 240 |
| Cys | Gly | Ser | His | Leu | Ile | Val | Val | Ser | Leu | Phe | Tyr | Gly | Thr | Gly |
|     |     |     |     | 245 |     |     |     |     |     | 250 |     |     |     | 255 |
| Phe | Gly | Val | Tyr | Leu | Ser | Ser | Gly | Ala | Thr | His | Ser | Ser | Arg | Lys |
|     |     |     |     | 260 |     |     |     |     |     | 265 |     |     |     | 270 |
| Gly | Ala | Ile | Ala | Ser | Val | Met | Tyr | Thr | Val | Val | Thr | Pro | Met | Leu |
|     |     |     |     | 275 |     |     |     |     |     | 280 |     |     |     | 285 |
| Asn | Pro | Leu | Ile | Tyr | Ser | Leu | Arg | Asn | Lys | Asp | Met | Leu | Lys | Ala |
|     |     |     |     | 290 |     |     |     |     |     | 295 |     |     |     | 300 |
| Leu | Arg | Lys | Leu | Ile | Ser | Arg | Ile | Pro | Ser | Phe | His |     |     |     |
|     |     |     |     | 305 |     |     |     |     |     | 310 |     |     |     |     |

<213> Homo sapiens

<223> Incyte ID No: 7483134CD1

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Gly | Ala | Lys | Asn | Asn | Val | Thr | Glu | Phe | Val | Leu | Phe | Gly | Leu |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |
| Phe | Glu | Ser | Arg | Glu | Met | Gln | His | Thr | Cys | Phe | Val | Val | Phe | Phe |
|     |     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |
| Leu | Phe | His | Val | Leu | Thr | Val | Leu | Gly | Asn | Leu | Leu | Val | Ile | Ile |
|     |     |     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |
| Thr | Ile | Asn | Ala | Arg | Lys | Thr | Leu | Lys | Ser | Pro | Met | Tyr | Phe | Phe |
|     |     |     |     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |
| Leu | Ser | Gln | Leu | Ser | Phe | Ala | Asp | Ile | Cys | Tyr | Pro | Ser | Thr | Thr |
|     |     |     |     | 65  |     |     |     |     | 70  |     |     |     |     | 75  |

|                                     |                         |     |
|-------------------------------------|-------------------------|-----|
| 95                                  | 100                     | 105 |
| Gly Gly Thr Glu Ile Phe Leu Leu Thr | Ala Met Ala Tyr Asp Arg |     |

PI-0236 PCT

|                 |                     |                         |     |  |     |
|-----------------|---------------------|-------------------------|-----|--|-----|
|                 | 110                 |                         | 115 |  | 120 |
| Tyr Val Ala Ile | Cys Arg Pro Leu His | Tyr Thr Ala Ile Met Asp |     |  |     |
|                 | 125                 |                         | 130 |  | 135 |
| Cys Arg Lys Cys | Gly Leu Leu Ala Gly | Ala Ser Trp Leu Ala Gly |     |  |     |
|                 | 140                 |                         | 145 |  | 150 |
| Phe Leu His Ser | Ile Leu Gln Thr Leu | Leu Thr Val Gln Leu Pro |     |  |     |
|                 | 155                 |                         | 160 |  | 165 |
| Phe Cys Gly Pro | Asn Glu Ile Asp Asn | Phe Phe Cys Asp Val His |     |  |     |
|                 | 170                 |                         | 175 |  | 180 |
| Pro Leu Leu Lys | Leu Ala Cys Ala Asp | Thr Tyr Met Val Gly Leu |     |  |     |
|                 | 185                 |                         | 190 |  | 195 |
| Ile Val Val Ala | Asn Ser Gly Met Ile | Ser Leu Ala Ser Phe Phe |     |  |     |
|                 | 200                 |                         | 205 |  | 210 |
| Ile Leu Ile Ile | Ser Tyr Val Ile Ile | Leu Leu Asn Leu Arg Ser |     |  |     |
|                 | 215                 |                         | 220 |  | 225 |
| Gln Ser Ser Glu | Asp Arg Arg Lys Ala | Val Ser Thr Cys Gly Ser |     |  |     |
|                 | 230                 |                         | 235 |  | 240 |
| His Val Ile Thr | Val Leu Leu Val Leu | Met Pro Pro Met Phe Met |     |  |     |
|                 | 245                 |                         | 250 |  | 255 |
| Tyr Ile Arg Pro | Ser Thr Thr Leu Ala | Ala Asp Lys Leu Ile Ile |     |  |     |
|                 | 260                 |                         | 265 |  | 270 |
| Leu Phe Asn Ile | Val Met Pro Pro Leu | Leu Asn Pro Leu Ile Tyr |     |  |     |
|                 | 275                 |                         | 280 |  | 285 |
| Thr Leu Arg Asn | Asn Asp Val Lys Asn | Ala Met Arg Lys Leu Phe |     |  |     |
|                 | 290                 |                         | 295 |  | 300 |
| Arg Val Lys Arg | Ser Leu Gly Glu Lys |                         |     |  |     |
|                 | 305                 |                         |     |  |     |

&lt;210&gt; 14

&lt;211&gt; 309

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7478550CD1

&lt;400&gt; 14

|                     |                     |                         |
|---------------------|---------------------|-------------------------|
| Met Met Thr Asn Arg | Asn Gln Val Val     | Leu Gly Arg Met Arg His |
| 1                   | 5                   | 10                      |
| Gln Cys Leu Pro Gln | Thr Glu Arg Ala His | Thr Lys His Asp Leu     |
|                     | 20                  | 25                      |
| Ser Leu Gln Ala Gln | Leu Gln Gln Lys Val | Phe Met Glu Lys Trp     |
|                     | 35                  | 40                      |
| Asn His Thr Ser Asn | Asp Phe Ile Leu Leu | Gly Leu Leu Pro Pro     |
|                     | 50                  | 55                      |
| Asn Gln Thr Gly Ile | Phe Leu Leu Cys Leu | Ile Ile Leu Ile Phe     |
|                     | 65                  | 70                      |
| Phe Leu Ala Ser Val | Gly Asn Ser Ala Met | Ile His Leu Ile His     |
|                     | 80                  | 85                      |
| Val Asp Pro Arg Leu | His Thr Pro Met Tyr | Phe Leu Leu Ser Gln     |
|                     | 95                  | 100                     |
|                     |                     | 105                     |



PI-0236 PCT

Leu Ser Leu Met Asp Leu Met Tyr Ile Ser Thr Thr Val Pro Lys  
 110 115 120  
 Met Ala Tyr Asn Phe Leu Ser Gly Gln Lys Gly Ile Ser Phe Leu  
 125 130 135  
 Gly Cys Gly Val Gln Ser Phe Phe Phe Leu Thr Met Ala Cys Ser  
 140 145 150  
 Glu Gly Leu Leu Leu Thr Ser Met Ala Tyr Asp Arg Tyr Leu Ala  
 155 160 165  
 Ile Cys His Ser Leu Tyr Tyr Pro Ile Arg Met Ser Lys Met Met  
 170 175 180  
 Cys Val Lys Met Ile Gly Gly Ser Trp Thr Leu Gly Ser Ile Asn  
 185 190 195  
 Ser Leu Ala His Thr Val Phe Ala Leu His Ile Pro Tyr Cys Arg  
 200 205 210  
 Ser Arg Ala Ile Asp His Phe Phe Cys Asp Val Pro Ala Met Leu  
 215 220 225  
 Leu Leu Ala Cys Thr Asp Thr Trp Val Tyr Glu Tyr Met Val Phe  
 230 235 240  
 Val Ser Thr Ser Leu Phe Leu Leu Phe Pro Phe Ile Gly Ile Thr  
 245 250 255  
 Ser Ser Cys Gly Arg Val Leu Phe Ala Val Tyr His Met His Ser  
 260 265 270  
 Lys Glu Gly Arg Lys Lys Ala Phe Thr Thr Ile Ser Thr His Leu  
 275 280 285  
 Thr Val Val Ile Phe Tyr Tyr Ala Pro Phe Val Tyr Thr Tyr Leu  
 290 295 300  
 Arg Pro Thr Glu Ser Pro Leu Thr Ser  
 305

&lt;210&gt; 15

&lt;211&gt; 315

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7483142CD1

&lt;400&gt; 15

Met Ser Ile Thr Lys Ala Trp Asn Ser Ser Ser Val Thr Met Phe  
 1 5 10 15  
 Ile Leu Leu Gly Phe Thr Asp His Pro Glu Leu Gln Ala Leu Leu  
 20 25 30  
 Phe Val Thr Phe Leu Gly Ile Tyr Leu Thr Thr Leu Ala Trp Asn  
 35 40 45  
 Leu Ala Leu Ile Phe Leu Ile Arg Gly Asp Thr His Leu His Thr  
 50 55  
 Glu Gln Lys Thr Ile Ser Phe Val Gly Cys Ala Ala Gln Phe Phe  
 80 85 90

PI-0236 PCT

|   |     |  |     |  |     |
|---|-----|--|-----|--|-----|
|   | 95  |  | 100 |  | 105 |
| Phe Phe Val Gly Met Gly Leu Ser Glu Cys Leu Leu Leu Thr Ala |     |  |     |  |     |
|   | 110 |  | 115 |  | 120 |
| Met Ala Tyr Asp Arg Tyr Ala Ala Ile Ser Ser Pro Leu Leu Tyr |     |  |     |  |     |
|   | 125 |  | 130 |  | 135 |
| Pro Thr Ile Met Thr Gln Gly Leu Cys Thr Arg Met Val Val Gly |     |  |     |  |     |
|   | 140 |  | 145 |  | 150 |
| Ala Tyr Val Gly Gly Phe Leu Ser Ser Leu Ile Gln Ala Ser Ser |     |  |     |  |     |
|   | 155 |  | 160 |  | 165 |
| Ile Phe Arg Leu His Phe Cys Gly Pro Asn Ile Ile Asn His Phe |     |  |     |  |     |
|   | 170 |  | 175 |  | 180 |
| Phe Cys Asp Leu Pro Pro Val Leu Ala Leu Ser Cys Ser Asp Thr |     |  |     |  |     |
|   | 185 |  | 190 |  | 195 |
| Phe Leu Ser Gln Val Val Asn Phe Leu Val Val Val Thr Val Gly |     |  |     |  |     |
|   | 200 |  | 205 |  | 210 |
| Gly Thr Ser Phe Leu Gln Leu Leu Ile Ser Tyr Gly Tyr Ile Val |     |  |     |  |     |
|   | 215 |  | 220 |  | 225 |
| Ser Ala Val Leu Lys Ile Pro Ser Ala Glu Gly Arg Trp Lys Ala |     |  |     |  |     |
|   | 230 |  | 235 |  | 240 |
| Cys Asn Thr Cys Ala Ser His Leu Met Val Val Thr Leu Leu Phe |     |  |     |  |     |
|   | 245 |  | 250 |  | 255 |
| Gly Thr Ala Leu Phe Val Tyr Leu Arg Pro Ser Ser Ser Tyr Leu |     |  |     |  |     |
|   | 260 |  | 265 |  | 270 |
| Leu Gly Arg Asp Lys Val Val Ser Val Phe Tyr Ser Leu Val Ile |     |  |     |  |     |
|   | 275 |  | 280 |  | 285 |
| Pro Met Leu Asn Pro Leu Ile Tyr Ser Leu Arg Asn Lys Glu Ile |     |  |     |  |     |
|   | 290 |  | 295 |  | 300 |
| Lys Asp Ala Leu Trp Lys Val Leu Glu Arg Lys Lys Val Phe Ser |     |  |     |  |     |
|   | 305 |  | 310 |  | 315 |

&lt;210&gt; 16

&lt;211&gt; 307

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7483151CD1

&lt;400&gt; 16

|   |    |    |
|---|----|----|
| Met Ala Glu Glu Asn Lys Ile Leu Val Thr His Phe Val Leu Thr |    |    |
| 1   | 5  | 10 |
| Gly Leu Thr Asp His Pro Gly Leu Gln Ala Pro Leu Phe Leu Val |    |    |
|   | 20 | 25 |
| Phe Leu Val Ile Tyr Leu Ile Thr Leu Val Gly Asn Leu Gly Leu |    |    |
|   | 35 | 40 |
| Met Ala Leu Ile Trp Lys Asp Pro His Leu His Thr Pro Ile Tyr |    |    |
|   | 50 | 55 |
| Leu Phe Leu Gly Ser Leu Ala Phe Ala Asp Ala Cys Thr Ser Ser |    |    |
|   | 65 | 70 |
| Ser Val Thr Ser Lys Met Leu Ser Ile Phe Leu Ser Lys Asn His |    |    |

PI-0236 PCT

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|     | 80  |     | 85  |     | 90  |     |     |     |     |     |     |     |     |     |
| Met | Leu | Ser | Met | Ala | Lys | Cys | Ala | Thr | Gln | Phe | Tyr | Phe | Phe | Gly |
|     | 95  |     |     |     |     |     |     |     | 100 |     |     |     |     | 105 |
| Ser | Asn | Ala | Thr | Thr | Glu | Cys | Phe | Leu | Leu | Val | Val | Met | Ala | Tyr |
|     | 110 |     |     |     |     |     |     |     | 115 |     |     |     |     | 120 |
| Asp | Arg | Tyr | Val | Ala | Ile | Cys | Asn | Pro | Leu | Leu | Tyr | Pro | Val | Val |
|     | 125 |     |     |     |     |     |     |     | 130 |     |     |     |     | 135 |
| Met | Ser | Asn | Ser | Leu | Cys | Thr | Gln | Phe | Ile | Gly | Ile | Ser | Tyr | Phe |
|     | 140 |     |     |     |     |     |     |     | 145 |     |     |     |     | 150 |
| Ile | Gly | Phe | Leu | His | Ser | Ala | Ile | His | Val | Gly | Leu | Leu | Phe | Arg |
|     | 155 |     |     |     |     |     |     |     | 160 |     |     |     |     | 165 |
| Leu | Thr | Phe | Cys | Arg | Ser | Asn | Ile | Ile | His | Tyr | Phe | Tyr | Cys | Glu |
|     | 170 |     |     |     |     |     |     |     | 175 |     |     |     |     | 180 |
| Ile | Leu | Gln | Leu | Phe | Lys | Ile | Ser | Cys | Thr | Asn | Pro | Thr | Val | Asn |
|     | 185 |     |     |     |     |     |     |     | 190 |     |     |     |     | 195 |
| Ile | Leu | Leu | Ile | Phe | Ile | Phe | Ser | Ala | Phe | Ile | Gln | Val | Phe | Thr |
|     | 200 |     |     |     |     |     |     |     | 205 |     |     |     |     | 210 |
| Phe | Met | Thr | Leu | Ile | Val | Ser | Tyr | Ser | Tyr | Ile | Leu | Ser | Ala | Ile |
|     | 215 |     |     |     |     |     |     |     | 220 |     |     |     |     | 225 |
| Leu | Lys | Lys | Lys | Ser | Glu | Lys | Gly | Arg | Ser | Lys | Ala | Phe | Ser | Thr |
|     | 230 |     |     |     |     |     |     |     | 235 |     |     |     |     | 240 |
| Cys | Ser | Ala | His | Leu | Leu | Ser | Val | Ser | Leu | Phe | Tyr | Gly | Thr | Leu |
|     | 245 |     |     |     |     |     |     |     | 250 |     |     |     |     | 255 |
| Phe | Phe | Met | Tyr | Val | Ser | Ser | Arg | Ser | Gly | Ser | Ala | Ala | Asp | Gln |
|     | 260 |     |     |     |     |     |     |     | 265 |     |     |     |     | 270 |
| Ala | Lys | Met | Tyr | Ser | Leu | Phe | Tyr | Thr | Ile | Ile | Ile | Pro | Leu | Leu |
|     | 275 |     |     |     |     |     |     |     | 280 |     |     |     |     | 285 |
| Asn | Pro | Phe | Ile | Tyr | Ser | Leu | Arg | Asn | Lys | Glu | Val | Ile | Asp | Ala |
|     | 290 |     |     |     |     |     |     |     | 295 |     |     |     |     | 300 |
| Leu | Arg | Arg | Ile | Met | Lys | Lys |     |     |     |     |     |     |     |     |
|     | 305 |     |     |     |     |     |     |     |     |     |     |     |     |     |

&lt;210&gt; 17

&lt;211&gt; 2422

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2536292CB1

&lt;400&gt; 17

gacaagggtc tcactttgtt gcccagggtg gtctcgaaact cccagggtcg agcgggtcctc 60  
 ctgtttttggc ctcccaaagc attgggatta caggcatgca ccacaattcc tgacctacag 120  
 tttttcttctt atgggctttg tacatttctt gctctctggg atttttaagg aaatgtaaga 180  
 gtgtgaatca ggtactgatg gttttgactt cattatgatc agcatctttg gcttccatca 240  
 gattagagac tgaacgtttt gattagagac gattagagac gattagagac gattagagac 300

ttccagga atacaattat gtaaatcttt ttcctctctt atattagat tgggatttgg 480  
 aggaacttac tgctactcct gatgcctatt tacacctttt tgatatgtcc ccagcagaag 540  
 aagcccatgg gcttgctttt ccttcacttg tetgttgcta atacgatgac acttctccgc 600

PI-0236 PCT

```
aaagttattc cattggcagt aaaatctttc aacactaaaa atcttttgaa ttatactgga 660
tgtagggaat ttgaattttt atatagagta tcttggggac ttccctatg tacgacatac 720
ctcctaagca tgggtgcaggc cctccgtggg agccccagca aatccagggt catcaacagt 780
ctcatctaca tcaagcttgt gccatttgtt gacactatca aatatggcag tgtcaccaag 840
aatctctcca taaaaatgtg tttagctaca ccacacatgg gcaacacaat tgctgtctct 900
catacgagtg ttatcacatt ccaggactta atttttctgg ttctcatgag ttgagccagt 960
ggctacttgg tgatttttct tcacagacac cagaaaaata atccacatct tcacaacaac 1020
agctgttctt ctatagcctc ccatgagacc ggaaccatca cgactgcgct gctgcttatg 1080
atttgcttct tggtatttta tgtgagcaac tcgtgccaca gcattttacct aagtacgggtg 1140
aagaaaaggg atcagttgtg gaccatctca gatttgattt cctcatgtta cccatttttt 1200
tggtccattt ttgctcattg gtagagaaag tcttatcttg aattcaaaat ctatgaagta 1260
gagaaagtcg tcttatccca tagatatgtc aaagtaaact ttcaccaata taaacttttt 1320
ccaaaacaac attctataaa gagttggtat tctgaagaaa tgatgggatt taggtctgaa 1380
aaatgagata tttctcagtt cactgcatga aatataatct aatgaccttt accttcagta 1440
aagacaatat tgcatagctt agtatttaat gtttgtatac atagatataa tcattttaata 1500
gacaagtaga tagataattt ttcattgtcag atgtttataat ggacttcttg cactagtcac 1560
tcaatatcca ttttttctt actttaattt gtgttcagca tgaaaaatca tttcaaaagg 1620
agatcagggg ctccaggaag cagagcgtaa ctcccactt ctaaactgtg ggcttcacat 1680
aatgacatcc taccaagaaa tcagtatagc aaaggaggaa aaagagtaac ttcgcattgg 1740
agaaacctaa caaacactgt ctcagccagg tgatcaaggc cactgtgagc agtgatcagt 1800
caagtcgaaa gtgcatatca tatgacagga tgagaatggc attttacctc gacatcttcc 1860
ctcccaaac taataatcct actacatcag acaaacctca gctgagaaac agtttccaaa 1920
aacacctgac tagtaccctt taaaaccatc aagggtcatca agaacaatgt agtcctgaga 1980
aatgatcaca gccgggaaga acctaggac ttggtgtcct ttggtatcct gatattggaat 2040
cctggagcag aaaaggacat taagtaaaaa ccaaggaaat agaaataaag tataaactta 2100
ataatatatc aatattaatt cattaattgt gacaaatgta acatagtaat gtaagacatt 2160
aaaatgggga aaattgggta tgatgtggag gagaactctg tgtattctat ttgcaactct 2220
tctgtaaatg taaacctatt tgaacaatta aaaattttat tttttcaaaa caaaaaaaa 2280
aaaacaaaac aacaacaaca caaaaacaca gaggggcgcg gcgacaaaaa atatcaaacg 2340
gcccaccgcg gggggggcgc cccaccata aagagataaa cacacacgga ggtaaaaaaac 2400
gggggaaagc ggtccctctc gc 2422
```

&lt;210&gt; 18

&lt;211&gt; 1912

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7477708CB1

&lt;400&gt; 18

```
aggaaacaag aaagtcagct gtgtggaaga caatgactca tatacttttg ctgtactact 60
tggtgtttct tttgccaca gagtctgtga ggacattgta tcagggtgat gcgatgggtg 120
ctgtacagac tactcccagt gtactcaacc ttgccctcca gacactcagg gaaatatggg 180
gttttcatgc aggcaaaaga catggcacaa gatcactgac acctgccgga ctcttaatgc 240
cctcaacatc tttgaggagg attcacgttt ggttcagcca tttgaagaca atataaaaat 300
aagtgtatat actggaaagt ctgagaccat aacagatatg ttgctacaaa agtgtccac 360
agatctgtct tgtgtaatta gaaacattca gcagtctccc tggataccag gaaacattgc 420
cgtaattgtg cagctcttac acaacatata aacagcaata tggacagggt ttgatgaggc 480
aaagatgcag agttacagca ccatagccaa ccacattctt aacagcaaaa gcattctcaa 540
ctggactttc attcctgaca gaaacagcag ctatatcttg ctacattcag tcaactcctt 600
```

|            |            |            |             |             |            |      |
|------------|------------|------------|-------------|-------------|------------|------|
| tgaagaagg  | ctattcatag | ataacatccc | tgttgacata  | tcagatgtct  | tcattcatac | 660  |
| tatgggcacc | accatatctg | gagataacat | tggaaaaaat  | ttcacttttt  | ctatgagaat | 720  |
| taatgacacc | agcaatgaag | tcactgggag | agtgttgatc  | agcagagatg  | aacttcggaa | 780  |
| ggtgccttcc | ccttctcagg | tcatcagcat | tgcatttcca  | actattgggg  | ctattttgga | 840  |
| agccagtctt | ttggaaaatg | ttactgtaaa | tgggcttgto  | ctgtctgcc   | ttttgcccc  | 900  |
| ggaacttaaa | agaatctcac | tgatttttga | aaagatcagc  | aagtccagagg | agaggaggac | 960  |
| acagtgtgtt | ggctggcact | ctgtggagaa | cagatgggac  | cagcaggcct  | gcaaaatgat | 1020 |
| tcaagaaaa  | tcccagcaag | ctgtttgcaa | atgtaggcca  | agcaaattgt  | ttacctcttt | 1080 |
| ctcaattctt | atgtcacctc | acatcttaga | gagtcctgatt | ctgacttaca  | tcacatatgt | 1140 |
| aggcctgggc | atttctattt | gcagcctgat | cctttgcttg  | tccattgagg  | tccatgtctg | 1200 |
| gagccaagtg | acaaagacag | agatcaccta | tttaagccat  | gtgtgcctta  | ttaacattgc | 1260 |
| agccactttg | ctgatggcag | atgtgtgggt | cattgtggct  | tcctttctta  | gtggcccaat | 1320 |
| aacacaccac | aagggatgtg | tggcagccac | attttttggt  | catttctttt  | acctttctgt | 1380 |
| atttttctgg | atgcttgcca | aggcactcct | tatcctctat  | ggaatcatga  | ttgttttcca | 1440 |
| taccttgccc | aagtcaqtcc | tqqtqccatc | tctgttttca  | gtgggctatg  | gatgcccttt | 1500 |
| ggccatttgt | gccatcactg | ttgctgccac | tgaacctggc  | aaaggctatc  | tacgacctga | 1560 |
| gatctgctgg | ctcaactggg | acatgaccaa | agccctcctg  | gccttcgtga  | cccagctttt | 1620 |
| ggccatcgtg | gtagtaaacc | tgatcacagt | cacactgggtg | attgtcaaga  | ccagcgagc  | 1680 |
| tgccattggc | aattccatgt | tccaggaagt | gagagccatt  | gtgagaatca  | gcaagaacat | 1740 |
| cgccactctc | acaccacttc | tgggactgac | ctggggattt  | ggagtagcca  | ctgtcatcga | 1800 |
| tgacagatcc | ctggccttcc | acattatctt | ctccctgctc  | aatgcattcc  | aggtaagtcc | 1860 |
| agatccttct | gaccaaagtc | aaagtgaag  | aattcatgaa  | gatgttctgt  | ga         | 1912 |

<213> Homo sapiens

<223> Incyte ID No: 7474823CB1

|            |             |            |            |             |            |     |
|------------|-------------|------------|------------|-------------|------------|-----|
| atggttctag | gtaaaaatgt  | ctccatgtct | ggcccaaggc | cagcatcatg  | gcagtccac  | 60  |
| cctcaagggc | ttgagcttgt  | ctttggaaaa | tggcctgca  | gatgtagtta  | ttcagcagtc | 120 |
| ctggtgatct | cctccatcag  | cagttctgga | gctggggaca | tccagatca   | agattctggc | 180 |
| caatattggt | tctgatgag   | ggctgtcttt | ctggctgca  | gacggctgcc  | gtctacctgc | 240 |
| gtcctcaaga | ggcctttctc  | tgagtgcgca | cagagagaga | gaactaattt  | ggttctcatg | 300 |
| aaaaaatggg | aattcctgga  | agtacctgat | acatttgaag | taactcaaca  | aagtgtgatc | 360 |
| tccattcctt | tgtacatccc  | tcacacgctg | ttcgaatggg | attttggaaa  | ggaaatctgt | 420 |
| gtattttggc | tcactactga  | ctatctgtta | tgtacagcat | ctgtatataa  | cattgtcctc | 480 |
| atcagctatg | atcgataacct | gtcagttctc | aatgctgtgt | cttatagaac  | tcaacatact | 540 |
| ggggctctga | agattgtttac | tctgatggtg | gccgtttggg | tgtctggcctt | cttagtgaat | 600 |
| ggggcaatga | ttctagtttct | agagctcttg | aaggatgaag | gtagtggaatg | tgaacctgga | 660 |
| tttttttcgg | aatggtacat  | ccttgccatc | acatcattct | tggaaatcgt  | gatcccagtc | 720 |
| atcttagtcg | cttatttcaa  | catgaatatt | tattggagcc | tgtggaagcg  | tgatcatctc | 780 |

ttagtgaaat atgagacatt gccagcttcg tgcctagcct caggagagcc ttgcctcatc 101  
 gttctatctc ttggcagttt tcccagctgc cagagctgcc ttagtgacca gatgtcaca 1080  
 tgtgatacag agccagagag gaagtcattt ttgtccatga tgcaaggaac ccagcatttt 1140

PI-0236 PCT

gacaacccag atggaatgtg gagctcccat ggaagaaacg tgtcatctgg aggccctgcat 1200  
aaccactgca ttctccagat gggcactgga agcgcctgggg ctccccaccc agaagggtcca 1260  
cgtgggtggac aaggggcaagt gacaaccaga gccacgactc aaaagagggg ggctgcttca 1320  
ggctga 1326

&lt;210&gt; 20

&lt;211&gt; 3058

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 644692CB1

&lt;400&gt; 20

aggaaattga aagcagagta tgcacctttt attaggagat tcaaactgca tcctactgga 60  
ttagcctcaa aagtccataa atacaaagac atccatctga cagatcactg aggggaggac 120  
ttgtttttct gttttagaat agtttccgat taaacttttt agctcaagaa gaaaagaagc 180  
tagttatttc tcacccagga gtggatttgt ggtttggctt caccatggct tcctgccgtg 240  
cctggaacct taggggtgctg gtggctgtcg tgtgtggact actgactggc atcatttttg 300  
gactgggcat ctggaggatt gtgatcagga tccaaagagg aaaatctact tcctcatcaa 360  
gcacccctac agagtctctg aggaatgggt gaacctggga aaatggcaga tgtatttgta 420  
cagaagagtg gaaaggactg agatgtacaa ttgctaattt ttgtgaaaat agtacctata 480  
tgggtttttac ttttgccaga atcccagtgg gcagatatgg accatccttg caaacatgtg 540  
gcaaggatac tccaaatgcg ggcaatccaa tggcagtcgg gttgtgcagt ctctctctat 600  
atggagagat agaattacaa aaagtgacaa taggaaattg caatgaaaat ctggaaaccc 660  
tggaaaagca ggtaaaggat gtcacagcac cacttaataa catttcttct gaagtccaga 720  
ttttaacatc tgatgccaat aaattaactg ctgagaacat cactagtgtc acgcgagtgg 780  
ttggacagat attcaacact tccagaaatg cttcacctga ggcaaagaaa gttgccatag 840  
taacagttag tcaactccta gatgccagtg aagatgcttt tcaaagagtt gctgctactg 900  
ctaagtatga tggccttaca acgcttattg agcaaatgga gacttattcc ttgtcttttg 960  
gtaatcaatc agtgggtggaa cctaacatag caatacagtc agcaaatttc tottcagaaa 1020  
atgcggtggg gccttcaaat gttcgcttct ctgtgcagaa aggagctagc agttctctag 1080  
tttctagttc aacattttata catacaaatg tggatggcct taaccacagat gcacagactg 1140  
agcttcaggt cttgcttaat atgacgaaaa attacaccaa gacatgcggc tttgtagttt 1200  
atcaaaatga caagcttttc caatcaaaaa cttttacagc taaatcggat tttagtcaaa 1260  
aaattatctc aagcaaaact gatgaaaatg agcaagatca gagtgccttct gttgacatgg 1320  
tcttttagtcc aaagtacaac caaaaagaat ttcaactcta ttcctatgcc tgtgtctatt 1380  
ggaatttgtc agcgaaggac tgggacacat atggctgtca aaaagacaag ggcactgatg 1440  
gattcctgcg ctgccgctgc aaccatacta ctaattttgc tgtattaatg actttcaaaa 1500  
aggattatca atatcccaaa tcacttgaca tattatocaa cgttggatgt gcactgtctg 1560  
ttactggtct ggctctcaca gttatatttc agattgtcac caggaaagtc agaaaaacct 1620  
cagtaacctg ggttttggtc aatctgtgca tatcaatgtt gattttcaac ctccctctttg 1680  
tgtttggaat tgaaaactcc aataagaact tgcagacaag tgatgggtgac atcaataata 1740  
ttgactttga caataatgac ataccagga cagacacat taacatcccg aatcccattg 1800  
gcactgcatg tgccgcctta ctgcactatt tccgtttagt gacatttacc tggaaacgcac 1860  
tcagcgtctg acagctctat taccttctaa taaggacct gaagcctctt cctcggcatt 1920  
tcattctttt catctcatta attggatggg gagtccagc tatagtgtg gctataacag 1980  
tgggagttat ttattctcag aatggaaata atccacagt ggaatttagac taccggcaag 2040  
agaaaatctg ctggctggca attccagaac ccaatgggtg tataaaaagt ccgctgttgt 2100  
ggatcattcat cgtacctgta accattatcc tcacagcaa tgttgttatg tttattacaa 2160  
tctcgatcaa agtgcgtgtg aagaataacc agaacctgac aagcacaaaa aaagtttcat 2220

|             |             |             |             |             |             |      |
|-------------|-------------|-------------|-------------|-------------|-------------|------|
| cacatgaagaa | gattgtttagc | acattatctg  | ttgcagttgt  | ttttggaatt  | acctggattc  | 2280 |
| tagcatacct  | gatgctagtt  | aatgatgata  | gcatacaggat | cgtcttcagc  | tacatatctt  | 2340 |
| gcctttttcaa | cactacacag  | ggattgcaaa  | tttttatcct  | gtacactgtt  | agaacaaaag  | 2400 |
| tcttcacagag | tgaagcttcc  | aaagtgttga  | tgttgctatc  | gtctattggg  | agaaggaagt  | 2460 |
| cattgccttc  | agtgacgcgg  | ccgaggctgc  | gtgtaaagat  | gtataatttc  | ctcaggtcat  | 2520 |
| tgccaacctt  | acatgaacgc  | tttaggctac  | tggaaacctc  | tccgagtact  | gaggaaatca  | 2580 |
| cactctctga  | aagtgacaat  | gcaaaggaaa  | gcatactagac | agtaaaactt  | acctgttggtg | 2640 |
| gtcttttttaa | tcacctcggt  | tgagttttat  | ctgtttctct  | cctttatttc  | ccagtcctct  | 2700 |
| cagaaagtct  | tcctcaatgt  | attttgctca  | ggattaagaa  | ttagataaaa  | cctgttggtt  | 2760 |
| attattatct  | ggcataatgg  | acttggtagt  | ttttctattt  | ttcaatagat  | ttgtacttga  | 2820 |
| ataaggtgaa  | gaatttcaca  | caacatacaa  | gagtaaccatt | gttcctttata | tcgttaaattc | 2880 |
| tttgtgacac  | acctttgacaa | aaattgtagaa | cctataacaa  | attctctttac | aagttactat  | 2940 |
| aaaggcacaca | aagagaaaac  | tttaccttcc  | agaacaaaat  | gactcctgat  | gaacagtggtg | 3000 |
| tggggatttg  | attgtatgta  | ttaaactttg  | gacctctgaa  | tatttttaaaa | aaaaaaaaa   | 3058 |

|             |              |             |            |            |             |      |
|-------------|--------------|-------------|------------|------------|-------------|------|
| ctaacttttgg | gaactcgtat   | agaccacagcg | tcgctccccg | cggtgcctcg | cctccacttt  | 60   |
| ggtttcccg   | gtcctgcccg   | ctctcttcgg  | tgcctcctct | tctccggga  | caaggatgga  | 120  |
| ggatctcttt  | agccctcaa    | ttctgccgc   | ggcgccaac  | atttcgtgc  | ccatcttgct  | 180  |
| gggctgggt   | ctcaacctga   | ccttggggca  | aggagccct  | gcctctgggc | cgccagccg   | 240  |
| ccgctcccg   | ctgggtgttc   | tgggggtcat  | cctggtggtg | gcggtggcag | gcaacaccac  | 300  |
| agtgtgtgc   | cgctgtgcg    | gcggcggcg   | gcctggggcg | ggccccaagc | gtcgcaagat  | 360  |
| ggacttcctg  | ctgggtgcagc  | tggccctggc  | ggacctgtac | gcgtgcgggg | gcacggcgct  | 420  |
| gtcacagctg  | gcctgggaac   | tgtctgggca  | gccccgcgcg | gccacggggg | acctggcgctg | 480  |
| ccgcttcctg  | cagctgtctg   | aggcatccgg  | gcggggcgcc | tgggccacc  | tcgtggtgtc  | 540  |
| catcgccctc  | gagcgccggc   | gcgcggtgcg  | tcttcgcac  | ggccggcgcc | tgcccgcgcg  | 600  |
| tgccctcgcc  | gccctggget   | ggctgtggc   | actgtgtctg | gcgtgcccc  | cggccttcgt  | 660  |
| ggtgcgcggg  | gactccccct   | cgccgctgcc  | gccgcgcgcg | ccgccaaagt | ccctgcagcc  | 720  |
| aggcgcgccc  | ccggccgccc   | gcgcctggcc  | gggggagcgt | cgctgccacg | ggatcttcgc  | 780  |
| gcccctgccg  | cgctggcacc   | tgcaggtcta  | cgcttctac  | gaggccgtcg | cgggcttcgt  | 840  |
| cgcgctgtt   | acggtcctgg   | gcgtcgcttg  | cgccaccta  | ctctccgtct | ggtggcgcca  | 900  |
| ccggccgcag  | gcccccgcg    | ctgcagcgcc  | ctggtcggcg | agcccaggtc | gagccctgc   | 960  |
| gcccagtcgcg | ctgccccgcg   | ccaaggtgca  | gagcctgaag | atgagcctgc | tgtggcgct   | 1020 |
| gctgttcgtg  | ggctgcgcgagc | tgcctactt   | tgcgcgccgg | ctggcgcccg | cgtggtcgct  | 1080 |
| cgggcccgcg  | ggagactggg   | agggagagg   | ctgtcggcg  | gcgctggcg  | tgttggcgat  | 1140 |
| ggccaacagc  | gctctcaatc   | ccttcgtcta  | cctcttctc  | cagcgccg   | actgcggct   | 1200 |
| cgggcgacag  | ctgcggaagc   | ggctgggctc  | tctgtgctgc | gcgcgcgagg | gaggcgcgga  | 1260 |

tttatattgt ggtataaggag taactctcag ggaatttcag gctgtctcag gctgtctcag 150  
 atcacaaggg gcaggagagt ctgtgagaga gtgacactga agttgtcccc ttcttccact 1560  
 ctcttatctc cttctcatgt ttacatttcc ctatgctctt ccagttttctc ttcttcccta 1620

PI-0236 PCT

```
cagttcctct catatctccc catttgagaga cagtgaagcca ctggaaagtt gtaaaaacaa 1680
aaacagttat ttttgcagtt ttctttcacg catttatagt gctctggata atgccattta 1740
tttttgctga ttacccaact ttcagtattt gctgtgttat catctgtatt tacttatttt 1800
gaatcgtgct taaatcaaact gtaccttcag cacctgcaag tttgcctttt ctttccagga 1860
ggaaaatccc cacgttgctc tccctgggga gtctgagaat tataccagtg ctgtcagaaa 1920
tgtaatcatg ctgtcatttc agagccacag agtatttata aaataaaaac ctttcccacg 1980
gaaaaaaaaa aaa 1993
```

&lt;210&gt; 22

&lt;211&gt; 1499

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 6157025CB1

&lt;400&gt; 22

```
aatgcatgc agagcatgga aatgccccca gctgccctgc tgttgaaaca gaatcctatt 60
tggaaggcag acatgtggcc catctctgta gccatcactg agaaatctgg attttcaagg 120
gcctttctct ctggtgocca ggctggagtt tagcgactca atcatggctc actgactgca 180
gcacgcacct cgggggctca agtgatcctt tcatctcagc ctcctcagta gctgagacta 240
caggttttcc tgggatcagc tgcactcctt agcaaaagta tattggagaa tcaactgaga 300
aagtaactga gacatttcaa tcatttctag gtgtaaagaa agaccagatc ccaggaaaat 360
attacggtga cttcccaagt atgcctggcc acaatacctc caggaattcc tcttgcgatc 420
ctatagtgac accccactta atcagcctct acttcatagt gcttattggc gggctgggtg 480
gtgtcatttc cattcttttc ctcttggtga aaatgaacac ccggtcagtg accaccatgg 540
cggtcattaa cttggtgggtg gtccacagcg tttttctgct gacagtgcc a tttcgcttga 600
cctacctcat caagaagact tggatgtttg ggctgccctt ctgcaaattt gtgagtgcc 660
tgctgcacat ccacatgtac ctcacgttcc tattctatgt ggtgatcctg gtcaccagat 720
acctcatctt cttcaagtgc aaagacaaag tggaattcta cagaaaactg catgctgtgg 780
ctgccagtg tggcatgtgg acgctggtga ttgtcattgt ggtaccctg gttgtctccc 840
ggtatggaat ccattgaggaa tacaatgagg agcactgttt taaatttcac aaagagcttg 900
cttacacata tgtgaaaatc atcaactata tgatgtcat ttttgtcata gccgttgctg 960
tgattctggt ggtcttccag gtcttcatca ttatgttgat ggtgcagaag ctacgccact 1020
ctttactatc ccaccaggag ttctgggctc agctgaaaaa cctatttttt ataggggtca 1080
tccttgtttg tttccttccc taccagttct ttaggatcta ttacttgaat gttgtgacgc 1140
attccaatgc ctgtaacagc aagggtgcat tttataacga aatcttcttg agtgtaacag 1200
caattagctg ctatgatttg cttctctttg tctttggggg aagccattgg ttttaagcaa 1260
agataatggc ttatggaatt gtgtttgtgc cgttagccac aaactacagt attcatattt 1320
gcttctttta tattgggaat aaaaatgggt atagggggagg taagaatggt atttcattac 1380
ttgatcaaag catgccttga tgtaacaaa acaaaaggac tataaatgca agagccctca 1440
ttgtagtctt attgggatcc tccatctcga gtgatggcgt acaagaccgc tgttgtcgc 1499
```

&lt;210&gt; 23

&lt;211&gt; 2455

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 55012817CB1



PI-0236 PCT

&lt;400&gt; 23

```
cgttgctgtc gagagctect ggcgtgggca aggctggcca aggatggcga cggccagggg 60
cctggggggc ctgctcctgc tctcctgct cccgacctca ggtcaggaaa agcccaccga 120
agggccaaga aacacctgcc tggggagcaa caacatgtac gacatcttca acttgaatga 180
caaggctttg tgcttcacca agtgcaggca gtccggcagc gactcctgca atgtggaaaa 240
cttgagaga tactggctaa actacgaggc ccatctgatg aaggaagggt tgacgcagaa 300
ggtgaacacg cctttcctga aggctttggg ccagaacctc agcaccaaca ctgcagaaga 360
cttctatttc tctctggagc cctctcaggt tccgaggcag gtgatgaagg acgaggacaa 420
gccccctgac agagtgcgac ttcccaagag cctttttcga tccctgccag gcaacagggtc 480
tgtggctcgc ttggccgtca ccattctgga cattgggtcca gggactctct tcaaggggccc 540
ccggctcggc ctgggagatg gcagcggcgt gttgaacaat cgctggtgg gtttgagtgt 600
gggacaaatg catgtcacca agctggctga gcctctggag atcgtcttct ctcaccagcg 660
accgccccct aacatgacct tcacctgtgt attctgggat gtgactaaag ggaccactgg 720
aactcgtct tctgagggt gctccaggga ggtcagacct gaggggaccg tgtgctgctg 780
tgaccacctg acctttttcg ccctgctcct gagaccacc ttggaccagt ccacggtgca 840
tactctcaca cgcctctccc aggcgggctg tgggtctcc atgatcttc tggecttcac 900
cattattctt tatgcctttc tgaggctttc ccgggagagg ttcaagtcag aagatgcccc 960
aaagatccac gtggccctgg gtggcagcct gttcctcctg aatctggcct tcttggtcaa 1020
tgtggggagt ggctcaaagg ggtctgatgc tgctgctgg gcccgggggg ctgtcttcca 1080
ctacttctct ctctgtgct tcacctggat gggccttgaa gccttcacc tctacctgct 1140
cgctgtcagg gtcttcaaca cctacttcgg gcactacttc ctgaagctga gcctggtggg 1200
ctggggcctg ccgcccctga tggtcacgg cactgggagt gccaacagct acggcctcta 1260
caccatccgt gatagggaga accgcacctc tctggagcta tgctgggtcc gtgaaggggac 1320
aaccatgtac gccctctata tcaccgtcca cggctacttc ctcatcacct tcctctttgg 1380
catggtggtc ctggccctgg tgggtctggaa gatcttcaac ctgtcccgtg ctacagcggg 1440
caaggagcgg gggaagaacc ggaagaagggt gctcaccctg ctgggcctct cgagcctggg 1500
gggtgtgaca tgggggttgg ccactctcac ccggttgggc ctctccaccg tctacatctt 1560
tgacttttc aactccttgc aagggtgtct catctgctgc tgggtcacca tcctttacct 1620
cccaagtacg agcaccacag tctcctcctc tactgcaaga ttggaccagg cccactccgc 1680
atctcaagaa taggaaggca cggccctgca atatggactc agctctggct ctctgtgtga 1740
ccttggggcag ctccgtgcct ctctctgtac tccctcagtt tccttctctg tacaatgtgg 1800
ctggggaggg agaggatggg accaggttgg accacgtggc atcagagggt ccatccagat 1860
ccaactatag gtccaagagt ccacgtaagc aggtttgcaa ggctctaaag ttcctatagt 1920
cctgagaccc cctgccagca aagagtgaca gtcacctcca tgccctgccc tcattgcaaa 1980
gccctcactc accttctggt ctacgaagg gaggagagtc tgttgctggc atagccctgg 2040
aaggagcccc cagcctctcc cctcctcctc cttgtcactg gcctcccaca actccccctc 2100
tggctgcctg taaccttgag gggcattcag gaggccagcg ttccctcagg cactgggggt 2160
ttgttttggg ggggtgggagt tgatcctccc acccagctctg ccctggtct ctgcccattc 2220
aatcagagcc caccctcctg gaagagaccc ccgtgttcag agtgctggca gccctgcacg 2280
tgtccagggg cactgcattt caaagaacca ctgagtgggt gagctacctt gggcaaacc 2340
cccactcctg actctgactg ccacgtgggt ggcccgacct ctgacctgct gtcactgtag 2400
aggtagaaag caaacaatct ggggctcagc acacctgggg gtgctccac tcatt 2455
```

&lt;210&gt; 24

&lt;211&gt; 2056

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7475061CB1

PI-0236 PCT

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; 1863

&lt;223&gt; a, t, c, g, or other

&lt;400&gt; 24

```
gatcacgagc caccaagccc cttccacaag ttcttaggaa gccagataag actagcaaca 60
caaaagctgt tagcaggaag ggcgttttta agacacaagc catgttttgt gcttctcac 120
ctcccagaag gattttccct ggatgatcca ctaacacacc ctttccgaga tgttttctca 180
agggcctcca ttgtcttcag catcctctca tctctttcct gtcccttttc ccagctgttg 240
tcacttctcc ctcccaaagc tcccagatgc ctagagaaaa ccttccaatt gtgttctcct 300
ggagaaaggg ccaagctctg gaactttttt ccgtttactc cactctccct caggcttcag 360
ttatctgccc aggtctccca gaaatcaatg gaataaatct ttggagggtg aatttgacat 420
atcgagggga ggtatctggg tgtagggcag attacatccg ggtaatgctt ttcttccgcc 480
tccaggggtt tggctgaaaa gaaagcacgc ctacatctgc ctggcagcca tctgggccta 540
tgcttctctc tggaccacca tgcccttggg aggtctgggg gactacgtac ctgagccctt 600
cggaacctcg tgcaccctgg actggtggct ggcccaggcc tcggtagggg gccaggtttt 660
catcctgaac atcctcttct tctgcctctt gctcccaacg gctgtgatcg tgttctccta 720
cgtaaaagatc attgccaagg ttaagtctct ttccaaagaa gtagctcatt tcgacagtcg 780
gatccatagc agccatgtgc tggaaatgaa actgacaaag gtagcgatgt tgatttgtgc 840
tggattcctg attgcctgga ttccctatgc agtggtgtct gtgtggtcag cttttggaag 900
gccagactcc attcccatat agctctctgt ggtgcccaacc ctacttgcaa aatctgcagc 960
gatgtacaat cccatcattt accaagtatt tgattacaaa tttgcctgtt gccaaactgg 1020
tggtttgaaa gcaaccaaga agaagtctct ggaaggcttc aggtgcaca ccgtaaccac 1080
agtcaggaag tcttctgctg tgctggaaat tcatgaagag gtatgaagat ggatacagca 1140
tactatgga cactcgtatt cacttatttg cctcttcact gctgtaaaca tttgattgtg 1200
gccacacttt tgtctttata ttatattttt atattttgta cagttttcct caagccaggg 1260
gttgctggga aattccaatg gctaaatgga aactagatta caggatacta atttaaggaa 1320
tattatcagg atgagcgtcc ctggaacttt cttttctcgt actttaaaac ctattgtcat 1380
gccaaacaga attgaatgtg agatagttag aaaaatgttg agaagtttta tattaggggg 1440
ttatttaatt ttattacatc attgtcatta ttgtttctta atgtcgggtt agggaggcag 1500
tttctggggc tcattcaggt ggacaatcat gtatgttggg ccatggctct ttggtaggta 1560
ctttgggtct cacagccatt ttcatgctg gaggagggtt gtactctgat ggcagtgatt 1620
ccacaaagga gtcctctggg gaaatcagtt ttgccttaaa tcaactcaatg gaaaactctc 1680
ctgtatctcc aaatttgaag acaacagtaa tttccgctga tgaaaaaaaa aaaaaggggc 1740
ggccgcccag ttagtgagcc tcgtcgaccc cggaataaaa ttccggaccg gtaccctggg 1800
agaggcgtcc ttccaagac acattgggag gctcaagggt gccccaagtt ctaatagtgt 1860
ccnctaaatc cgtttgtgtt gacacatcag gtctggatat tgaccggcta aggagcgaac 1920
aaataaaaaca acaacaaga aaaataagaa aacgtactca cacggaacac aaaacacaaa 1980
caaaaagaca aacaaatca gaataaaaaa aaaacaacag acatacaaca caaaccaaca 2040
aacaataaca aacaaa
```

2056

&lt;210&gt; 25

&lt;211&gt; 999

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7477374CB1

PI-0236 PCT

&lt;400&gt; 25

```
atggtgaaca atttctccca agctgaggct gtggagctgt gttacaagaa cgtgaacgaa 60
tcctgcatta aaactcetta ctgccaggt cctcgatcta tcctctacgc cgtccttggg 120
tttggggctg tgctggcagc gtttggaac ttactggta tgattgctat ccttcacttc 180
aaacaactgc acacacctac aaactttctg attgctgcgc tggcctgtgc tgacttcttg 240
gtgggagtc cgtgatgcc ctccagcaca gtgaggtctg tggagagctg ttggtacttt 300
ggggacagtt actgtaaatt ccatacatgt ttgacacat ccttctgttt tgcttcttta 360
tttcatttat gctgtatctc tgttgataga tacatgctgg gatatgcatg gttctttcct 420
ggtttctttt ctgtcacata cagcttttcg atctttaaca cgggagccaa cgaagaagga 480
attgaggaat tagtagttgc tctaacctgt gtaggaggct gccaggctcc actgaatcaa 540
aactgggtcc tactttgttt tcttctatct tttataccca atgtcgccat ggtgtttata 600
tacagtaaga tatttttggg ggccaagcat caggctagga agatagaaag tacagccagc 660
caagctcagt cctcctcaga gagttacaag gaaagagtag caaaaagaga gagaaaggct 720
gcaaaaacct tgggaattgc tatggcagca tttcttgtct cttggctacc atacctcgtt 780
gatgcagtga ttgatgctta tatgaatttt ataactctc cttatgttta tgagatttta 840
gtttgggtgtg tttattataa ttcagctatg aacccttga tttatgcttt cttttaccaa 900
tggtttggga aggcaataaa acttattgta agcggcaagg tcttaaggac tgattcgtca 960
acaactaatt tattttctga agaagtagag acagattaa 999
```

&lt;210&gt; 26

&lt;211&gt; 3429

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7479890CB1

&lt;400&gt; 26

```
atgcccagcc cgcgggggct ccgggcgcta tggctttgct ccgcgctgtg cgttcccg 60
agggccggcg gcgcccccca gccggccccg ggcccaccg cctgcccgcc cccctgccac 120
tgccaggagg acggcatcat gctgtctgcc gactgctctg agctcgggct gtccgctgtt 180
ccggggggacc tggacccctt gacggcttac ctggtgggat gtccccctcc actccaaaag 240
gcacaggctg tgggcccagc gggggagtat gagaagcagt ttggccctcg acaggttaag 300
ctgtttcccc agagcctaag caagcccga ctggccctgt aggtccctgc taatctgccc 360
cattactgca ggcgcctaga tgccaacctc atctccctgg tcccgagag gagctttgag 420
gggctgtcct cctccgcca cctctggctg gacgacaatg cactcacgga gatccctgtc 480
agggccctca acaacctccc tgccctgcag gccatggccc tggccctcaa ccgcctcagc 540
cacatccccg actacgcgtt ccagaatctc accagccttg tgggtgctgca tttgcataac 600
aaccgcatcc agcatctggg gacccacagc ttcgaggggc tgcacaatct ggagacacta 660
gacctgaatt ataacaagct gcaggagttc cctgtggcca tccggaccct gggcagactg 720
caggaactgg ggttccataa caacaacatc aaggccatcc cagaaaaggc cttcatgggg 780
aaccctctgc tacagacgat acacttttat gataacacaa tccagtttgt gggaagatcg 840
gcattccagt acctgcctaa actccacaca ctatctctga atggtgccat ggacatccag 900
gagtttccag gtctcaaagg caccaccagc ctggagatcc tgacctgac ccgcgcaggc 960
atccggctgc tcccacgggg gatgtgcaa cagctgccc ggtccgaat cctggaactg 1020
ggtgcaatc cctgggtcaa ggggacctg acagacaacc agctgaccac actgcccctg 1260
gctggacttg ggggcttgat gcctctgaag ctcaaaggga accttgctct ctcaccagcc 1320
ttctccaagg acagtttccc aaaactgagg atcctggagg tgccttatgc ctaccagtgc 1380
```

PI-0236 PCT

```
tgtccctatg ggatgtgtgc cagcttcttc aaggcctctg ggcaagtggga ggctgaagac 1440
cttcaccttg atgatgagga gtcttcaaaa aggcccttgg gcctccttgc cagacaagca 1500
gagaaccact atgaccagga cctggatgag ctccagctgg agatggagga ctcaaagcca 1560
caccaccagt tccagtgtag cctacttcca ggcccttcca agccctgtga gtacctcttt 1620
gaaagctggg gcatccgcct ggccgtgtgg gccatcgtgt tgctctccgt gctctgcaat 1680
ggactgggtg tgctgaccgt gtccgttggc ggccctgccc cctgcccccc ggtcaagttt 1740
gtggtaggtg cgattgcagg cgccaacacc ttgactggca tttcctgtgg ccttctagcc 1800
tcagtgcgat ccttgacctt tgggtcagttc tctgagtacg gagcccgctg ggagacgggg 1860
ctaggctgcc gggccactgg ctctctggca gtacttgggt cggaggcatc ggtgctgctg 1920
ctcactctgg ccgcagtgca gtgcagcgtc tccgtctcct gtgtccgggc ctatgggaag 1980
tccccctccc tgggcagcgt tcgagcaggg gtccctaggt gcctggcact ggcagggctg 2040
gccgcgcac tgcccttggc ctcaagtggga gaatacgggg cctccccact ctgcctgccc 2100
tacgcgccac ctgaggggtca gccagcagcc ctgggcttca ccgtggccct ggtgatgatg 2160
aactccttct gtttcttggg cgtggccggg gccatcatca aactgtactg tgacctgccg 2220
cggggcgact ttgaggccgt gtgggactgc gccatggtga ggcacgtggc ctggctcatc 2280
ttcgcagacg ggctcctcta ctgtcccgtg gccttcttca gctttgcctc catgctgggc 2340
ctcttccctg tcacgcccga ggccgtcaag tctgtcctgc tgggtgtgct gccctgcct 2400
gcctgcctca acccactgct gtacctgtc ttcaaccccc acttccggga tgacctcgg 2460
cggcttcggc cccgcgcagg ggactcaggg ccctagcct atgctgcggc cggggagctg 2520
gagaagagct cctgtgattc taccaggcc ctggtagcct tctctgatgt ggatctcatt 2580
ctggaagctt ctgaagctgg gcggccccct gggctggaga cctatggctt cccctcagt 2640
accctcatct cctgtcagca gccagggggc ccagggctgg agggcagcca ttgtgtagag 2700
ccagagggga accactttgg gaacccccaa cctccatgg atggagaact gctgctgagg 2760
gcagagggat ctacgccagc aggtggaggc ttgtcagggg gtggcggctt tcagccctct 2820
ggcttggcct ttgcttcaca cgtgtaaata tccctcccca ttcttctctt cccctctctt 2880
ccctttcctc tctccccctc ggtgaatgat ggctgcttct aaaacaaata caacaaaaac 2940
tcagcagtgat gatctatagc aggatggccc agtacctggc tccactgatc acctctctcc 3000
tgtgaccatc accaacgggt gcctcttggc ctggctttcc cttggccttc ctcagcttca 3060
ccttgatact gggcctcttc cttgtcatgt ctgaagctgt ggaccagaga cctggacttt 3120
tgtctgctta agggaaatga gggaaagtaa gacagtgaag ggggtggagg ttgatcaggg 3180
cacagtggac agggagacct cacagagaaa ggccctggaag gtgatttccc gtgtgactca 3240
tggataggat acaaaatgtg ttccatgtac cattaatctt gacatatgcc atgcataaag 3300
acttctatt aaaataagct ttggaagaga ttacacatga tgtctttttc ttagagattc 3360
acagtgcgat ttagtgtaat aaagagataa gtccctacagt agtaaaatct attgaacttt 3420
gtttcaaaa 3429
```

&lt;210&gt; 27

&lt;211&gt; 948

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7482825CB1

&lt;400&gt; 27

```
atggaaattg tctccacagg aaacgaaact attactgaat ttgtcctcct tggcttctat 60
gacatccctg aactgcattt cttgtttttt attgtattca ctgctgtcta tgtcttcac 120
atcatagggg atatgctgat tattgttagc gtggttagct ccagaggct ccacaaaccc 180
atgtatatatt tcttggcgaa tctgtccttc ctggatattc tctacacctc cgcagtgatg 240
ccaaaaatgc tggaggggctt cctgcaagaa gcaactatct ctgtggctgg ttgcttgctc 300
cagttcttta tcttcggctc tctagccaca gctgaatgct tactgctggc tgtcatggca 360
```

|             |            |            |            |            |            |     |
|-------------|------------|------------|------------|------------|------------|-----|
| tatgaccgct  | acctggcaat | ttgtaccca  | ctccactacc | cactcctgat | ggggcccaga | 420 |
| cggtagatgg  | ggctgggtgg | cacaacctgg | ctctctggat | ttgtggtaga | tggactgggt | 480 |
| gtggccctgg  | tggcccagct | gaggttctgt | ggccccaacc | acattgacca | gttttactgt | 540 |
| gacttttatgc | ttttcgtggg | cctggcttgc | tcggatccca | gagtggctca | ggtgacaact | 600 |
| ctcattctgt  | ctgtgttctg | cctcactatt | ccttttggac | tgattctgac | atcttatgcc | 660 |
| agaattgtgg  | tggcagtgtc | gagagttcct | gctggggcaa | gcaggagaag | ggctttctcc | 720 |
| acatgctect  | cccacctagc | tgtagtgacc | acattctatg | gaacgctcat | gatcttttat | 780 |
| gttgacccct  | ctgctgtcca | ttcccagctc | ctctccaagg | tcttctccct | gctctacact | 840 |
| gtggtcacc   | ctctcttcaa | tcctgtgatc | tataccatga | ggaacaagga | ggtgcatcag | 900 |
| gcacttcgga  | agattctctg | tatcaaacaa | actgaaacac | ttgattga   |            | 948 |

|             |             |            |             |             |            |     |
|-------------|-------------|------------|-------------|-------------|------------|-----|
| atgaaagcag  | gaaactttctc | agacactcca | gaattcttttc | tcttgggatt  | gtcaggggat | 60  |
| ccggagctgc  | agcccatcct  | cttcagtctg | ttcctgtcca  | tgtacctggc  | cacaatgctg | 120 |
| gggaacctgc  | tcatcatcct  | ggcgtcaac  | tctgactccc  | acctccacac  | ccccatgtac | 180 |
| ttcctcctct  | ctatcctgtc  | cttggtcgac | atctgtttca  | cctccaccac  | gatgcccaag | 240 |
| atgctgggtga | acatccaggc  | acaggctcaa | tccatcaatt  | acacaggctg  | cctcacccaa | 300 |
| atctgctttg  | tccctggtttt | tgttggattg | gaaaatggaa  | ttctgggtcat | gatggcctat | 360 |
| gatcgatttg  | tggccatctg  | tcaccactg  | aggtacaatg  | tcatcatgaa  | ccccaaactc | 420 |
| tgtgggctgc  | tgctttctgt  | gtccttcatc | gttagtgctc  | tggatgctct  | gctgcacacg | 480 |
| ttgatgggtgc | tacagctgac  | cttctgcata | gacctggaaa  | ttccccactt  | ttctgtgtaa | 540 |
| ctagctcata  | ttctcaagct  | cgctgttct  | gatgtcctca  | tcaataacat  | cctgggtgat | 600 |
| ttgggtgacca | gcctgttagg  | tgttgttctc | ctctctggga  | tcattttctc  | ttacacacga | 660 |
| attgtctcct  | ctgtcatgaa  | aattccatca | gctgggtggaa | agtataaagc  | tttttccatc | 720 |
| tgcgggtcac  | atttaactcg  | tgtttccttg | ttttatggaa  | caggggtttgg | ggtgtacctt | 780 |
| agttctgggg  | ctaccactc   | ctccaggag  | ggtgcaatag  | catcagtgat  | gtataccgtg | 840 |
| gtcaccccca  | tgctgaacc   | actcatttac | agcctgagaa  | acaaggacat  | gttgaaggct | 900 |
| ttgaggaaaac | taatatctag  | gataccatct | ttccattga   |             |            | 939 |

<223> Incyte ID No: 7483134CB1

cttcagcgtt cttgcttctt gttattcttt gtttttctt gttttctctt cttggggttt 210  
ctttctgggtc tctatcccat caatgctaga aagacctga agtctcccat gtattttctt 180  
ctgagccagt tgtctttttg tgacatatgt tatccatcca ctaccatacc caagatgatt 240

PI-0236 PCT

```
gctgacactt ttgtggagca taagatcatt tccttcaatg gctgcatgac ccagctcttt 300
tctgcccact tctttgggtg cactgagatc ttctctctta cagccatggc ctatgaccgc 360
tatgtggcca tctgtaggcc cctgcactac acagccatca tggattgccg gaagtgtggc 420
ctgctagcgg gggcctcctg gttagctggc ttctgcatt ccctcctgca gacctcctc 480
acggttcagc tgcctttttg tgggcccatt gagatagaca acttcttctg tgatgttcat 540
ccccctgctc agttggcctg tgcagacacc tacatggtag gtctcatcgt ggtggccaac 600
agcgggtatga tttcttttag atcctttttt atccttatca tttcctatgt tatcatctta 660
ctgaacctaa gaagccagtc atctgaggac cggcgtaagg ctgtctccac atgtggctca 720
cacgtaatac ctgtcctttt ggttctcatg ccccccattg tcatgtacat tcgtccctcc 780
accaccctgg ctgctgacaa acttatcatt ctctttaaca ttgtgatgcc acctttgctg 840
aaccctttga tctatacact aaggaacaac gatgtgaaaa atgccatgag gaagctgttt 900
agggtaaga ggagcttag ggagaagtga 930
```

&lt;210&gt; 30

&lt;211&gt; 1161

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7478550CB1

&lt;400&gt; 30

```
gaggacgcgc tgctgcgaga ccagccgcgg cgtctttggc agtagtgggc gtccttgccg 60
gtccaggagg gccctctcc cgcgaccgcc gaccacgatg agagcgtgaa gacctctcg 120
aaaggaaggg ctctgctcta cacactggtg tctcctgcgg aagggcagct gggcacgcct 180
tccagaccga gcaaaagtgt aaaaatcagt aaccatga tgactaaccg aaatcaagta 240
gtgctgggca ggatgagaca tcagtgtctg cctcagacag aacgagcaca cacaaaacat 300
gacctctcac tccaagccca gttacagcag aaagttttca tggagaaatg gaatcacact 360
tcaaatgatt tcattttgtt gggctctgct ccccaaatc aaactggaat atttctcttg 420
tgcttatca tctctatatt cttcttgcc tcgggtggga actcggccat gattcacctc 480
atccacgtgg atcctcgtct ccacacacc atgtacttct ttctcagcca gctctccctt 540
atggacctga tgtacatctc caccaccgtc ccaagatgg cgtacaactt cctgtccggc 600
cagaaaggca tctccttctt gggatgtggg gtgcaaagct tcttcttctt gaccatggcg 660
tgttctgaag gcttactcct gacctccatg gctacgacc gttatttggc catctgccac 720
tctctctatt atcctatccg catgagtaaa atgatgtgtg tgaagatgat tggaggctct 780
tggacactgg ggtccatcaa ctcttggca cacacagtct ttgcccttca tattccctac 840
tgcagggtcta gggctattga ccatttcttc tgcgatgtcc cagccatggt gcttcttgcc 900
tgtacagata cttgggtcta tgaatatatg gtttttgtaa gtacaagcct ctttctcctt 960
ttccctttca ttggcatcac ttcttctgtt ggccgagtc tatttgctgt ctatcatatg 1020
cactcaaagg aggggagaaa aaaggccttc accaccattt caacacattt aactgtagtg 1080
atcttttact atgcacctt tgtctacacc tatcttcggc ccacggaatc tccgtcacc 1140
agctgaagac aagatcctgg c 1161
```

&lt;210&gt; 31

&lt;211&gt; 948

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7483142CB1

PI-0236 PCT

&lt;400&gt; 31

```
atgtccataa ccaaagcctg gaacagctca tcagtgacca tgttcatoct cctgggattc 60
acagaccatc cagaactcca ggccctcctc tttgtgacct tcttgggcat ctatcttacc 120
accctggcct ggaacctggc cctcattttt ctgatcagag gtgacacca tctgcacaca 180
cccatgtact tcttcctaag caacttatct ttcattgaca tctgctactc tctgctgtg 240
gctcccaata tgctcactga cttcttctgg gagcagaaga ccatatcatt tgtgggctgt 300
gctgctcagt tttttttctt tgtcggcatg ggtctgtctg agtgccctct cctgactgct 360
atggcatacg accgatatgc agccatctcc agcccccctc tctacccac tatcatgacc 420
cagggcctct gtacacgcat ggtggttggg gcataatgtt gtggcttctc gagctccctg 480
atccaggcca gctccatatt taggcttcac ttttgccggac ccaacatcat caaccacttc 540
ttctgcgacc tcccaccagt cctggctctg tcttgctctg acaccttctc cagtcaagtg 600
gtgaatttcc tcgtggtggt cactgtcgga ggaacatcgt tctccaact ccttatctcc 660
tatggttaca tagtgtctgc ggtcctgaag atcccttcag cagagggccg atggaaagcc 720
tgcaacacgt gtgcctcgca tctgatggtg gtgactctgc tgtttgggac agcccttttc 780
gtgtacttgc gaccagctc cagctacttg ctaggcaggg acaagggtgt gtctgttttc 840
tattcattgg tgatcccat gctgaacct ctcatttaca gtttgaggaa caaagagatc 900
aaggatgcc tgtggaaggt gttggaaggt aagaaagtgt tttcttag 948
```

&lt;210&gt; 32

&lt;211&gt; 924

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7483151CB1

&lt;400&gt; 32

```
atggcagaag aaaataagat tctggtgact cactttgtcc tcacaggact cacagatcat 60
ccagggtgc aggcgccccct gttcctggtg ttcttggtca tctacctcat caccctggtg 120
ggcaaccttg gcctgatggc tctcatctgg aaggaccccc accttcacac ccccatatac 180
ttatttcttg gcagtttagc ctttgagat gcattgactt catcctctgt aacttctaag 240
atgctttcaa tttttttatc aaagaatcat atgctatcca tggctaagtg tgccaccag 300
ttttactttt ttggttccaa tgcaaccaca gaatgcttcc tgctggtagt gatggcctat 360
gaccgctatg tagccatag caatcccttg ctttatccag tgggtgatgt caatagcctc 420
tgtactcagt ttataggtat ttcataattt attggttttc tgcattcagc gattcatgtg 480
ggtttgttat ttagattaac tttctgcagg tccaatatta tacattattt ctactgtgaa 540
attttacagc tgttcaaaat ttcttgacc aatcctacag ttaataact tctgatttcc 600
atcttttcag catttataca agtcttact tttatgactc ttatcgtctc ttactctat 660
attctctctg ccacctgaa aaagaagtct gagaagggtg gaagcaaagc cttctctact 720
tgcagtgcc atctgctctc tgtctctttg ttctacggca cctcttctt catgtatgtg 780
agttctaggt ctggatcagc tgcagatcag gccaaaatgt attctttatt ttacacaata 840
ataattcctt tactaaatcc ttttatttac agcctaagga acaaagaggt tatagatgcc 900
ctgagaagaa tcatgaagaa ataa 924
```

